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The combined efforts of countries and international partners have 
resulted in substantial advances in HIV treatment and prevention. 
Nonetheless, access to key HIV services remains low in many 
settings around the world, and there are still major research 
gaps about the best way to expand HIV testing, prevention and 
treatment, especially in resource-limited settings. The World 
Health Organization (WHO) has endorsed the “learning by 
doing” approach, which advocates that public health strategies to 
scale up HIV treatment and prevention services be continuously 
reviewed, evaluated and revised, so that the results of research 
can inform programmes as quickly as possible (WHO 2006). 
Along with monitoring and evaluation, operational research is a 
central component of the process of gathering and analysing data 
to inform HIV programmes and policies. 
There are many different definitions of operational research 
(WHO and the Global Fund 2008), and here, we use a pragmatic 
definition of operational research as “the science of better” or, more 
specifically, as research designed to improve the performance of 
programmes and policies. This volume focuses on health services 
and is, therefore, addressed to programme managers and 
researchers with an interest in conducting operational research 
to inform HIV policies, programmes and services. 
While numerous instruments have been developed for operational 
research on HIV, there have been few efforts to review what is 
known about existing data collection tools or to help researchers 
select among the many tools that are available. The multiplicity 
of tools and approaches hinders efforts to track progress in 
providing services for testing, treatment and prevention. The 
lack of standardized approaches to data collection also hampers 
comparisons across settings, limiting the potential to draw lessons 
about how different models of service provision function in the 
field. To address this gap, in 2006, the World Health Organization’s 
HIV Department initiated a project to develop generic tools for 
operational research on HIV. These tools are designed for data 
collection on HIV testing, treatment and prevention programmes 
in multiple settings. They are called generic because, while they 
are standardized, they lend themselves to adaptation to particular 
country situations.
2. DESCriPTiON OF THE GENEriC TOOLS 
PrOjECT
The Generic Tools project is part of WHO’s broader efforts to 
facilitate operational research on HIV testing, treatment and 
prevention. To identify the information needed to improve HIV 
programmes, the HIV Department of WHO held international 
meetings, multi-stakeholder consultations and local workshops, 
and reviewed the evidence and the availability of data collection 
tools. These activities highlighted a number of research questions 
that were amenable to operational research, had relevance in 
diverse settings, and had the potential to improve programmes 
and strengthen the evidence base for policies. These research 
questions are grouped under the following four broad topics, which 
correspond to the four substantive chapters in this volume: 
1. The utilization of HIV testing and counselling. In particular, 
what are the barriers and facilitators to the uptake of HIV 
testing and counselling? How do different service provision 
models influence the uptake and quality of services? And, what 
are the ethical implications of practices related to consent, 
confidentiality and counselling?
2. HIV stigma and discrimination. What are the consequences 
of disclosure, including patterns and levels of HIV stigma 
and discrimination? To what extent are HIV stigma and 
discrimination associated with the utilization of health 
services?
3. Adherence to antiretroviral therapy. Specifically, how can 
researchers measure adherence and the factors that influence 
adherence? What are levels and patterns of adherence 
in different settings? And, how can programmes support 
adherence?
4. HIV prevention in the context of scaled-up access to HIV 
treatment. What are the levels and patterns of high-risk 
behaviours among patients receiving HIV treatment? Does 
access to antiretroviral therapy influence risk behaviour and 
perceptions of the risks of HIV? 
These research questions represent a first phase of work in 
this area, to be complemented by others as resources become 
available.
INTRODUCTION
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3. DEFiNiTiONS AND TErMiNOLOGy
Because the words “topics”, “questions” and “tools” have 
multiple meanings that can lead to confusion, we propose to use 
these terms as follows. Topics refer to the four topics identified 
by the chapter titles, noted above. Questions may refer to either 
research questions or to items in a questionnaire that respondents 
are asked during an interview (survey questions). Throughout 
this volume, we have tried to use specific wording to distinguish 
between the two. The survey questions are clustered together to 
form modules, and the modules combine into two main research 
instruments: a Client Instrument and a Provider Instrument. 
The word “tools” refers to the complete set of literature reviews, 
research questions, methodological recommendations, variables 
and instruments provided in this volume for each of the four 
selected topics. 
4. APPrOACH AND METHODOLOGy
The research questions formulated in this volume can be 
investigated through various study designs, but the volume 
focuses primarily on health facility-based, cross-sectional survey 
research. When information at more than one point in time is 
desirable, researchers can conduct repeated cross-sectional 
surveys or use the instruments with longitudinal study designs. In 
most cases, the study populations for data collection envisioned 
by these chapters include clients and providers at health facilities; 
however, the chapters suggest ways to include study populations 
outside the clinic, such as non-users of services, when such 
comparisons are needed. Researchers who would like more 
detailed suggestions for designing operational research projects 
on HIV may find it helpful to consult the publication entitled, 
Designing HIV/AIDS intervention studies: an operations research 
handbook, published by the Population Council (Fisher et al 
2002). 
While simple survey designs facilitate the conduct of research, it 
is often desirable to triangulate multiple sources of information 
and to combine different approaches to data collection. For 
example, qualitative methods provide an important complement 
to quantitative surveys, and it is recommended that they be 
included in the design of operational research whenever possible. 
Qualitative methods can elicit respondents’ perspectives on 
key topics and provide broad insights into the situations that 
are investigated. In this volume, the qualitative component is 
limited to some open-ended questions in the Client and Provider 
Instruments. Further use of qualitative methods is encouraged, 
however, including semi-structured key informant interviews, 
observations at health facilities, in-depth interviews, focus groups 
and textual analyses of important documents, such as guidelines 
or media reports. For more guidance, we recommend: Qualitative 
research methods: a data collector’s field guide, published by 
Family Health International (Mack et al. 2005).
5. HOW THiS vOLUME WAS PUT TOGETHEr 
The Generic Tools volume is the result of the collective efforts of 
many individuals. During the first phase of the work, a team of 
researchers reviewed the published and unpublished literature 
on each selected topic, summarized the evidence, compiled 
available instruments, took stock of existing data collection 
approaches and identified the essential information needed for 
operational research on HIV. In parallel with this process, the 
WHO held several international consultations with researchers, 
managers and country representatives to discuss research 
priorities in the field of HIV. Subsequently, a group of experts 
drafted chapters summarizing the evidence on the four selected 
topics. These chapters formulated priority operational research 
questions, recommended preferred approaches to data collection 
and included draft research instruments for data collection. The 
Population Council collaborated closely with WHO on this phase 
of the work. After the four chapters were drafted, they were 
extensively revised to produce the consolidated set of tools and 
instruments included in this volume. 
While the organization of the four chapters varies, they all share 
a common core structure, as follows:
1. A background section that spells out the rationale for 
conducting operational research on the selected topic, based 
on a review of the literature; 
2. A summary of the literature concerning what is known about 
the factors that influence the key outcome; 
3. A section that formulates the operational research questions 
to be addressed; 
4. A methodology section about study populations and study 
design;
5. A discussion of variables and survey questions/questionnaire 
items.
This volume also includes two data collection instruments that 
address the research questions developed in the four chapters. 
The first instrument is designed to be used with clients at 
health facilities, while the second instrument is designed for 
use among health care providers. Each instrument includes at 
least one module that corresponds to each of the four chapters. 
As a result, the full instruments are very long, and it is clearly 
neither feasible nor desirable to administer them in full. To 
help researchers select the sections that are most relevant to 
a given research project, the instruments are organized into 
modules that correspond to different chapters. Much effort was 
invested to maximize consistency, minimize redundancies, and 
simplify skip patterns in order to enable researchers to keep 
only those sections that are most pertinent to their project. Even 
within individual modules, however, researchers may need to 
identify which sections to include and which to omit. A detailed 
description or “map” of the Client Instrument is provided at the 
end of this introduction to help researchers select the appropriate 
sections. Electronic versions of the instrument are also provided 
on the WHO website.




Although the full instruments in this volume have not been 
subjected to a formal validation process, they are based on a 
number of recognized instruments that have been validated 
or at least field-tested. For example, previous versions of the 
Testing and Counselling Client and Provider Modules were 
used in the Multi-country African Testing and Counselling 
(MATCH) study, coordinated by WHO in four African countries. 
The Disclosure, Support and Stigma Modules in the Client and 
Provider Instruments are based on validated instruments in the 
literature, the field testing experience of the Horizons Program/
Population Council, and recommendations of the USAID-
convened Interagency Stigma and Discrimination Indicators 
Working Group. The Adherence Module includes survey items 
that were part of several research projects recently conducted 
by the French National Agency for Research on AIDS (ANRS, 
Agence Nationale de Recherche sur le Sida), including the VESPA 
survey on HIV-positive individuals in France, the EVAL survey on 
access to antiretroviral therapy in Cameroon and the MANIF2000 
cohort of drug users in France. The Prevention Module is based 
on well recognized instruments that have been widely used 
for population-based HIV surveys, including those conducted 
by the Centers for Disease Control and Prevention and by the 
Demographic and Health Surveys. While the instruments in this 
volume are expected to perform well in the field, it is important 
for researchers to pilot and pre-test them, in order to assess 
whether they are appropriate to the context in which they will 
be used. Improved versions are planned on the basis of further 
use in the field.
6. HOW TO USE THE CHAPTErS AND 
iNSTrUMENTS 
Researchers should engage in a careful preparatory phase of 
work before using the operational research tools presented 
in this volume. They will need to assess the situation being 
investigated, identify the specific problem to be addressed, 
refine the research questions, select the most appropriate study 
design, define the study population(s), design a sampling plan, 
develop field procedures and anticipate how they will analyse 
their data. The chapters in this volume can serve as a basis for 
such discussions, but they are not fully formed research protocols 
or simple recipes to be applied. Other steps, both technical and 
strategic are necessary. Regarding technical content, researchers 
may find it useful to consult the publication entitled, Framework 
for operations and implementation research in health and 
disease control programs, a document designed for Global 
Fund-supported operational research programmes (The Global 
Fund 2008). In addition, WHO encourages researchers to use 
a multi-stakeholder process that involves researchers, national 
programme managers, those who support research and those 
who may use the results. Researchers can find advice about this 
phase of work in the brochure entitled, Conducting operational 
research: strategic and managerial guide for applicants (WHO 
2007). Other preparatory tasks may include the following:
4	Conduct a situation analysis or rapid assessment to summarize 
what is known about the selected topic in the country. This 
will be the basis for formulating the research questions to 
be addressed through operational research, discussing the 
feasibility and trade-offs of different study designs and deciding 
how to design sampling plans and field procedures. 
4	Develop a multi-stakeholder process to commission the 
situation analysis, discuss the results, and foster a common 
approach to the project.
4	Conduct formative research in order to gain information about 
the context and gather locally appropriate terminology.
4	Adapt, translate, field-test and revise the instruments. Include 
country-specific information in the instruments as needed, by 
revising the survey questions and the response categories.
4	Combine these tasks with training members of the research 
team. 
4	Secure ethical clearance for the research and adapt 
the informed consent sections of the instruments (see the 
WHO Research Ethics website for guidance and useful 
documents on ethical clearance at www.who.int/rpc/research_
ethics/en/.) 
The instruments presented in this volume have been extensively 
revised, but they would benefit from further improvements based 
on additional field experiences in different settings. WHO is 
planning to disseminate these tools and encourage their use in 
countries around the world, with the goal of regularly updating, 
improving and possibly expanding them to address other topics 
on which further evidence is needed.
The operational research section of the WHO HIV Department 
website includes electronic versions of the chapters and 
instruments, information about operational research activities, as 
well as links to instruments and email addresses. Researchers who 
use these tools in the field are urged to share their experiences 
and suggestions by going to the following link: http://www.who.
int/hiv/topics/operational/generic.
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DETAILED CONTENTS (OR “MAP”) OF THE CLIENT INSTRUMENT













Sociodemographics All respondents 2.1–2.15 4 4 4
Testing and Counselling Module
HIV testing: filter questions All respondents 3.1–3.3 4 4 4
First HIV test Tested more than once 3.4–3.10 4 4
Most recent test Have tested, ever 3.11–3.23 4 4
Pre-test services and experience Have tested, ever 3.24–3.28 4 4
Consent Have tested, ever 3.29–3.37 4 4
Results of HIV test Have tested, ever 3.38–3.41 4 4
Post-test services Received results 3.42–3.47 4 4
Confidentiality Received results 3.48–3.49 4 4
HIV status Received results 3.50–3.51 4 4
HIV-negative or indeterminate results Results negative or indeterminate 3.52–3.54 4
HIV-positive results HIV+ 3.55–3.56 4
Follow-up care and support HIV+ 3.57–3.63 4
Non-user, attitudes and knowledge Never tested 3.64–3.83 4
General knowledge and attitudes about testing All respondents 3.84–3.94 4 4 4
Disclosure, Support and Stigma Module
Disclosure All respondents 4.1–4.6 4 4 4
Stigma — negative judgements, fear of contact and enacted stigma HIV- and status unknown 4.7–4.14 4 4
Disclosure to others, HIV-positive HIV+ 4.15–4.23 4
Reactions to the disclosure of HIV-positive status HIV+ who disclosed to others 4.24–4.31 4
Experience with stigma and discrimination HIV+ 4.32–4.42 4
Support HIV+ 4.43–4.51 4
Adherence Module
Antiretroviral therapy Receiving ART 5.1–5.6 4
Social support Receiving ART 5.7–5.18 4
Access Receiving ART 5.19–5.22 4
Food security Receiving ART 5.23–5.24 4
Health status Receiving ART 5.25–5.26 4
Perceived side-effects Receiving ART 5.27–5.34 4
Antiretroviral therapy regimen (prescribed doses) Receiving ART 5.35 4
Adherence over the past three days Receiving ART 5.36–5.37 4
Adhering on weekends Receiving ART 5.38–5.39 4
Adherence over the past one month Receiving ART 5.40–5.46 4
Treatment interruption Receiving ART 5.47–5.49 4
Changes in adherence over time Receiving ART 5.50–5.54 4
Prevention Module
Time since diagnosis and ART initiation All HIV+ respondents 6.1–6.3 4
Sexual activity and partners All HIV+ respondents 6.4–6.8 4
Regular partner relationships Sexually active HIV+ 6.9–6.17 4
Non-regular partner relationships Sexually active HIV+ 6.18–6.24 4
Commercial sex Sexually active HIV+ males 6.25–6.29 4
MSM Sexually active HIV+ males 6.30–6.38 4
Concurrency Sexually active HIV+ 6.39 4
Fertility intentions and family planning methods HIV+ with regular partner 6.40–6.44 4
Knowledge and attitudes related to HIV and ART All HIV+ respondents 6.45–6.49 4
Knowledge of people infected with HIV All HIV+ respondents 6.50–6.52 4
Treatment optimism All HIV+ respondents 6.53 4
Alcohol and Drug Module
Alcohol use All HIV+ respondents 7.1–7.2 4
Drug use All HIV+ respondents 7.3–7.12 4





THE UTILIZATION OF HIV TESTING AND 
COUNSELLING
1. bACKGrOUND
1.1 rationale: Why operational research is needed on the 
utilization of Hiv testing and counselling
While there is consensus that knowledge of HIV status should be 
universal and that rapid scale-up of testing is needed at the global 
level, there are debates about the best way to expand testing 
and counselling for HIV. Before treatment became available, the 
possibility that routine testing might lead to adverse consequences 
for individuals seemed to outweigh the public health benefits of 
people knowing their status; consequently, there was little support 
to expand testing other than through client-initiated testing 
(commonly known as Voluntary Counselling and Testing). With 
the availability of treatment, however, the debate has shifted. The 
exceptionalism that characterized public health responses to HIV 
— whereby measures such as routine testing and notification, 
widely practiced for other diseases, were not acceptable for HIV 
— came to be less defensible (Bayer 1991). 
Scaled-up testing has been increasingly advocated both as a 
gateway to treatment and prevention and as a way to “normalize” 
and destigmatize HIV (De Cock and Johnson 1998; De Cock et 
al. 2006; Koo et al. 2006). Research showing that screening for 
HIV is cost-effective (Bozzette 2005) bolstered the position of 
those in favour of expanding testing programmes, and there have 
been calls to incorporate HIV testing and counselling into health 
services such as prenatal care, care for sexually transmitted 
infections (STIs), hospitalization and even general primary care. 
Mathematical models suggest that universal testing followed 
by immediate antiretroviral therapy for all individuals who test 
positive could, in theory, reduce new HIV cases by 95% within 
10 years (Granich et al. 2008). This analysis has re-energized the 
debate about the desirability and feasibility of rapidly scaling up 
testing. It has also highlighted the important research gaps that 
remain about the best way to expand testing and counselling. 
The need for operational research is especially acute in resource-
limited settings where health systems are weak, in low-prevalence 
epidemics where key populations at higher risk are hard to 
reach and in settings where there are particular concerns about 
protecting individual rights as testing becomes routinized.
barriers and facilitators to uptake of testing and counselling
One important research gap is the need to understand more 
about the barriers to the uptake of testing. Around the world, 
the proportion of the population who know their HIV status is 
generally low. In 23 countries that conducted Demographic and 
Health Surveys between 2005 and 2007, the proportion of adult 
women who reported having ever been tested and received their 
results ranged from a low of 2% in Niger to a high of 45% in 
Ukraine; the median was about 11% for women and 10% for 
men, and the figures were slightly lower for countries of sub-
Saharan Africa (9% of women and 8% of men) (WHO 2008). 
Even in more developed countries, such as the United States of 
America, an estimated 20% to 30% of HIV-positive individuals 
are unaware of their serostatus (Glynn and Rhodes 2005). Such 
low utilization of testing and counselling indicates that obstacles 
are considerable, and programmes need a better understanding 
of how to overcome them.
In recent years, numerous projects have tried to expand access 
to both client- and provider-initiated testing, through routine 
testing in prenatal care programmes, home-based testing, free-
standing testing and counselling centres, and national campaigns 
to encourage key populations at higher risk to be tested. The 
diversity of testing models underscores the need for comparative 
analyses of how different policies and programmes operate, how 
they affect the uptake of testing, whether uptake is accelerated 
when treatment becomes available, to what extent stigma acts 
as a barrier to testing and, conversely, whether expanded testing 
increases awareness and reduces stigma. 
Changes in the provision of testing and counselling in resource-
limited settings
Operational research is also needed to examine how different 
models of testing and counselling affect quality of care, health 
outcomes and patient rights. There are wide variations in the 
quality and acceptability of different models of testing and 
counselling around the world. Differences in the availability and 
organization of human and financial resources affect the quality 
of counselling. In resource-limited settings, staffing constraints, 
overloaded facilities and ambivalence among providers often 
result in insufficient counselling. And in many settings, questions 
have been asked about the usefulness of pre-test counselling at 
health facilities, with some observers recommending that it be 
omitted altogether (Koo et al. 2006). It is unclear whether the 
omission of pre-test counselling facilitates testing by eliminating a 
possibly cumbersome practice or whether it diminishes the quality 
of testing services because clients do not receive needed advice 
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or information. Understanding the issues surrounding counselling 
represents a major challenge for the utilization of testing, and 
more evidence is needed to inform guidelines regarding pre- and 
post-test counselling, and to tailor requirements to the particular 
type of testing, whether client- or provider-initiated.
Another research gap is the effect of different models of HIV 
testing and counselling services on sexual risk behaviour, because 
results of studies have not been consistent. On the one hand, 
studies from Kenya, Trinidad and Tobago and the United Republic 
of Tanzania suggested that testing and counselling could have 
a beneficial effect on prevention behaviour among couples who 
were counselled together (The Voluntary HIV-1 Counseling and 
Testing Efficacy Study Group 2000). A meta-analysis of seven 
studies from developing countries published between 2000 and 
2005 found that testing and counselling was associated with a 
significant but moderate decline in unprotected sex (Denison et al. 
2008). Recent research from Uganda suggests that appropriate 
provision of testing and counselling can lead to adopting safer 
behaviour among HIV-positive individuals (Bunnell et al. 2006). 
On the other hand, the meta-analysis mentioned above did not 
find a decline in the number of sex partners among HIV-positive 
individuals or serodiscordant couples, and studies from the 
United States and Zimbabwe have reported that high-risk sex 
increased following rapid HIV testing among men who tested 
negative (Metcalf et al. 2005; Corbett et al. 2007). Thus, the 
evidence supports both caution and optimism about the effect of 
HIV testing on sexual risk behaviour, and more research is needed 
to determine what type of service delivery or package of services 
maximizes the preventive effects of testing and counselling while 
minimizing any potential negative consequences. 
Ethical dimensions of testing and counselling
Last but not least, operational research is needed to address 
the ethical dimensions of HIV testing and counselling practices. 
Recommendations to expand testing raise numerous questions 
about how to protect public health while safeguarding individual 
rights and minimizing the potential stigma, discrimination and 
violence that may follow disclosure of HIV-positive status (Maher 
et al. 2000; UNAIDS Reference Group on HIV/AIDS and Human 
Rights 2005; Rennie and Behets 2006). These questions are 
especially important in settings where HIV is found predominantly 
among marginalized groups, such as sex workers, men who have 
sex with men or injecting drug users. Different models of testing 
may require different strategies to ensure informed consent and 
confidentiality. Research is needed to examine the circumstances 
under which consent is obtained, the extent to which health 
services protect confidentiality in different settings, and whether 
referral, treatment and prevention services are provided after 
clients receive their test results. 
Special attention needs to be directed to fear of stigma and 
discrimination, reportedly one of the main obstacles to the 
use of HIV services. Comparisons across settings can help 
contribute to a better understanding of how stigma varies from 
setting to setting. One important hypothesis to examine relates 
to the influence of the epidemiological context. Stigma and 
discrimination are generally thought to be higher in settings where 
HIV is concentrated among marginalized populations such as 
injecting drug users, sex workers or men who have sex with men. 
Systematic evidence is, however, scant. One comparative study in 
low (Viet Nam) and high prevalence settings (Ethiopia, the United 
Republic of Tanzania and Zambia) found more commonalities 
than differences in the forms and levels of HIV stigma and 
discrimination (Ogden and Nyblade 2005). This underscores the 
need for better documentation of the links between measures of 
stigma and contextual factors. 
1.2 Definitions and terms for different types of testing and 
counselling
The terminology regarding testing has evolved in response to 
changes in policies and in the debates surrounding HIV testing, 
treatment and prevention. In 2007, the World Health Organization 
(WHO) and the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) issued a publication entitled, Guidance for Provider-
Initiated Testing and Counselling in Health Facilities, which 
built on earlier consultations and policy statements (WHO and 
UNAIDS 2007). Just under a year earlier, the Centers for Disease 
Control and Prevention (CDC) had called for routinely testing 
people aged 13 to 64 years and for simplifying the process of 
obtaining consent (CDC 2006). In a number of countries around 
the world, policies have also shifted towards increasing access 
to HIV testing. The 2007 WHO-UNAIDS guidance recommends 
that health care providers advise patients to take an HIV test as a 
standard part of medical care in the following situations: for any 
patients exhibiting signs that may be related to HIV infection; for 
all patients attending health facilities in settings with generalized 
HIV epidemics; and, in settings with low HIV prevalence, for 
patients who are seen at certain types of health facilities, such 
as those providing services for tuberculosis or STIs.
The WHO-UNAIDS guidance document seeks to avoid the 
potential confusion of earlier terminology about “opt-in” and “opt-
out” testing in medical settings. It also aims to prevent possible 
misunderstandings about the word “routine”, which can mean 
offering testing to all patients, but has sometimes been used to 
refer to “routinely” testing without informing patients or seeking 
their consent. The new formulation distinguishes between two 
types of HIV testing, both voluntary: 
4	Client-initiated Hiv testing and counselling (commonly known as 
Voluntary Counselling and Testing or VCT) involves individuals 
actively seeking HIV testing and counselling. Client-initiated 
HIV testing and counselling is conducted in a wide variety of 
settings including health facilities, stand-alone facilities outside 
health institutions, mobile services, community-based settings 
and even people’s homes.
4	Provider-initiated Hiv testing and counselling refers to HIV 
testing and counselling recommended by health care providers 
to patients attending health care facilities. Providers are to 
recommend testing as a standard component of medical 
care when patients exhibit clinical manifestations that might 
result from underlying HIV infection, at health facilities that 
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serve populations where the risks of exposure to HIV infection 
are thought to be considerable and to all patients in high 
prevalence settings. While this type of testing can be routine 
under certain conditions, it should never be mandatory or 
compulsory. 
2. FACTOrS AND PrOGrAMME STrATEGiES
The socio-behavioural factors that influence HIV testing and 
counselling can be assessed by gathering information about 
users, providers, their interactions and the context of those 
interactions. These factors can be grouped as follows: 
4	those related to the demand for testing and counselling, 
including access to services and expectations regarding 
care, risk perceptions, attitudes and behaviours regarding 
disclosure, stigma and gender; 
4	those related to the provision and quality of testing and 
counselling services, including providers’ abilities and 
attitudes, institutional support for providers, the resources 
available in health facilities and interactions around testing 
and counselling;
4	the ethical dimensions of testing and counselling, including 
practices around consent and confidentiality that affect 
patients’ rights, and clients’ attitudes towards consent, 
confidentiality and counselling.
The way in which these factors influence the uptake and quality 
of testing services depends on the type of epidemic. For example, 
in low prevalence settings, obstacles such as access and stigma 
may disproportionately affect key populations at higher risk, such 
as sex workers, men who have sex with men and injecting drug 
users. (While earlier formulations referred to “risk groups”, more 
recent literature refers to “most-at-risk-populations” (MARPs) 
or key populations at higher risk.) Concerns about scaling up 
HIV testing are heightened in settings where such groups are 
marginalized from a legal, economic or social point of view. 
The next chapter in this volume identifies some key operational 
research questions related to HIV stigma and discrimination 
and proposes a tool to collect the data needed to address those 
questions. These materials can be adapted to address the issues 
that are most relevant to the particular populations at higher risk 
in a given setting.
2.1 Factors that influence the demand for Hiv testing and 
counselling 
barriers to access
Studies of health care utilization repeatedly document the 
importance of barriers to access, including distance to a facility, 
cost of services, transportation and time constraints. That these 
factors may influence the decision to seek HIV testing as well as 
the decision to return for results is suggested by global statistics 
showing low use of testing services, especially in resource-limited 
settings. Before rapid tests became widely available, a number of 
studies also showed that a substantial proportion of individuals 
who were tested did not receive their results. In some settings 
where the percentage of the population tested reached 80% to 
90%, the percentage who returned for results hovered around 
60% (Cartoux et al. 1998; Coovadia 2000). Such discrepancies 
have been documented in populations as diverse as clients at STI 
clinics in the United States, male factory workers in Zimbabwe 
and women receiving antenatal care services in Côte d’Ivoire, 
Kenya, South Africa and Zambia (Obermeyer and Osborn 2007). 
Rapid tests, testing at convenient locations and times, as well as 
home-based testing have the potential to reduce these obstacles 
(Wolff et al. 2005), and operational research can document how 
different models for providing testing and counselling may or may 
not increase access and uptake. 
reluctance to acknowledge risk
An important barrier to testing is the reluctance of individuals to 
acknowledge that they are at risk, as documented in a recent 
literature review (Obermeyer and Osborn 2007). In settings 
as diverse as Brazil, Canada, Ethiopia, Thailand, the United 
Kingdom, the United Republic of Tanzania and the United States, 
individuals’ behaviours and risk perceptions are frequently at 
odds with objective measures of risk and with professional 
recommendations (Moatti and Souteyrand 2000; Obermeyer 
2005). The reasons for this discrepancy are complex. Risk 
perceptions are shaped by social and psychological factors; the 
meaning of HIV tests is not simply a matter of information about 
serostatus; and the decision to be tested is tied to relationships, 
emotions and the resources that individuals have for dealing with 
the diagnosis (Antelman et al. 2001; Klitzman and Bayer 2003). 
Research can contribute to uncovering how these complicated 
social factors play out in particular contexts.
Fear of stigma, discrimination and violence
Often the explanation for why people do not take HIV tests or return 
for results is fear. People may fear the life-threatening nature of 
HIV infection, as well as the negative social consequences that 
may accompany a diagnosis, such as rejection by loved ones, loss 
of a job or housing, discrimination and even physical violence. 
Fear of stigma and discrimination is reported to be a major barrier 
to testing in countries as diverse as Botswana, Ethiopia, Ghana, 
India, Indonesia, South Africa, Thailand, Uganda, the United 
Republic of Tanzania, the United States and Zimbabwe (ICRW 
2002; Day et al. 2003; Herek et al. 2003; Hutchinson et al. 2004; 
Kalichman and Simbayi 2003; Weiser et al. 2006). In view of 
such fears, some studies suggest that clients’ perceptions of how 
confidentiality is handled in a health facility may also influence 
their willingness to be tested (Fylkesnes and Siziya 2004). 
Fear of stigma, discrimination and violence also affects the 
decision to disclose HIV status (Yoshioka and Schustack 2001; 
Medley et al. 2004). Rates of partner disclosure by those living 
with HIV vary widely from study to study, but they are generally 
low, typically ranging from one fifth to slightly more than one-half 
(Heyward et al. 1993; Kalichman and Nachimson 1999; Nebie et 
al. 2001; Maman et al. 2003). Solid evidence about the adverse 
consequences of HIV disclosure is still limited; however some 
studies have documented negative reactions from family, friends, 
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employers and the community in 3% to 15% of cases (Gielen 
et al. 2000; Medley et al. 2004; Passin et al. 2006). Evidence 
suggests that discrimination is also a problem in health care 
settings, and some observers have noted that health workers 
may discourage testing if they discriminate against HIV-positive 
patients by treating them differently, using excessive precautions 
or withholding appropriate care (Bishop et al. 2000; Foreman et 
al. 2003; Paxton et al. 2005). 
Few studies have explored the effect of stigma on HIV testing 
using quantifiable measures, and most of these consist of 
cognitive measures (e.g. what percentage of a given population 
hold particular negative beliefs about people living with HIV) 
rather than measures of actual attitudes or behaviours (Parker 
and Aggleton 2003; Deacon et al. 2005; Nyblade 2006). In order 
to have a better understanding of the role of stigma and fear of 
discrimination as a deterrent against testing and as an adverse 
consequence for those who disclose their HIV status, there is a 
need for well designed measures of stigmatizing attitudes and 
behaviours and for better evidence about the extent of stigma 
and discrimination in health facilities and in the broader society. 
To that end, the next chapter in this volume summarizes the 
evidence on HIV stigma and discrimination, formulates possible 
operational research questions and suggests approaches to 
measurement in different settings.
Gender
Gender is another factor that powerfully shapes motivations to 
test and the consequences of testing. Evidence suggests that 
women and men experience different barriers to access, perceive 
risks differently and fear different sorts of discrimination. In some 
settings, men tend to underestimate their risk for HIV infection 
more frequently than do women, despite reporting more high-
risk behaviours (Riess et al. 2001). Women often have more 
fears about testing than men (Sahlu et al. 1999; Stein and 
Nyamathi 2000). The negative consequences of disclosure are 
more frequently documented for women, and several studies 
show that it is among pregnant women that fears of abuse as 
a possible consequence of testing positive for HIV are most 
manifest (Temmerman et al. 1995; Coulibaly et al. 1998; Gielen 
et al. 2000; Gielen et al. 2001; Maman et al. 2001a; Maman et 
al. 2001b; Manzi et al. 2005). 
Women’s decisions about testing may be complicated by their 
plans to have children, their husbands’ opinions and considerations 
such as breastfeeding (Aka-Dago-Akribi et al. 1999; Sahlu et al. 
1999; de Paoli et al. 2004). A recent comparative study in four 
Asian countries (India, Indonesia, the Philippines and Thailand) 
found that men were more likely than women to be tested 
because they had HIV-related symptoms, whereas women were 
more likely to test because their partner tested positive (Paxton et 
al. 2005). In these and other settings, women may become aware 
of risks only once their partner is ill, and they may not suspect that 
they were exposed until then (Obermeyer et al. Forthcoming). For 
all these reasons it is important for operational research studies 
to conduct gender analyses of behaviours and attitudes related 
to HIV testing.
2.2 Factors that influence the uptake and quality of testing 
and counselling services 
How testing and counselling are provided: different models
New approaches to the delivery of testing services are showing 
some success. Rapid tests at convenient times (such as night-
time) and locations (such as homes, workplaces, health facilities 
and mobile clinics) have increased the numbers of people who 
have been tested as well as the proportion of clients who receive 
their results (Day et al. 2004; Mahto and Higgins 2004; Mermin et 
al. 2005; Corbett et al. 2006; Rotheram-Borus et al. 2006). Home-
based testing and counselling in four Ugandan villages increased 
acceptance of testing from 10% to 46%, eliminated differences 
in acceptance between women and men and appeared to be 
an effective way to reach family members (Wolff et al. 2005). 
Interviews and focus group discussions suggested that home 
testing avoided some of the inconvenience, fears and costs of 
facility-based tests. National level data from Uganda confirmed 
the high acceptability of giving blood and receiving results in the 
course of a household survey; and a qualitative study conducted 
in parallel with that Demographic and Health Survey did not 
uncover major problems of understanding or coercion (Yoder 
et al. 2006). The vast majority of respondents consented to give 
blood samples for HIV tests and to receive the results at home. A 
Cochrane review confirms that home-based testing does increase 
uptake (Bateganya et al 2007).
Integrating provider-initiated testing in clinical settings appears 
to overcome many of the barriers that hindered earlier efforts 
and has been found to have unexpectedly high acceptability. 
In settings around the world, utilization increases rapidly when 
testing is routinely offered during antenatal care (Simpson et al. 
1998; Etiebet et al. 2004). Pregnant women are often inclined 
to be tested if they think it can benefit their baby (Simpson et al. 
1998; Jha et al. 2003; Etiebet et al. 2004; Perez et al. 2006). 
Routine provider-initiated (“opt-out”) testing seems to be more 
acceptable and to cause less anxiety for women than “opt-in 
testing”, perhaps because this approach is ostensibly done for the 
benefit of the baby, does not make assumptions about women’s 
behaviours and hence does not threaten women’s sense of moral 
worth (Sobo 1994; Boyd et al. 1999; Etiebet et al. 2004).
Similar positive attitudes towards provider-initiated HIV testing 
have been observed outside of prenatal care as well. When 
hospitalized patients in the United States were asked how they 
would feel about provider-initiated HIV testing, most responded 
positively (Greenwald 2006). More than two thirds of clients 
at a tuberculosis clinic in Kinshasa, the Democratic Republic 
of the Congo, preferred provider-initiated (“opt-out”) testing 
(whereby the test would be performed unless they declined), 
notwithstanding common perceptions that it would be difficult to 
decline the test (Corneli et al. 2008). The acceptance of testing 
increased considerably after providers began to recommend 
the test routinely in postpartum wards in Botswana (Thior et 
al. 2007), paediatric wards in Uganda (Nawavvu et al. 2006) 
and Zambia (Kankasa et al. 2006), maternity wards in Uganda 
(Homsy et al. 2006) and STI clinics in Uganda (Semafumu and 
Ngabirano 2006).
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Such results are encouraging, and they highlight the different 
factors that can facilitate the uptake of HIV testing. Operational 
research is needed to examine whether they will be replicated 
as expansion continues (Glick 2005) and to establish whether 
the successes observed in well-resourced projects can also be 
achieved in resource-limited settings.
 
Communication strategies and provider-client interactions
Research on programmes provides useful insights into the types 
of communication strategies that may increase the uptake of 
HIV testing at the individual and community levels. Operational 
research can also help to evaluate the messages that accompany 
the offer of an HIV test and the communication of results. 
When providers personalize information about the risks of HIV 
and frame messages in terms of personal gains and losses, 
clients are more likely to decide to be tested, consistent with 
research showing that individuals need to translate abstract 
notions of risk into personal terms (Kalichman and Coley 1995; 
Apanovitch et al. 2003; Tambashe et al. 2003). Because of 
the implications of a positive diagnosis, health workers need to 
take great care when communicating about the test, in order to 
avoid misunderstandings and to convey the seriousness of the 
diagnosis without leading the patient to despair. 
Other aspects of the provider-client interactions influence clients’ 
decision to have an HIV test and to comply with recommendations. 
These include providers’ background characteristics (such 
as gender or ethnic group), attitudes, perseverance and the 
extent to which providers are able to gain clients’ trust and 
build good rapport (Marelich et al. 2002; Worthington and 
Myers 2003; Anderson et al. 2005; Passin et al. 2006; Zimba 
et al. 2006). Operational research can evaluate the extent to 
which strategies effectively communicate key messages about 
HIV test results, treatment and prevention. At the community 
level, media campaigns have been effective in increasing the 
uptake of testing in some settings. For example, Burkina Faso 
documented a relatively high rate of testing (at a time when 
treatment availability was limited), thanks in large part to yearly 
national campaigns designed to reach the general population 
as well as key populations at higher risk (Some 2003; PAMAC 
2004). Comparisons of different approaches can help identify 
the elements that contribute to improved communication 
strategies. 
Health care facility resources and the role of counselling
Although numerous guidelines have been formulated to improve 
testing and counselling, there are great variations in the quality 
of these services around the world. When health systems are 
weak and resources are stretched too thin, providers may have 
insufficient training, time or space to provide high quality testing or 
counselling. Studies from both developed and developing country 
settings have found widespread problems such as insufficient 
time for counselling (Ruiz et al. 2002), inadequate information 
and poor quality counselling for clients from less-privileged 
segments of society (Brown 1993). Even when a facility has a 
policy of routinely recommending HIV testing and counselling, 
providers may not consistently follow the policy (Coovadia 2000). 
In some settings, providers decide to whom to recommend 
a test based on subjective criteria such as their assumptions 
about which clients can handle bad news (Gibney et al. 1999). 
Operational research can help identify those dysfunctions that 
may be amenable to improvements.
Until recently, pre- and post-test counselling have always been 
considered integral and essential parts of HIV testing. Pre-test 
counselling is typically designed to give information and obtain 
consent, while post-test counselling may address additional 
information, encourage preventive behaviours and include 
referrals to care depending on the test results. What exactly is 
conducted under the heading of “counselling” varies a great deal, 
however, and evidence is needed about the effect of different 
approaches on the uptake of testing and access to follow-up care. 
Resource constraints and a lack of evidence about usefulness 
have eroded support for pre-test counselling in some settings, in 
favour of concentrating those resources on post-test counselling 
(Koo et al. 2006). The implications of this type of change are 
unclear, and operational research is needed to explore the 
consequences of different approaches to counselling. 
 
Providers and the institutional support they receive
In recent years, attention has increasingly been drawn to the 
implications of the serious human resource crisis in many settings 
for HIV service provision (WHO 2006). It is important to distinguish 
different types of providers in terms of their background and 
training, including whether they are specialists or laypersons who 
received training, for example as counsellors. When it comes to 
HIV testing, much is expected of providers “on the front lines”, 
but little is known about how they cope. In addition to practical 
difficulties, resource constraints and the emotional dimension 
of their work on HIV, providers may have justifiable concerns 
about occupational exposure to HIV, particularly where protective 
measures are inadequate or are difficult to implement. There 
are also considerable variations in the availability and quality 
of the services that health providers can access for their own 
needs. For example, some research suggests that providers 
need access to self-testing for HIV or other special services to 
encourage them to learn their own HIV status in a confidential 
and non-stigmatizing way (Bongololo et al. 2007). In terms of 
the quality of HIV services, while some health care providers are 
effective, others may feel ambivalent about testing or may have 
doubts about their ability to provide care (Brouwer et al. 2000; 
Sherr et al. 2001; Sliep et al. 2001; de Paoli et al. 2002; Chi et 
al. 2004). Operational research is needed to gain insights into 
testing and counselling from the perspective of providers and to 
understand the training, time, resources and institutional support 
that providers need. The question of how to support providers so 
that they gain clients’ trust is an important one, and answers are 
likely to refer to both the capacity of the providers themselves and 
the functioning of the health system in which they operate.
2.3 Factors that influence the ethical dimensions of 
testing and counselling 
Attitudes, practices and policies regarding consent
The expansion of testing has heightened awareness of the 
ethical dimensions of testing and counselling and the need to 
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protect the rights of those who are tested (Rennie and Behets 
2006); however, evidence about the magnitude of the problem 
of testing without consent is limited. There are indications that 
nearly everywhere, clients are sometimes tested without their 
knowledge; this was documented a decade ago in Europe, 
where an estimated 10% to 20% of respondents had been tested 
without their knowledge (McCann and Wadsworth 1991; McCann 
1992; Schrooten et al. 2001). Similarly, India’s private hospitals 
are said to conduct mandatory testing on prospective surgical 
patients, and some studies have documented that many Indian 
patients are tested without consent (Elamon 2005; Sheikh et al. 
2005). More information is needed about the extent to which 
guidelines about consent are in fact implemented. Even when 
given a choice, clients or survey respondents do not always feel 
free to decline the offer of an HIV test. They may accept an HIV 
test because they are used to agreeing to health professionals’ 
requests, because they think that agreeing to a test will improve 
the care they receive, because they do not think they can decline, 
or because they have a diffuse sense that refusing would have 
adverse consequences (Williams et al. 1997; Abdool Karim et al. 
1998; Leach et al. 1999; Mitchell et al. 2002; Yoder and Konate 
2002; Weiser et al. 2006). It is important to document problems 
related to obtaining consent in different settings, to assess the 
extent to which client perceptions and expectations influence 
their willingness to be tested, and to explore which forms of 
consent are appropriate in different settings.
Attitudes, practices and policies regarding confidentiality
Confidentiality is another important ethical dimension of testing 
and counselling that has implications both for patients’ rights and 
for the public health objective of increasing utilization of testing, 
since perceptions of how confidentiality is handled may influence 
clients’ willingness to be tested (Fylkesnes and Siziya 2004). Laws, 
governmental policies, institutional policies, available resources 
and prevailing attitudes are all factors that influence the extent 
to which health workers protect the confidentiality of medical 
information in health care settings. Policies differ considerably 
across settings and are rapidly changing. In Singapore, for 
example, the Health Ministry made it mandatory to inform the 
spouses of HIV patients several years ago (Anon. 2005); and the 
possibility of allowing health workers to disclose patients’ status 
to their partners has been discussed in some African countries, 
where it has been referred to as “beneficial disclosure” (National 
AIDS and STD Control Programme of Kenya 2004; Jack 2005).
Evidence suggests that lack of confidentiality can be a serious 
problem in many settings. In a comparative study in India, 
Indonesia, the Philippines and Thailand, 34% of HIV-positive 
respondents reported that health care workers had revealed their 
HIV status to someone else without their consent (Paxton et al. 
2005). In some settings, health workers do not have a positive 
view of patient confidentiality and may even see confidentiality as 
a way to protect irresponsible individuals (Seidel 1996). Patient 
confidentiality is often compromised by established practices in 
health services and by differential regard for clients’ rights (Brown 
1993; Sherr et al. 2001).
More information is needed about how changes in the provision 
of testing and counselling and in the process of securing consent 
and ensuring confidentiality will affect utilization, quality of care, 
and the protection of clients. Empirical evidence on practices 
and attitudes in multiple settings can be drawn from reports by 
clients of their experiences, providers’ views and reports of what 
happens at health facilities, as well as observations of the process 
of testing and counselling at health facilities. This evidence can 
help identify innovative ways to expand testing while protecting 
patient rights. 
3. rESEArCH ObjECTivES AND QUESTiONS
It may be useful to organize the many operational research 
questions that can be formulated regarding HIV testing and 
counselling into three groups: those dealing with users of services, 
those dealing with providers and those related to practices around 
testing (see box on next page).
Other operational research questions may also be relevant in 
different settings. For example, researchers may want to explore 
whether the use of testing and counselling influences preventive 
behaviour, such as levels of unprotected sex, and questions 
may be formulated to examine the links between HIV testing 
and high- or low-risk behaviours. Researchers may also need 
to refine their research questions depending on the nature of 
the epidemic in a given setting. For example, in concentrated 
epidemics, researchers may need to focus on lines of enquiry 
most relevant for understanding the implications of scaling up 
testing and counselling for key populations at higher risk, such 
as sex workers or men who have sex with men.
4. METHODS
4.1 Study populations and study design
In this volume, we have opted for simple study designs that make 
it possible to investigate these research questions mostly by 
gathering cross-sectional data at health facilities. The instruments 
presented in this volume combine quantifiable, closed-ended 
questions with open-ended questions to elicit information about 
attitudes, perceptions and experiences. Information is to be 
collected in the following ways:
4	conducting surveys to interview users and non-users of testing 
services to compare the factors that influence the uptake of 
testing (e.g. gender and stigma) and to find out about the 
conditions of testing and the consequences of disclosure; 
and 
4	interviewing providers and key informants to obtain information 
about policies, programmes and services related to testing, 
counselling, confidentiality and consent. 
The two core instruments presented in this volume are: a 
Client Instrument that can be administered at health facilities 
and a Provider Instrument, to be used with health personnel 
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OPERATIONAL RESEARCH qUESTIONS AbOUT TESTINg AND COUNSELLINg (T&C)
1. Understand motivations, behaviours and experiences related to testing and disclosure: 
n How do users and non-users of T&C services compare in terms of sociodemographic variables such as residence, gender, 
socioeconomic status and profession? 
n To what extent are knowledge of HIV, attitudes about risks, access to services and other social factors associated with testing 
behaviour?
n What experiences have clients had with regard to different models of testing?
n What factors are associated with clients’ perceptions, motivations and behaviours related to T&C and obtaining results?
n What are patterns and levels of disclosure? What factors influence disclosure?
n How do users and non-users of T&C services compare in terms of attitudes about and fear of stigma and discrimination? 
n To what extent is the availability of testing, counselling and treatment associated with stigma and discrimination?
n Using a gender analysis, how and to what degree does gender influence the T&C experience, disclosure behaviours and consequences? 
How and to what degree does gender influence attitudes about, fear of, and actual experiences of stigma and discrimination?
2. Analyse the provision of appropriate services around testing and counselling:
n How are T&C services delivered in different facilities and settings, and how do these different models vary in terms of uptake, clients’ 
responses to the offer of testing and disclosure behaviours? 
n What are providers’ experiences with T&C in relation to their own life trajectories, training, work conditions, perceptions, motivations 
and satisfaction?
n To what extent do health workers fear exposure to HIV in the course of their work, what protective measures do they have access to, and 
what is their experience with accidental exposure?
n What interactions and communication patterns occur between providers and clients in the context of T&C? To what degree are providers 
able to gain the trust of clients?
n How do different service delivery models link clients to needed care, treatment and support services after testing?
3. Investigate the ethical dimensions of testing and counselling:
n What are practices related to informed consent and confidentiality in different facilities and settings?
n Which practices related to informed consent and confidentiality result in better outcomes regarding clients’ satisfaction with their 
decision and the protection of their privacy?
n What constraints and challenges do providers face in relation to informed consent and confidentiality?
n What are the experiences, attitudes, priorities and concerns of clients with regard to consent and confidentiality; and how do these 
attitudes and beliefs influence their choices with respect to testing, counselling and disclosure?
n To what degree do ethical practices (or perceptions about the ethical practices in a given facility) influence clients’ responses to T&C 
services?
and counsellors at health facilities. We recommend collecting 
additional qualitative data through in-depth interviews with people 
living with HIV, focus group discussions with individuals who 
have not been tested and key informants who are knowledgeable 
about programmes and health facilities, and by developing an 
observation checklist to be used at health facilities.
5. vAriAbLES AND SUrvEy QUESTiONS 
The Testing and Counselling Modules of the Client and Provider 
Instruments in this volume were originally developed as part of 
the MATCH (Multi-site African Testing and Counselling for HIV) 
study that addressed some of the research questions formulated 
in this chapter. Earlier versions of the instruments were used in 
Burkina Faso, Kenya, Malawi and Uganda, and they were revised 
prior to being included here. 
5.1 variables and survey questions to ask among clients
Several modules of the Client Instrument in this volume gather 
data to address the research questions identified in this chapter, 
including the following:
4	the Sociodemographic Module, which collects data on variables 
such as gender, socioeconomic status, ethnicity, residence 
(etc.) that are clearly important for understanding uptake and 
other dimensions of testing; 
4	the Testing and Counselling Module, which gathers data on 
variables related to service provision and factors that influence 
the uptake, quality and ethics of testing and counselling; 
and
4	the Disclosure, Support and Stigma Module, which collects 
data on levels of stigma, patterns of disclosure and reactions 
of friends, family and community members.
Even though the Disclosure, Support and Stigma Module of 
the Client Instrument is formatted as a separate module, it 
was designed to be used together with the Testing and 
Counselling Module to ensure that operational research on 
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testing and counselling consider the consequences of disclosure. 
Researchers who wish to study the effects of testing and 
counselling (or a combination of testing and other services) on 
sexual behaviour may want to use the Testing and Counselling 
Module in combination with the Prevention Module to compare 
those who have been tested with those who have not. This would 
require some adaptation of the questionnaire, however, since 
the Prevention Module was designed for respondents who have 
already tested positive for HIV.
The particular survey questions that respondents are asked in 
the Client Instrument will depend on whether or not respondents 
have had an HIV test, and if so, whether they have tested positive 
for HIV and are willing to disclose their status to the interviewer. 
The instrument is designed with skip patterns to accommodate 
these different possibilities, and the table below lists key variables 
or topics included in the Client Instrument.
The Testing and Counselling Modules of the Client and Provider 
Instruments in this volume were designed to consider the 
possibility that some HIV testing may occur outside a health 
facility, in settings such as people’s homes and workplaces. 
Researchers who are specifically interested in testing in such 
settings may want to adapt the questionnaire by adding some 
questionnaire items and deleting others. Types of questions that 
may be explored in relation to home testing include:
4	whether respondents were informed about providers coming 
to their home in advance; how they were informed and what 
they were told about testing;
4	who and how many health workers came to the home to offer 
and conduct testing and counselling; 
4	whether other household members were offered testing and 
whether they accepted;
4	whether respondents discussed the test with other household 
members before and after the test;
4	whether respondents were influenced by other household 
members;
4	the extent to which respondents perceived that providers 
who came to the home were able to protect their privacy and 
confidentiality; and
4	what respondents think about being offering HIV testing and 
counselling in the home.
An instrument to be used during an HIV testing campaign would 
likely have to be considerably shortened to make it possible to 
recruit participants. In that case, it may be necessary to omit all 
the open-ended questions and to add a few questions to ask 
vARIAbLES AND TOPICS RELATED TO TESTINg AND COUNSELLINg, DISCLOSURE, 
SUPPORT AND STIgMA IN THE CLIENT INSTRUMENT
TESTINg AND COUNSELLINg MODULE DISCLOSURE, SUPPORT AND STIgMA MODULE
For respondents who have never been tested:
n Knowledge and attitudes about HIV
n Knowledge of anyone who has been tested, of someone living 
with HIV
n Knowledge of testing facilities 
n Access to testing facility
n Attitudes towards HIV testing, confidentiality of results and 
disclosure
n Ever experienced an offer of a test
n Reasons for not having/refusing a test
For all respondents who have been tested, regardless of HIV 
status:
n HIV test (first and most recent), circumstances and reasons for 
testing
n Experience of testing, counselling and consent
n Attitudes about consent, confidentiality and disclosure 
n Obtaining results and post-test care: experience and attitudes
For respondents who inform interviewer that they are HIV 
negative:
n Reaction to test results
For all respondents who inform interviewer about their HIV-
positive status: 
n Follow-up received, including medication and care
n Reaction to test results
For respondents who are HIV-negative, do not know their status 
or decline to reveal their status to an interviewer:
n Stigmatizing attitudes
n Personal knowledge of people who have experienced HIV stigma, 
discrimination or violence
n Knowledge of support groups for people with HIV
For respondents who disclose their HIV-positive status to an 
interviewer:
n Disclosure behaviours and motivations
n Reactions to disclosure by family and friends
n Experiences of stigma and discrimination by others
n Negative self-perception and behaviours (internalized stigma)
n Discrimination in health care settings
n Participation in support groups, social services or other 
assistance programmes
n Perceptions about negative and positive consequences of 
learning HIV status
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clients and providers how testing during a campaign compares 
to testing at other times, in terms of the factors that encourage 
or hinder people from testing.
5.2 variables and survey questions in the Provider 
instrument
Similar to the Client Instrument, there are several modules in the 
Provider Instrument that are important for operational research 
on Testing and Counselling, including the Sociodemographic and 
Work Module, the Testing and Counselling Module, the Fear of 
Infection and Work Safety Module, and the Disclosure, Support 
and Stigma Module. The box to the right presents an overview 
of key variables addressed in these modules of the Provider 
Instrument.
vARIAbLES RELEvANT TO TESTINg 
AND COUNSELLINg IN THE PROvIDER 
INSTRUMENT
n Demographics 
n Work background (work history, job function, education, 
training and work routine)








n Fear of infection
n Practices related to implemention of universal precautions
n Accidental exposure and action taken
n Observation of discrimination at health facilities
n Stigma
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CHAPTER 2
HIV STIGMA AND DISCRIMINATION
1. bACKGrOUND
1.1 rationale: why operational research is needed on Hiv 
stigma and discrimination
Since the early days of the AIDS epidemic, stigma and discrimination 
have been recognized as obstacles to HIV prevention, treatment 
and support (UNAIDS 2007). The classic definition of stigma 
refers to “an attribute that is deeply discrediting”, which results 
in the reduction of a person or group “from a whole and usual 
person to a tainted, discounted one” (Goffman 1963). It has been 
argued that stigma may also reflect and reinforce existing power 
structures, social control, mistreatment and marginalization of 
disenfranchised groups (Parker et al. 2002; Parker and Aggleton 
2003; Link and Phelan 2006). HIV discrimination may include 
behaviour that is harmful, intolerant, underrating or prejudicial 
against people living with HIV and their families and is often called 
“enacted stigma” to underscore the idea that discrimination can 
be considered a manifestation of stigma, or at least, an end result 
(Jacoby 1994; Nyblade and MacQuarrie 2006).
Operational research is needed to address a number of key 
research gaps regarding HIV stigma and discrimination. First, 
there is a need for better definitions and quantitative measures. 
Such measures could be used to gather comparable data about 
patterns and levels across different geographic, sociodemographic 
and cultural settings. Standardized, reliable measures could also 
facilitate baseline data collection for programmes designed 
to reduce stigma and discrimination. There is also a need for 
qualitative research to explore the experiences and perspectives 
of those living with HIV and to assess the extent to which they 
encounter stigma and discrimination on the one hand, and 
support, tolerance and compassion on the other. 
Quantitative and qualitative research can be used to help 
programme managers and policy-makers formulate more 
effective interventions to improve the health, wellbeing and 
quality of life of individuals living with HIV in various cultural and 
demographic contexts. Measuring stigma can also help alert 
programme implementers to negative unintended consequences 
of interventions. For example, highlighting certain risk behaviours 
as ‘bad’ may exacerbate stigma against those who engage in 
those behaviours; and tailoring HIV prevention messages for 
populations that are already marginalized — such as sex workers 
or men who have sex with men — may increase discrimination 
against those groups (Nyblade and MacQuarrie 2006). 
While many studies have suggested that stigma and discrimination 
are obstacles to HIV prevention, testing and treatment, their precise 
role is poorly understood. As noted in the previous chapter, there 
are particular research gaps about the role of stigma that have 
important implications for testing and counselling policies. For 
example, proponents of provider-initiated testing and counselling 
argue that these policies may decrease levels of HIV stigma by 
normalizing testing and increasing access to treatment (Weiser et 
al. 2006; Wynia 2006). On the other hand, many opponents fear 
that provider-initiated testing may jeopardize the confidentiality 
and voluntariness of testing, with negative consequences for 
vulnerable populations (Kippax 2006; Wynia 2006). Future 
research has the potential to clarify some of these questions as 
well as to indicate whether stigma may become less pervasive 
in a society once health-preserving treatments are accessible to 
most people living with HIV (Castro and Farmer 2005).
In the remainder of this chapter, we summarize information on the 
manifestations and correlates of HIV stigma and discrimination, 
the implications for HIV prevention, testing and treatment, and the 
measures and methods used to study stigma and discrimination. 
The chapter also formulates a number of operational research 
questions and proposes a set of easily administered measures 
of stigma.
1.2 Manifestations and patterns of Hiv stigma and 
discrimination
The precise nature of HIV stigma and discrimination varies 
depending on the setting; the local context influences which 
attitudes and behaviours are most salient and the extent to which 
certain groups are stigmatized, such as female sex workers, 
men who have sex with men, injecting drug users or migrant 
populations. However, evidence suggests that stigma has some 
broadly similar manifestations around the world, across a wide 
range of cultural, environmental and sociodemographic settings 
(Aggleton et al. 2005; Nyblade and MacQuarrie 2006). The 
following are commonly documented expressions of stigma:
4	Fear of casual transmission and refusal of contact. In 
some settings, HIV stigma manifests as an exaggerated or 
unreasonable fear of contracting HIV through casual or non-
invasive contact (Nyblade et al. 2005). This can lead to a 
desire to avoid casual or social contact with those living with 
HIV in schools, marketplaces, workplaces and health care 
settings.
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4Negative judgements about people living with Hiv. Value 
judgements about the moral conduct or the worth of people 
living with HIV may express blame, accusation and moral 
condemnation (Policy Project 2003; Ogden and Nyblade 
2005; Pulerwitz et al. 2008). 
4internalized stigma, also called self-stigma. Internalized stigma 
is a frequently described experience of individuals living with 
HIV and may include feelings of shame, hopelessness and 
guilt, social withdrawal and a tendency not to use existing 
treatment or support services (Thomas et al. 2005; Brouard 
and Wills 2006; Simbayi et al. 2007a). Evidence suggests that 
internalized stigma may aggravate psychiatric morbidity among 
people living with HIV (Van Brakel 2006).
 
4	Discrimination (‘enacted stigma’) in family or community 
settings. Enacted stigma may include a broad range of harmful 
actions against individuals who are known or suspected of 
having HIV or AIDS (and/or their families), including rejection, 
exclusion from social or ritual events, gossip, ridicule, verbal 
harassment, abandonment, divorce, expulsion from their 
homes, removal of economic support, denial of property and, 
in some cases, physical violence (Aggleton et al. 2005; Varas-
Diaz et al. 2005; Maman et al. 2006). 
4	Discrimination (‘enacted stigma’) in institutional settings. 
Enacted stigma may occur within institutions such as 
workplaces, health-care services, prisons and schools. 
Increased attention to the possibility of stigma in medical 
settings has resulted in studies documenting discrimination 
against people living with or suspected of having HIV in 
health care settings in a variety of contexts (Bharat et al. 
2001; Mahendra et al. 2007; Oanh et al. 2008), including 
withholding medical care, providing inadequate care and 
implementing discriminatory policies regarding patient consent 
and confidentiality (Aggleton et al. 2005). 
4	Discriminatory laws and policies. In many countries, legal 
systems have limited the rights of HIV-positive individuals, 
either explicitly or by failing to enforce the laws or protect 
human rights. For example, in some settings, laws or policies 
have restricted the right of people living with HIV to travel 
or migrate internationally, to receive comprehensive care, 
to consent freely to testing or even to engage in certain 
professions (Aggleton et al. 2005). In other settings, laws are 
not enforced, and legal systems do not protect the rights of 
people living with HIV.
4	Compounded or “layered” stigma. Compounded stigma refers 
to HIV-related stigma that mutually reinforces and legitimates 
pre-existing stigma and discrimination against marginalized 
groups such as sex workers, injecting drug users or men who 
have sex with men (Parker et al. 2002). Increased levels of 
stigma and discrimination may also be directed against HIV-
positive individuals who contribute relatively few economic or 
social resources to their communities (Reidpath et al. 2005). 
When HIV comes to be associated with certain marginalized 
groups, individuals living with HIV may be afraid to disclose 
their HIV status because they think others may suspect 
them of being homosexual (in the case of men) or accuse 
them of being promiscuous or sex workers (in the case of 
women) (Parker et al. 2002). In concentrated epidemics, 
marginalized groups at higher risk of HIV may come to be 
seen as responsible for the spread of HIV, and members of the 
‘general’ public may be less likely to perceive themselves to 
be at risk, even when they engage in high-risk behaviours.
2. FACTOrS AND PrOGrAMME STrATEGiES
Stigma can be considered both a determinant of health-related 
outcomes and an outcome in itself. For programmes that aim 
to achieve other health behaviours or outcomes, operational 
research may explore stigma as a factor that may influence the 
programme’s intended key outcomes. For example, a study 
may investigate the influence of stigma on uptake of testing and 
counselling or adherence to treatment. In other cases, operational 
research may focus on stigma reduction as a central programme 
objective. For example, a programme might aim to increase HIV-
related knowledge as a means of reducing unreasonable fear 
of contagion and the resulting avoidance of people living with 
HIV. This section summarizes what is known about the extent to 
which stigma and discrimination influence HIV testing, treatment 
and disclosure, the key factors that are correlated with stigma 
and the main programme strategies that have been developed 
to address stigma. 
2.1 The influence of stigma on Hiv testing, treatment, 
disclosure and prevention
Utilization of Hiv testing and counselling
As noted in the previous chapter, numerous qualitative and 
quantitative studies from around the world have found that stigma 
and fear of discrimination are associated with a reluctance to 
seek HIV testing and counselling or with client anxiety at testing 
sites (Fortenberry et al. 2002; Herek et al. 2003; Kalichman et al. 
2005; Hutchinson and Mahlalela 2006; Iyaniwura 2006; Weiser 
et al. 2006; Obermeyer and Osborn 2007). For example, studies 
from South Africa and Botswana found that individuals who had 
not been tested for HIV reported significantly higher levels of 
stigmatizing attitudes than those who had been tested (Kalichman 
and Simbayi 2003; Hutchinson and Mahlalela 2006; Weiser et 
al. 2006). A study of truck drivers in Brazil found that the odds of 
having had an HIV test decreased by 4% for every unit increase 
on a 15-item scale measuring stigmatizing attitudes (Pulerwitz et 
al. 2008). And, fear of the negative consequences of a positive 
test result, such as social rejection, abandonment and violence, 
has been reported as an impediment to testing in settings around 
the world — particularly by women (Maher et al. 2000; Maman 
et al. 2001; UNAIDS 2007; Sambisa 2008).
Care and treatment-seeking
Research has documented that fear of stigma and discrimination 
represents an important barrier to treatment and care (Heijnders 
and van der Meij 2006). Fear of stigma and discrimination 
has been identified as a barrier to adherence to antiretroviral 
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therapy in research from settings such as China, South Africa 
and the United States (Nachega et al. 2006; Peretti-Watel et al. 
2006; Rintamaki et al. 2006; Weiser et al. 2003). For example, 
respondents receiving HIV treatment in urban areas of the United 
States reported skipping doses because they were afraid that 
their status would become known to family or friends (Rao et 
al. 2007). In South Africa, adherence was considerably lower 
among respondents who reported fear of being stigmatized by 
their sexual partner (Nachega et al. 2004; Rintamaki et al. 2006). 
This evidence suggests that studies on adherence to antiretroviral 
therapy should include variables related to fear of stigma and 
should ask respondents whether they feel a need to take their 
medications in secret. Questions on these factors are, therefore, 
included in the Adherence Module of the Client Instrument in 
this volume.
Hiv status disclosure and prevention
Evidence suggests that stigma and fear of discrimination may 
represent an important barrier to certain types of harm-reduction 
behaviours (Chen et al. 2005; Liu et al. 2006) and may decrease 
willingness to disclose HIV status (Clark et al. 2003; Ford et al. 
2004; Dias et al. 2006; Liu et al. 2006; Simbayi et al. 2007b; 
Pulerwitz et al. 2008). Stigma and fear of discrimination have 
frequently been studied as factors that influence levels of HIV 
disclosure. In fact, disclosure has often been considered a proxy 
measure for stigma, as people living with HIV are more likely to 
disclose their status to those around them in low-stigma contexts, 
where they expect fewer negative consequences (Nyblade and 
MacQuarrie 2006). As noted in the previous chapter, rates of 
partner disclosure by people who know that they are HIV-positive 
vary widely, but these rates are often low (Heyward et al. 1993; 
Kalichman and Nachimson 1999; Nebie et al. 2001; Maman et 
al. 2003). For example, a review of 15 studies from sub-Saharan 
Africa and Asia found that rates of partner disclosure by women 
who tested positive for HIV ranged from 17% to 80%, with the 
lowest rates reported by women tested in prenatal care settings 
(Medley et al. 2004). Lowering fears of stigma, discrimination and 
violence might reduce barriers to HIV disclosure and contribute 
to better HIV prevention.
2.2 Factors that influence levels and patterns of Hiv 
stigma and discrimination
Studies from diverse settings have found a number of factors 
to be correlated with levels and patterns of HIV stigma and 
discrimination at the individual, community and societal level. 
At the individual level, research has often explored the link 
between HIV knowledge and stigma, including understanding 
the modes of transmission or personally knowing someone with 
HIV. Evidence suggests that personal contact with individuals 
living with HIV is associated with fewer stigmatizing beliefs 
(Bermingham and Kippax 1998; Schiff et al. 2003). Some 
studies have found evidence that lower knowledge about HIV 
transmission is correlated with greater stigmatizing attitudes 
against people living with HIV (Dias et al. 2006; Kalichman 
et al. 2006); however, other evidence suggests that a better 
understanding of HIV transmission alone does not necessarily 
reduce the fear of casual contact (Herek et al. 2002). One study 
found that higher levels of medical knowledge about HIV among 
health workers was correlated with higher levels of stigmatizing 
attitudes and discriminatory behaviours; researchers suggested 
that job seniority may have allowed highly educated senior 
doctors to avoid caring for HIV-positive patients by delegating 
these tasks to junior level staff (Deacon and Boulle 2007). Thus, 
operational research should be mindful of the complex links 
between knowledge and stigma. 
Sociodemographic characteristics such as gender, ethnicity, 
class, profession and identification with a marginalized group (e.g. 
sex workers, injecting drug users, men who have sex with men or 
mobile populations) also influence stigma (Parker et al. 2002). In 
many settings, women’s lower socioeconomic status appears to 
increase their vulnerability to discrimination following a positive 
HIV test. In locations as diverse as Ethiopia, India, Mozambique, 
the United Republic of Tanzania, Viet Nam and Zambia, studies 
have found that women experience more HIV-related stigma than 
men (ICRW 2006). A study from the United Republic of Tanzania 
found that nearly two thirds of women with HIV reported stigma 
in the past year, compared with less than half of men. Women 
may also be more vulnerable than men to extreme consequences 
such as physical violence by intimate partners (UNAIDS 2007). 
Qualitative research in settings such as Côte d’Ivoire found that 
women’s reluctance to be tested or to disclose their HIV status 
was closely related to their perceived socioeconomic vulnerability 
(Coulibaly et al. 1998). 
At the community or societal level, HIV stigma and discrimination 
may be influenced by factors such as the prevalence and 
patterns of HIV in the area, the degree of competition and conflict 
over scarce resources, the availability of testing and treatment 
services, the extent of programmatic activity that has taken 
place and the levels of pre-existing stigma against marginalized 
groups (Parker et al. 2002; Parker and Aggleton 2003; Castro 
and Farmer 2005; Deacon et al. 2005; Reidpath et al. 2005). For 
example, as mentioned earlier, it is possible that compounded 
stigma may be especially prevalent in settings where the epidemic 
is concentrated among marginalized groups. 
Laws and policies are other institutional or societal level factors 
that can influence levels of discrimination against those living 
with HIV, including policies that restrict their right to travel, to opt 
out of testing, to give consent before partner notification and to 
obtain certain kinds of medical treatment (Parker et al. 2002). 
An analysis of HIV stigma and discrimination in Latin American 
health care settings concluded that institutional policies have 
discriminated against people living with HIV indirectly by failing 
to ensure that staff are adequately trained to diagnose and treat 
HIV and AIDS and directly through policies that explicitly refuse 
care for AIDS patients (Foreman et al. 2003). A study from 
Beijing, China, found that hospital and government policies were 
the major source of discriminatory interactions between health 
workers and people living with HIV (Yang et al. 2005). 
2.3 Programme strategies to reduce stigma and 
discrimination
Many programmes have aimed to reduce HIV stigma and 
discrimination and to increase support for people living with 
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HIV (Aggleton et al. 2005). The following section summarizes 
some common strategies drawn from reviews of published and 
unpublished programme evaluations (Brown et al. 2001; Brown 
et al. 2003; Heijnders and van der Meij 2006), including a 2005 
UNAID review of “successful” programmes (Aggleton et al. 
2005). Except where noted, many of these strategies have not 
been rigorously evaluated, so while some show promise, more 
research is needed before we can say which approaches are 
effective in different settings.
Counselling and peer support groups 
Counselling has been used to resolve issues with family and 
community members and to teach coping skills. Interventions 
studies suggest that counselling may reduce anxiety and distress, 
reduce negative consequences of disclosure and improve attitudes 
towards people living with HIV (Brown et al. 2003). Counselling 
and “mediated disclosure” can be used to help clients who test 
positive for HIV consider how to disclose their status to partners 
and others in a way that reduces risks to their physical safety and 
emotional wellbeing (Maman et al. 2006). Peer support groups 
have also been shown to benefit people living with HIV in terms 
of self-esteem, coping skills and social integration (Heijnders and 
van der Meij 2006). 
 
Mobilizing care and support among family and community 
members
Numerous initiatives have included efforts to recruit, mobilize, 
support and/or train family members, local volunteers, traditional 
healers, religious leaders and other community members to 
support and care for HIV-positive individuals and their families 
(Aggleton et al. 2005). In addition to improving health outcomes, 
these initiatives generally aim to increase emotional and material 
support for HIV-positive individuals, to improve their quality of life, 
to reduce stigma and discrimination and, in some cases, to improve 
adherence to HIV treatment. A qualitative evaluation from Haiti 
suggests that recruiting community members as peer supporters 
(accompagnateurs) to provide psychosocial support has lowered 
the levels of social isolation and stigma experienced by individuals 
living with HIV (Behforouz et al. 2004; Mukherjee et al. 2006).
Education, awareness raising and advocacy
Many initiatives have aimed to raise awareness, dispel 
misconceptions and reduce negative attitudes about people 
living with HIV at the national level, the community level or 
among key populations at higher risk for HIV. Strategies include 
mass media, participatory education, mobilizing community 
leaders and empowering individuals living with HIV to lead 
advocacy or awareness activities. Some initiatives focus narrowly 
on HIV or AIDS, while others address broader issues such as 
pre-existing stigma against marginalized populations at higher 
risk, issues related to sexuality or tolerance and compassion 
towards those affected by HIV (Aggleton et al. 2005). Information-
based strategies seem to be most effective at reducing stigma 
when combined with other approaches (Brown et al. 2001); 
for example, simply increasing knowledge about transmission 
has not always reduced concern about contracting HIV through 
casual contact (Herek et al. 2002). 
Antidiscrimination measures within institutions
Institutional initiatives have included efforts to reduce HIV stigma 
and discrimination within health facilities, workplaces, schools, 
prisons, etc. (Aggleton et al. 2005). For example, health sector 
initiatives have included efforts to increase access to integrated, 
comprehensive HIV care, antidiscrimination health care policies, 
and sensitizing and training health workers to change attitudes 
and reduce discriminatory behaviour within health care facilities 
(Aggleton et al. 2005).
Human rights, legal and policy interventions 
There have been many efforts to address HIV discrimination by 
promoting and protecting the human (and legal) rights of people 
living with HIV, including the rights to freedom of movement, 
property, employment, education, consent, confidentiality and 
access to services. Specific strategies have included mobilizing 
communities to demand respect for the rights of those living 
with HIV, advocating for legal and policy reforms (e.g. at the 
government level) and efforts to enforce laws or seek redress in 
the courts when rights are violated (Parker and Aggleton 2003; 
Aggleton et al. 2005; Heijnders and van der Meij 2006). 
3. rESEArCH QUESTiONS
The box on the following page presents selected operational 
research questions that are likely to be relevant in multiple 
settings. The first, third and fifth questions are descriptive, 
designed to assess the extent and manifestations of stigma 
among different study populations. Two questions concern the 
association between stigma and health behaviours, including 
HIV testing and disclosure. Questions six and seven explore the 
factors that influence health workers’ fears about HIV exposure. 
The final research question addresses the effectiveness of 
strategies to reduce stigma, though it may require instruments 
and study designs such as comparison groups that go beyond 
the materials provided in this volume.
4. METHODS
4.1 Study populations and study design
This chapter highlights three key populations (listed below) for 
the operational research on stigma and discrimination proposed 
in this volume. Triangulating data by including more than one of 
these populations as participants in a study is a way to get a more 
complete picture of stigma from multiple perspectives. 
4	People living with Hiv. Research among people living with 
HIV can provide insights into the patterns and levels of HIV 
stigma and discrimination, the patterns and consequences 
of disclosure and the ways in which experiences and fears 
of stigma and discrimination influence testing, treatment, 
adherence, disclosure and prevention. 
4	Health care workers. Research among health care workers can 
give an indication of the forms of stigma and discrimination 
and barriers to appropriate care that people living HIV may 
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OPERATIONAL RESEARCH qUESTIONS AbOUT HIv STIgMA AND DISCRIMINATION
1. To what extent do people living with HIV experience different forms of stigma, discrimination and (conversely) support in different 
contexts (family, community and health facilities)? 
2. To what degree are levels of stigma or fear of discrimination associated with HIV disclosure? 
 
3 What are the forms and levels of HIV stigma and discrimination as reported or observed by the general population (specific populations 
to be determined by the research project)?
4.  To what extent does stigma or fear of discrimination influence service utilization, including HIV testing and treatment; and to what 
extent do the availability and utilization of HIV testing and treatment influence levels of stigma in a community?
 If data on stigma and on testing can be collected at more than one point in time, then the question may also be formulated as follows: 
To what extent does the normalization or routinization of HIV testing and treatment decrease the extent of stigma towards people living 
with HIV?
5. What are the levels and patterns of stigma and discrimination in health care settings as reported or observed by health care workers?
6. To what extent do health care workers fear occupational exposure to HIV through invasive procedures (e.g. needle sticks) on the one 
hand, and through casual or non-invasive contact on the other?
7 To what extent are health workers fears of transmission associated with the levels of protective measures in the facility?
8. For interventions research studies: What combination of interventions leads to reduced levels of stigma and discrimination on the one 
hand, and increased support for people living with HIV on the other?
face within the health care system, as well as the challenges 
that health care workers face as they carry out their work and 
try to help patients protect their health and wellbeing.
4	‘General’ populations and key populations at higher risk of Hiv. 
The Client Instrument in this volume is designed to collect 
information on HIV stigma and discrimination among general 
users of health facilities (specifically, those who have not 
been tested for HIV, those who do not wish to reveal their HIV 
status and those who have tested negative). With adaptation, 
this portion of the instrument can be used to gather data on 
levels of stigma among a general population of adults living in 
a particular community. 
Depending on the local epidemiology of HIV, portions of the 
instrument can also be adapted for use among key populations 
at higher risk of HIV (e.g. sex workers, men who have sex with 
men or injecting drug users). 
When designing HIV studies and programmes, several issues 
related to sampling methodology and ethics should be considered. 
First, HIV-positive individuals who are particularly at risk of stigma 
and discrimination may be marginalized and hard-to-reach. The 
sampling strategy for studies among people living with HIV may 
need to go beyond members of organizations such as support 
groups, in order to avoid sampling only those people who are 
well integrated into known social networks (UNAIDS 2005). To 
reach individuals who are not easily accessible, special data 
collection strategies can be used, such as Respondent Driven 
Sampling, a variant of “snow-ball” sampling (Abdul-Quader et 
al. 2006; Johnston et al. 2008). However, it should be noted that 
programmes that are designed for key populations at higher risk 
must take special care not to stigmatize these populations further 
by drawing attention to their particular HIV-related vulnerability.
Studies that explore discrimination and violence against 
individuals living with HIV should also consider the ethical 
guidelines developed by WHO for researching violence against 
women (Watts et al. 2001). While these guidelines were not 
developed for research on HIV stigma, they are relevant for 
research that asks women direct questions about physical or 
emotional violence, as the Client Instrument does in this volume. 
In particular, researchers should ensure that: 
4	Field procedures should ensure privacy during interviews and 
the confidentiality of respondents’ answers. 
4	All interviewers who ask respondents about violence should 
receive training in HIV stigma and violence against women. 
Interviewers gathering this type of data among marginalized, 
most-at-risk populations, such as sex workers or men who 
have sex with men, may also need training about the nature 
and patterns of pre-existing stigma and discrimination against 
those groups.
4	Researchers should choose a study design that minimizes 
distress for respondents as a result of participating in the 
research. One important strategy is to offer respondents 
information about local sources of violence-related services 
and support at the end of each interview, if any such resources 
are available. 
4	In settings where these resources do not exist, researchers 
should consider developing some short-term support 
mechanisms by collaborating with local health care or social 
services organizations.
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 4. 2 Measuring HIV stigma and discrimination
Nyblade and MacQuarrie (2006) and other have synthesized 
what is known about how to operationalize various “domains” 
or dimensions of stigma and discrimination for different study 
populations. The box below lists examples of ways to measure 
stigma among people living with HIV, health workers and the 
general population.
If the study design requires a summary measure of stigma, 
multiple survey items can be combined into an index whereby 
responses for each item are summed together to form a stigma 
score. Using a greater number of items is generally preferable, 
since each item may capture important nuances in attitudes and 
behaviours. Alternatively, the items can be analysed individually to 
explore specific elements of stigma (Berger et al. 2001). It should 
be noted, however, that while most survey items presented in this 
chapter are framed negatively (e.g. “HIV is a punishment for bad 
behaviour”), items can be framed positively (e.g. “clients who are 
sex workers deserve to receive the same level and quality of care 
as other clients”). During the creation of an index, researchers 
need to code items in the same direction, so that both negatively 
and positively framed items have higher scores for more highly 
stigmatizing responses.
As noted earlier, the manifestations of stigma and discrimination 
are often very context specific, and it is essential to pre-test 
instruments in order to ensure that selected items are appropriate 
and relevant for the local context. Comparative research across 
different contexts can also help identify core quantitative measures 
that can be used across diverse settings.
Most items presented in this chapter are designed to be used 
with Likert-style response categories. Studies using these 
items generally used 3- or 5-point response categories. Five-
point response categories may include: strongly agree, agree, 
undecided/unsure, disagree and strongly disagree. Using five 
options enhances the variability of responses and permits greater 
understanding of the nuances of stigma. However, five options can 
be difficult to respond to, particularly for respondents with limited 
literacy skills. A 3-point scale — including: agree, undecided/
unsure and disagree — permits more variability and nuance than 
a simple yes/no response; it is more intuitive for respondents and 
easier to administer than the 5-point option.
Finally, this chapter focuses on quantitative measures of stigma 
and discrimination that may have the potential to provide 
comparable data on across different cultural and epidemiological 
contexts. However, purely quantitative studies can miss rich 
and nuanced information that can be tapped using qualitative 
methods. Triangulating quantitative and qualitative data can 
provide a more complete picture of stigma in a particular setting, 
as well as explain behaviours or detect unintended consequences 
of programmes. Both the Client and the Provider Instruments 
in this volume contain open-ended questions. In particular, the 
Client Instrument contains a detailed set of open-ended questions 
about disclosure behaviours and outcomes. Researchers may 
want to administer these questions to a subset of respondents, 
depending on the study objectives and resources available.
The types of research questions that can be answered through 
qualitative research are different from those that are typically 
answered using quantitative methods. Rather than measuring 
wAyS TO OPERATIONALIzE THE ExTENT OF STIgMA FOR DIFFERENT STUDy POPULATIONS
Extent of stigma and discrimination feared or experienced by HIV-positive individuals
What proportion of people living with HIV:
n report internalized stigma such as feelings of shame because of their HIV-positive status;
n report experiencing stigma, discrimination or violence; 
n express fear of stigma and discrimination if their HIV status were suspected or known, including fear of being seen using HIV services; 
fear of disclosing their status or fear of having their status disclosed by others;
n (or conversely) report support, compassion or tolerance from family members, members of social network, health care workers, 
community at large, etc.; or
n express fear of stigma or discrimination because they belong to a marginalized group (compounded stigma).
Extent of fears, discriminatory behaviours or negative attitudes expressed or observed by health workers
What proportion of health workers:
n express fear of contracting HIV in the course of their work through casual contact;
n express negative judgements against those living with HIV; 
n report discrimination against HIV-positive patients at health facilities; or
n express negative judgements about key marginalized populations at higher risk of HIV (compounded stigma).
Extent of stigma and discrimination among general populations
What proportion of the general population:
n have adequate knowledge about HIV transmission and treatment;
n fear contagion through casual contact with people living with HIV;
n report knowing an HIV-positive individual who has experienced stigma or discrimination;
n (or conversely) report instances of support or tolerance towards people living with HIV; or
n express negative judgements about key marginalized populations at higher risk of HIV (compounded stigma).
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the extent of stigma or testing hypotheses about the amount 
of change associated with a programme strategy, qualitative 
methods are well suited to gather contextual information, to 
explore the expressions of stigma that occur in a community and 
to investigate the reasons why certain quantitative results were 
found. To answer these questions, a study might use an array 
of methods such as observation, life stories, in-depth interviews 
and document reviews, in addition to more common qualitative 
methods such as focus groups or key informant interviews.
5. vAriAbLES AND SUrvEy QUESTiONS
This section describes variables and survey questions that can be 
included in research instruments on stigma and discrimination. 
It is based on a review of the literature, the comments of experts 
on drafts of this document, and the recommendations and field-
testing experience of the Interagency Stigma and Discrimination 
Indicators Working Group convened by the United States Agency 
for International Development (USAID) (Nyblade et al. 2005; 
Nyblade and MacQuarrie 2006; Nyblade 2006). The items 
recommended here have been chosen in part because they are 
believed to be least context-specific. Additional ways to formulate 
survey items to measure different dimensions of stigma can be 
found in the references cited in this chapter. 
Some but not all survey items discussed in this chapter are 
included in the Client or Provider Instruments in this volume — 
where multiple items were available, we have selected the most 
frequently recommended and/or the least context-specific. Most 
stigma-related items in the Client Instrument can be found in 
the Disclosure, Support and Stigma Module, but some appear 
in the Testing and Counselling Module (such as those related 
to forced testing). Similarly in the Provider Instrument, stigma-
related items may appear in the Disclosure, Support and Stigma 
Module, but some appear in the Fear of Infection and Work Safety 
Module. As a result, researchers who want to investigate HIV 
stigma without using the full Testing and Counselling Module of 
the Client Instrument may need to extract some of the stigma-
related questions from the Testing and Counselling Module for 
that purpose.
a. Attitudes about and patterns of Hiv disclosure
Many studies (along with the instruments in this volume) have 
included survey questions to explore attitudes, behaviours 
and experiences related to HIV disclosure, including whether 
individuals living with HIV have revealed their status and the role 
of health workers in that process (Medley et al. 2004; Maman 
et al. 2006).
b. Fear of contagion through casual contact
Fear of HIV transmission through casual contact has been 
measured in many quantitative and qualitative studies. Survey 
items gauging this dimension of stigma typically measure the 
percentage of respondents who express fear of contracting HIV 
from casual contact with HIV-positive individuals or a desire to 
avoid casual contact. One way to formulate this type of question 
is: “Would you rather not touch someone with HIV (or AIDS) 
because you are scared of infection?” Frequently recommended 
questionnaire items for surveys among the general population 
have included:
Would you fear getting Hiv from any of the following:
4	hugging a person with Hiv or AiDS?
4	working next to a person with Hiv or AiDS?
4	sitting next to a person with Hiv or AiDS?
4	caring for a person with Hiv or AiDS?
4	buying fresh vegetables or meat from a shopkeeper 
with Hiv or AiDS?
Among individuals living with HIV, survey questions can be used 
to explore their personal perceptions of inappropriate fears of 
contagion among the people with whom they interact, as in the 
following: 
Please indicate whether you agree or disagree with each of 
the following statements:
4	Some people are afraid to touch me once they know i 
have Hiv.
4	Some people have physically backed away from me 
once they learned i have Hiv. 
c. Fear of contagion through occupational exposure (for health 
workers)
In some situations, a research goal may be to understand the 
prevalence of reasonable fears of HIV transmission by health 
workers as compared with inappropriate fears of contagion 
through non-invasive contact. For example, items exploring this 
issue may include:
How concerned would you feel about getting Hiv if you had 
to do any of the following. Would you feel very concerned, 
somewhat concerned or not at all concerned if you had to:
4	take the blood pressure of a person with Hiv or AiDS?
4	change the bed linens of a person with Hiv or AiDS?
4	change the clothes of a person with Hiv or AiDS?
4	give an injection to a person with Hiv or AiDS?
4	dress the wound of a person with Hiv or AiDS?
Researchers can assess health workers’ access to and use of 
protective measures and the proportion of health workers who 
express fear of contracting HIV because of inadequate safeguards 
in the facility. The Provider Instrument in this volume contains 
kEy vARIAbLES RELATED TO STIgMA AND 
DISCRIMINATION
a. Attitudes and behaviours related to disclosure
b. Fear of contagion through casual contact
c. Fear of contagion through occupational exposure (for 
health workers)
d. Negative judgements about people living with HIV/
Internalized stigma
e. Discrimination and violence (’enacted stigma’)
f. Compounded/layered stigma
g. Community norms 
h. Attitudes about human rights (e.g. forced testing)
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detailed questions about these topics. The extent of institutional 
safeguards available to health workers may be measured by 
determining what proportion of health workers report access to 
universal precautions, cases of accidental exposure to HIV in their 
workplace and access to HIV post exposure prophylaxis in cases 
of accidental exposure.
d. Negative judgements about people with Hiv/internalized 
stigma
Many quantitative studies have measured the percentage 
of a population who express negative judgements or blame 
towards people living with HIV. This dimension has been less 
frequently measured than the fear of casual contact (Nyblade 
and MacQuarrie 2006), but a variety of survey items have been 
developed for use among the general population, health care 
workers and individuals living with HIV. These measures focus 
on whether respondents view HIV infection as a punishment, 
whether respondents believe that individuals living with HIV 
deserve blame for getting infected, and whether respondents 
believe that HIV infection brings shame upon those living with 
HIV or those associated with them.
e. Discrimination and violence (enacted stigma)
Among the general population, discrimination can be measured 
by gathering data on the proportion of respondents who personally 
know someone who has experienced HIV-related discrimination. 
To minimize under-reporting, discrimination is usually measured 
by asking respondents to report ‘observed’ stigma rather their 
own discriminatory behaviours. To reduce the possibility that 
respondents might refer to the same incidents reported by the 
media or well-known throughout a community, it is recommended 
that survey items ask about whether the respondent personally 
knows anyone who has experienced HIV-related discrimination. 
The reference period should be relatively long (most commonly 
12 months), since observable acts of discrimination may not 
occur with great frequency. Surveys of the general population 
can use the following recommended items for measuring 
discrimination:
Do you personally know someone who has had the following 
happen to him/her in the past 12 months because they had 
Hiv or AiDS? Someone you know was: 
4	excluded from social events?
4	abandoned by a spouse or partner?
4	abandoned by other family members?
4	verbally abused or ridiculed?
4	physically assaulted?
4	fired from work or lost their job?
4	expelled from their home?
4	had property taken away?
4	denied health services?
For research among people living with HIV, personal experiences 
of discrimination can be measured using the same sub-items, 
prefaced with the question: “In the last 12 months, has any of 
the following happened to you when you thought it was because 
of your HIV status?”
For research among health workers, survey questions can ask 
whether respondents have observed colleagues treating patients 
with HIV differently than other patients. Because of concerns about 
social desirability bias and reporting personal discrimination, it 
is preferable to ask providers about observed discrimination 
among colleagues rather than their own discriminatory behaviour. 
Examples of items measuring discrimination in health care 
settings include:
in the past 12 months, have you seen or observed the 
following happen in this health facility because a client was 
known to have or was suspected of having Hiv or AiDS? 
4	Staff seemed uncomfortable with a client because of 
his or her Hiv status?
4	Health worker gossiped about a client’s status?
4	Client was ignored or received less care than other 
clients?
4	Client was denied care that he or she should have 
received?
4	Staff used excessive precautions with clients 
suspected of having Hiv or AiDS (e.g. used latex gloves 
for non-invasive procedures)? 
4	Client was treated with disrespect or abused?
When measuring discrimination in health care settings, it can 
be difficult to determine whether discrimination results from 
institutional policies or from personal attitudes and choices on 
the part of individuals, but this is an important factor to consider. 
Qualitative methods are useful for investigating the institutional 
policy environment in which discrimination takes place. 
f. Compounded or layered Stigma
Compounded stigma is complex and difficult to measure 
accurately through survey questions. Examples of traditional 
survey items that have been used to gain a preliminary sense of 
layered stigma include:
negative judgements about people living with hiv: 
examples of survey items
For measuring attitudes among the general population
indicate your agreement or disagreement with each statement:
4 aids is a punishment for bad behaviour.
4 people with aids deserve blame for getting the disease.
4 people with aids should be ashamed of themselves.
For measuring experiences of negative judgements by individuals living 
with HIV
indicate your agreement or disagreement with each statement:
4 some people act as though it is my fault i have hiv.
4 people say i deserve it for things that i have done.
4 people seem uncomfortable being around me once they learn i 
have hiv. 
For measuring self-directed negative judgement by individuals living 
with HIV (internalized stigma)
indicate your agreement or disagreement with each statement:
4 i sometimes feel worthless because i am hiv positive. 
4 i feel guilty because i have hiv.
in the past 12 months, have you ever found yourself avoiding or 
isolating yourself from friends or family because of your hiv status?
HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH
26
HIV STIGMA AND DISCRIMINATION
27
indicate your agreement or disagreement with each 
statement (specific most-at-risk-populations can be 
substituted depending on local contexts): 
4	Female sex workers are to blame for spreading Hiv.
4	Clients who are sex workers deserve to receive the 
same level and quality of care as other clients when 
they need health care.
4	Homosexuality is the cause of Hiv.
4	injecting drug users are to blame for spreading Hiv in 
this community.
4	Men who have sex with other men are to blame for 
spreading Hiv in this community.
One challenge, however, is that in concentrated epidemics, 
the belief that HIV prevalence is highest among a particular 
marginalized group may be a component of compounded stigma 
as well as an accurate reflection of the epidemiology of HIV in 
that setting. There are no well-established quantitative measures 
of compounded stigma, but some researchers have suggested 
that a factorial design can be used to disentangle different layers 
of stigma. For example, researchers can ask the same question 
about men and women living with HIV, or about different groups 
such as sex workers on the one hand and injecting drug users on 
the other (Reidpath and Chan 2005; Chan et al. 2007). Properly 
disentangling compounded or layered stigma may require 
detailed instruments and analyses across different variables that 
are beyond the scope of the instruments in this volume. Whether 
it is worth investing in such research depends on the particular 
context. Qualitative research can also be used to explore these 
connections and may yield useful insights. 
g. Measures of social norms and anticipated reactions
A number of studies of stigma include questions about what 
attitudes and behaviours respondents would expect from others 
(usually other people in their community), but these have not 
been included in the Client Instrument in this volume. Some 
researchers think that such questions provide a measure of social 
norms and of inclinations to stigmatize, while others are sceptical 
of hypothetical questions about undefined “communities”. The 
extent to which hypothetical questions are useful may depend on 
the context and study objectives. Anticipated reactions to people 
living with HIV can be measured by whether respondents agree 
or disagree that:
in my community (to be defined): 
4	A man who has Hiv would be abandoned by his partner. 
4	A woman who has Hiv would be abandoned by her 
partner. 
4	A person living with Hiv would be neglected.
4	A person living with Hiv would be avoided.
4	A person living with Hiv would be verbally abused or 
teased.
4	A person living with Hiv would not be allowed to go to 
work/school.
 
Another variable that has been used to measure stigma is the 
percentage of people reporting willingness to care for or to help 
people living with HIV or AIDS. The survey questions can be 
phrased as: “Imagine that you find out that one of your friends is 
HIV-positive. Would you still be friends with him or her?” Another 
possible survey question is: “If a member of your family became 
sick with AIDS, would you be willing to care for her or him?”
h. Attitudes about the rights of individuals living with Hiv
Some studies have sought to explore opinions among the general 
population or among health workers about human rights issues 
that affect people living with HIV. For example, this dimension 
can be gauged by asking respondents about their support for 
specific rights of people living with HIV such as:
indicate your agreement or disagreement with each 
statement: 
4	i think patients with AiDS do not have the right to the 
same quality of care as other patients.
4	Women with Hiv should be prevented from having 
children.
4	People suspected of having Hiv should be required to 
be tested.
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CHAPTER 3
ADHERENCE TO ANTIRETROVIRAL THERAPY
1. bACKGrOUND
1.1 rationale: Why research is needed on adherence to 
antiretroviral therapy
Adherence, “the extent to which a person’s behaviour – taking 
medication, following a diet and/or executing lifestyle changes, 
corresponds with agreed recommendations from a health care 
provider” (WHO 2003), is a crucial element for scaling up HIV 
treatment. Concerns about poor adherence have sometimes been 
used to deny or delay access to care to those populations that 
were expected to be less adherent to antiretroviral therapy, even 
though it has been shown that “pre-treatment” information is less 
predictive of adherence than a patient’s experience with treatment 
(Spire et al. 2002). Recent evidence shows that good adherence 
can be achieved in low-resource settings (Fong et al. 2003; WHO 
2003; Mills et al. 2006), but it is clear that maintaining high 
adherence over time requires adequate support and remains 
one of the greatest challenges in both high- and low-resource 
settings (Gill et al. 2005). 
Suboptimal adherence to antiretroviral therapy has implications at 
both an individual and a population level. For individual patients, 
studies have demonstrated that adherence to antiretroviral therapy, 
however it is measured (unannounced pill count, electronic 
monitoring systems or self-reports), is a strong predictor of HIV 
outcomes, as measured by virological response (Bangsberg et 
al. 2000; Paterson et al. 2000; Nieuwkerk et al. 2001a), CD4 
lymphocyte count (Paterson et al. 2000; Carrieri et al. 2003; 
Wood et al. 2004), progression to AIDS (Bangsberg et al. 2001; 
Bouhnik et al. 2005), hospitalization (Paterson et al. 2000) and 
death (Hogg et al. 2000; Garcia de Olalla et al. 2002; Wood et al. 
2003). The clinical implications of adherence are most evident in 
the initial months of treatment (Carrieri et al. 2003), supporting an 
argument that research and interventions should pay particular 
attention to the factors that influence adherence in the earliest 
phase of treatment.
One of the greatest public health concerns about poor adherence 
to antiretroviral therapy is that suboptimal adherence — including 
taking fewer pills than prescribed, taking doses at the wrong time 
and interrupting treatment — may lead to the development of 
drug-resistant viral strains. Drug resistance can render first-line 
drugs ineffective for patients and require second-line drugs that 
are more complex, more costly and carry greater side-effects 
and risks of drug interactions (Clotet 2004; Negredo et al. 2006). 
Among small cohorts of patients in African populations, drug-
resistant strains of HIV have emerged in both treatment-naive and 
treatment-experienced patients (Adje-Toure et al. 2003; Koizumi 
et al. 2006). The risk of drug resistant strains as a consequence 
of suboptimal adherence has also been documented in settings 
such as China (Han et al. 2005) and India (Hira et al. 2004; 
Balakrishnan et al. 2005).
Many research gaps remain about the best way to monitor 
patterns of adherence over time (Bangsberg 2008), the levels 
and patterns of adherence in different settings, and the factors 
and circumstances that lead to suboptimal adherence, including 
treatment interruption. Addressing these research gaps may 
contribute to improved clinical care and better informed 
HIV treatment policies and programmes. Researchers may 
also want to explore the links between poor adherence and 
treatment abandonment, though a full exploration of treatment 
discontinuation and retention issues is beyond the scope of the 
instruments in this volume.
1.2 Definitions: how researchers define adherence to 
antiretroviral therapy
Nonadherence to treatment can occur when a patient takes 
medication at the wrong time, skips doses, interrupts treatment 
for a period of time or abandons treatment altogether (WHO 
2003). It should be noted that this chapter concentrates on 
medication taking — the first element of the WHO definition of 
adherence. Diet and lifestyle changes, the other two elements, 
are addressed to some degree in this volume (e.g. a few questions 
about food security in the Client Instrument and a detailed 
discussion of sexual behaviour in the Prevention chapter); 
however, researchers who want to explore these elements in more 
depth may need additional data collection tools, depending on 
the purpose of the research.
Adherence to antiretroviral therapy has been measured in different 
ways, most commonly as a percentage of prescribed pills taken or 
picked up on time over a given period of time (Bangsberg 2008). 
Adherence can be analysed as a continuous variable (Gross et 
al. 2006) or as a categorical variable that distinguishes ‘optimal’ 
from ‘suboptimal’ adherence (high from moderate from low, good 
from poor). While some researchers have reported adherence 
as a percentage of prescribed pills taken over a given period 
HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH
30
ADHERENCE TO ANTIRETROVIRAL THERAPY
31
of time, suboptimal adherence can also be defined to include 
patterns such as mistimed doses (Liu et al. 2006), treatment 
interruptions (Raffa et al. 2006) and treatment discontinuation 
(Bangsberg 2008).
Studies have traditionally used a threshold of 95% or more 
to distinguish between optimal and suboptimal adherence 
(Ammassari et al. 2001; Cederfjall et al. 2002; da Silveira et al. 
2003; Weber et al. 2004; Chesney 2006; Simoni et al. 2006a). 
This threshold was based on evidence that near perfect adherence 
(95% or more) to existing regimens was needed to achieve 
optimal patient outcomes, such as a lower risk of virological 
failure, increased CD4 lymphocyte count and lower hospitalization 
rates, especially during the early phase of treatment (Paterson 
et al. 2000; Arnsten et al. 2001; Carrieri et al. 2003). Similarly, 
several studies found a skewed bell-shaped relationship between 
drug-resistance and adherence to single protease inhibitor 
therapy, whereby moderate to high (80% - 90%) adherence 
was associated with the greatest risk of drug-resistant mutations 
(Bangsberg et al. 2004; Harrigan et al. 2005; King et al. 2005). 
However, this body of research was largely based on non-boosted 
protease inhibitors which are being rendered obsolete by newer 
treatment regimens (Bangsberg et al. 2007).
Recent studies suggest that ritonavir-boosted protease inhibitors 
(and to a lesser degree non-nucleoside reverse transcriptase 
inhibitors — NNRTIs) appear to be more ‘forgiving’ than older 
regimens, as they achieve viral suppression even in the face 
of moderate adherence of 70% or more (Weiser et al. 2004; 
Maggiolo et al. 2005; Bangsberg et al. 2007; Wainberg et 
al. 2007). Evidence also suggests that the adherence level 
needed to prevent drug resistance depends on the length of 
time on treatment, the variant of the virus and the host genome 
(Bangsberg et al. 2007). For example, near perfect adherence 
(95–100%) appears to be especially important during the first 
four to six months of treatment, before viral suppression has 
been achieved, regardless of regimen (Wainberg et al. 2007). 
Therefore, researchers agree that maximum adherence remains 
a worthy goal for all regimens, though it may be difficult to attain 
for many patients (Gardner et al. 2006; Wainberg et al. 2007). 
It is also important to note that average adherence levels are only 
one dimension of optimal adherence. Research indicates that 
patterns of adherence over time, including selective drug taking, 
treatment interruptions and treatment discontinuation may be just 
as important as average adherence levels (Gardner et al. 2005; 
Bangsberg 2008). Treatment interruption — missing pills for at least 
48 consecutive hours — appears to have a considerable influence 
on virological response (Raffa et al. 2006) and is a major risk factor 
for resistance to nevirapine and probably to other NNRTIs (Oyugi 
et al. 2007). Studies indicate that treatment modification and 
discontinuation of at least part of their drug regimen occurs among 
a substantial proportion of patients, with serious consequences for 
health outcomes and drug resistance (Ahdieh Grant et al. 2001; 
Bangsberg et al. 2007; Kiguba et al. 2007).
In sum, while clinical practice is changing rapidly, the evidence 
underscores the importance of high levels of adherence, including 
the lack of treatment interruptions, for the successful scale-up and 
sustainability of antiretroviral therapy programmes. Researchers 
continue to recognize a threshold of 95% or higher as ‘optimal’ 
adherence, especially during the early phase of treatment. After 
six months, researchers may want to measure adherence as a 
continuous variable, especially for more forgiving regimens, rather 
than using rigid distinctions between adherent and nonadherent 
patients. Ideally, researchers will also use operational definitions 
of adherence that include patterns of medication taking (e.g. 
interruptions) in addition to overall averages, as well as measures 
that monitor adherence levels over time.
1.3 Patterns and levels of adherence
Adherence to treatment of chronic diseases in general tends 
to be around 60% (WHO 2003). Studies that have examined 
adherence to antiretroviral therapy around the world have found 
a wide range of levels. A meta-analysis of published studies found 
that 55% of North American patients (range: 26%-86%) and 
77% of African patients (range: 30%-100%) achieved ‘optimal’ 
adherence to antiretroviral therapy (Mills et al. 2006). These 
observed proportions of patients who achieve high adherence are 
similar to the findings of longitudinal studies of French patients 
initiating antiretroviral therapy (Carrieri et al. 2001). Observed 
adherence levels have been slightly higher in the Italian and the 
Swiss cohorts (70%) (Ammassari et al. 2004; Glass et al. 2006) 
and lower in the Dutch cohort (47%) (Nieuwkerk et al. 2001b). 
Evidence indicates that high adherence to antiretroviral therapy 
may be difficult to sustain over time. For example, a study 
from France followed patients over three years and found that 
only 26% of patients were able to maintain consistently “high” 
adherence throughout the follow-up period (Carrieri et al. 
2003). Similar findings have been reported from other settings 
(Bangsberg 2008). As patients’ trajectories of adherence may 
diminish over time, it is crucial for clinicians to monitor adherence 
levels and intervene before the virus has an opportunity to 
rebound (Bangsberg 2008). It is also important for researchers 
to learn more about why — and to what degree — individual and 
contextual factors influence adherence to antiretroviral therapy 
over time. This may require two levels of information, namely: 
measures to assess patients’ adherence levels at different points 
in time and information about contextual and individual factors 
that influence adherence. One area that remains to be fully 
explored is whether there are relationships between patterns 
and factors associated with missing doses and those involved in 
stopping treatment altogether. For example, do most patients who 
abandon treatment do so after missing more and more doses, 
and are those who adhere poorly to antiretroviral therapy at risk 
of abandoning treatment altogether? 
2. FACTOrS AND PrOGrAMME STrATEGiES
2.1 Factors that influence adherence to antiretroviral 
therapy
Understanding the factors that influence adherence to 
antiretroviral therapy is essential for designing strategies to 
optimize adherence, and the evidence has been growing rapidly, 
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both in high-resource settings (Chesney 2000; Ammassari et 
al. 2001; Ickovics et al. 2002; Spire et al. 2002; Reynolds et al. 
2004) as well as in resource-limited settings (Pinheiro et al. 2002; 
Fong et al. 2003; Orrell et al. 2003; Weiser et al. 2003; Nachega 
et al. 2004; Nemes et al. 2004; Stout et al. 2004; Byakika-Tusiime 
et al. 2005; Safren et al. 2005). Qualitative studies carried out 
in resource-limited settings provide useful insights regarding 
contextual barriers to adherence and how to design programme 
strategies to address them (Hardon et al. 2006).
There are different ways to group the factors that influence 
adherence to antiretroviral therapy, ranging from conceptual 
frameworks that simply distinguish between individual and 
contextual factors, to those frameworks that include more 
detailed categories. Here, we adapt the framework used in the 
WHO review of adherence (2003) and distinguish the following 
interacting dimensions:
4	Health care and system-related factors (service delivery of 
ArT). These include reimbursement systems and the cost of 
medications and consultations, drug distribution systems and 
the availability of medicines, access to health services, levels 
of confidentiality in the health care setting and the conditions 
of the medical encounter.
4	Patients’ clinical condition and therapy-related factors. 
These include stage of the disease, severity of symptoms, 
complexity of drug regimens, side-effects, toxicities and their 
management, degree of diet restrictions and lifestyle changes 
required by the regimen and the occurrence of co-morbidities, 
e.g. depression or drug or alcohol abuse.
4	Social and demographic patient-related factors. These include 
socioeconomic status, food security, residence, employment 
and other sociodemographic variables. 
4	Other patient factors, such as how treatment fits into patients’ 
lives. These factors may include forgetfulness, schedule, 
attitudes and knowledge about HIV treatment, and whether 
patients feel they need to take their medications in secret (for 
more detail, see the chapter on stigma and discrimination in 
this volume). 
4	Social context and social interactions. These include factors 
such as the degree of social support (and conversely 
discrimination) that patients experience from partners, families 
and friends (etc.), as well as interactions with providers and 
trust of health services.
It is sometimes useful as a first step to conduct a situation 
analysis in order to identify the general structural and social 
factors that influence access to medicines and the ability to 
take them. These factors may include, for example, the costs of 
medications in a given country, the extent to which antiretroviral 
therapy medications are regularly supplied to health facilities, the 
availability of food and water in the area, the accessibility of the 
health facilities where HIV treatment and care are provided, the 
extent of law enforcement actions against groups such as drug 
users or those exchanging sex for survival and the degree to which 
stigma discourages HIV-positive individuals from revealing their 
status. This information can be collected at the aggregate level 
through key informant interviews and also by asking individuals 
about their experiences. Other factors, particularly those related 
to patients, require individual data collection. 
It is also important for researchers to examine the length of time 
that patients have been taking antiretroviral therapy. Factors 
associated with poor or nonadherence in the first few months 
may be quite different than those factors that have the greatest 
role in poor adherence over the long run. For example, those who 
have just begun taking antiretroviral therapy may have to deal with 
major physical and social changes, including side-effects, new 
daily routines, fear of disclosing their status to others (in some 
cases), uncertainty about the benefits of antiretroviral therapy 
and possible modifications to their regimen. On the other hand, 
after two or three years, patients may experience improvements 
in their overall health, but fatigue from having to take medication 
multiple times a day.
2.2 interventions and programming to support adherence
Although substantial descriptive data are now available on the 
consequences and factors that influence nonadherence in 
a variety of populations, until recently, much of the available 
evidence on adherence interventions consisted of descriptions 
of demonstration projects (Williams et al. 2006), and few studies 
were able to determine whether adherence interventions are 
associated with improved virological or immunological outcomes 
(Pradier et al. 2003). More recently, the evidence has grown, 
and a number of controlled studies have examined programme 
strategies to improve antiretroviral therapy adherence. Programme 
strategies to improve adherence can be categorized as follows:
4	treatment-related, including simplification or correction of 
regimens, management of side-effects, treatment of depression, 
improved drug management and supply systems;
4	adherence patient education and counselling, including 
counselling to improve medication management skills and to 
help patients overcome barriers to adherence;
4	community/peer support, including the peer support, 
(accompagnateurs) programme in Haiti (see Stigma chapter), 
or support groups for people living with HIV; and
4	programmes that address socioeconomic constraints, such 
as free or subsidized medicines, transportation or food 
supplements, or income-generating opportunities.
individual level interventions
A systematic review, based on 19 relevant randomized controlled 
trials from high-income countries, found that programmes that 
were most successful in improving adherence were provided to 
individuals over long periods of time and emphasized practical 
medication management skills (Rueda et al. 2006). A meta-
analysis of randomized controlled trials of clinic-based patient 
education, counselling and various devices to prompt patients 
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to take their medications found that participants who received 
education and counselling were significantly more likely (OR=1.5) 
to reach the optimal level of 95% adherence and to have an 
undetectable viral load (OR=1.25) than those who were not 
offered such counselling (Simoni et al. 2006b). 
The importance of counselling, over and above external reminders 
(as highlighted in the meta-analysis) was confirmed by a recent 
multi-centre trial in the United States. This trial compared the 
effects of an electronic medication alarm system with those of 
“medication managers” — clinic staff who were given two days 
of training on how to conduct adherence counselling and how 
to help patients identify and overcome barriers to adherence. 
Medication managers were found to significantly increase levels 
of optimal adherence, which was not the case for the electronic 
medication alarms (Mannheimer et al. 2006).
While randomized controlled trials are important ways to measure 
the effect of individual interventions, they are limited when trying 
to assess the effectiveness of community-based approaches or 
programmes that aim to overcome socioeconomic constraints. 
Also, trials that standardize interventions cannot assess the effect 
of tailored approaches that match adherence interventions to 
patient needs at different stages of treatment (Gordon 2006). 
Therefore, it is necessary to complement randomized controlled 
trials with other sorts of intervention studies, especially in low-
resource settings. 
Community level interventions
Evidence about the potential benefits of a variety of community 
level strategies is growing. Community-based interventions 
in Haiti and Rwanda, including the use of peer supporters 
(accompagnateurs), have been shown to improve adherence 
and outcomes (Mukherjee et al. 2006). Home-based counselling 
and home-delivery of drugs appear to be effective in increasing 
adherence and decreasing viral loads (Weidle et al. 2006). 
Directly administered antiretroviral therapy (DAART) has been 
adapted and modified from the directly observed therapy (DOT) 
strategy used in the management of tuberculosis, and this 
approach seems to be acceptable (Pearson et al. 2006) and 
to increase optimal adherence (Luchters et al. 2008). Some 
evidence suggests that strategies that alleviate the cost of 
transportation and address food insecurity — which represent 
major obstacles in resource-limited settings (Hardon et al. 2007) 
— may improve Body Mass Index (BMI), weight and CD4 counts 
(Gisha Mugisha et al. 2006; Samuels et al. 2008a; Samuels et 
al. 2008b). However, confirmation of these findings will require 
further studies with careful measurement of adherence levels 
and the use of control groups.
3. rESEArCH ObjECTivES AND QUESTiONS
In order to monitor adherence and inform interventions to support 
adherence, it is essential to have standardized information across 
sites and over time. But since adherence is a dynamic process 
that changes over time and is shaped by multiple factors, an 
overly rigid “determinants” framework would miss important 
dimensions of the process of adherence — in particular, the 
patient perspective and the broader societal forces that influence 
behaviours. Even within the context of operational research, it is 
possible to consider some of these factors, including patients’ 
experiences, the strategies they use to adhere to treatment and 
the wider social context of medication taking, including social 
networks. 
Recent research has begun to pay attention to such factors 
and has recognized the contribution of qualitative methods in 
improving explanations for adherence, particularly those that 
have to do with patients’ views, what influences those views and 
how those views affect behaviour (Golin et al. 2002; Nachega 
et al. 2006; Sankar et al. 2006). There are calls for combining 
medical and social perspectives and for using multi-disciplinary 
teams (Frick et al. 2006; Friedland 2006). This chapter focuses 
on ways to standardize the measurement of adherence and its 
key determinants using closed-ended questions that can be 
asked in all settings, but it also includes open-ended questions 
that can capture the individual and context-specific dimensions 
of adherence.
The Adherence Module of the Client Instrument in this volume 
is designed to facilitate operational research in order to inform 
programmes and improve antiretroviral therapy delivery. The 
instrument addresses the operational research questions listed 
in the box on the next page. 
The first of these three research questions (adherence levels 
over time) can be answered by analysing the quantitative survey 
data from the Adherence Module of the Client Instrument in this 
volume. The second set of questions (about factors that influence 
adherence) can be answered through regression analyses of 
survey data collected using various modules in this volume. The 
third set of research questions can best be answered using both 
statistical analyses of quantifiable data and qualitative methods 
based on responses to the open-ended questions in the Client 
Instrument. Further data collection and analysis can be carried 
out to explore patients’ own perspectives on the factors that 
influence adherence, using qualitative methods such as narrative 
techniques.
Additional research questions that may be considered in 
different settings
In addition to the core research questions addressed by the 
instruments in this volume, researchers may want to investigate 
a host of other factors that influence adherence, as illustrated 
in the box on page 35. In some cases, the Adherence Module 
already includes the survey questions needed to investigate 
these questions; in other cases, researchers would need to add 
additional survey items.
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kEy OPERATIONAL RESEARCH qUESTIONS AbOUT ADHERENCE
1. What proportion of antiretroviral therapy patients have suboptimal adherence? 
n What proportion of patients have suboptimal (or high, moderate and low) adherence after 4 months, 6 months, 1 year, 2 years (etc.)?
2. What factors are associated with optimal or suboptimal adherence?
n Health care system: Is poor adherence associated with inconsistent supply of ART, higher cost of treatment, distance from the clinic or other  
facility-related barriers to access?
n Patients’ clinical condition and therapy: Is poor adherence associated with more complex treatment regimens or occurrence of side-effects or  
co-morbidities?
n Social and demographic patient-related factors: Is poor adherence associated with patients’ socioeconomic status? Is it associated with food 
security?
n Other patient factors: Is adherence associated with factors such as attitudes and knowledge about ART and HIV and whether patients take their 
medications in secret?
n Social context: Is poor adherence associated with low levels of social support, high perceived stigma or experiences of discrimination?
3. How does the situation of patients’ lives influence sustained adherence to antiretroviral therapy?
n How do patients fit antiretroviral therapy into their daily routines? 
n What are the primary reasons that nonadherent patients skip doses or interrupt their therapy? Do these patterns differ at different times of year or 
over the course of treatment?
n How do factors such as patients’ socioeconomic status, food security, knowledge and attitudes and income-generating activities influence adherence?
n How do family members and other social networks support or impede patients’ adherence?
ADDITIONAL RESEARCH qUESTIONS AbOUT THE INFLUENCE OF vARIOUS FACTORS ON ADHERENCE
Health Care Delivery
art initiation and retention criteria Do guidelines with more stringent criteria for patients initiating and remaining in antiretroviral therapy 
programmes result in better adherence? 
waiting and consultation time Does the time patients must spend in the clinic influence their adherence?
availability of essential medications Does the availability and cost of drugs for AIDS-related illnesses influence adherence?
Comprehensive care Do services that provide comprehensive care and treatment for co-morbidities (malaria, TB, substitution 
treatment, hepatitis, etc.) achieve higher levels of adherence than those that do not? 
laboratory services and clinical 
monitoring
Does the availability of laboratory services and regular feedback to patients on their clinical indicators 
influence adherence? 
refill interval Do patients at facilities that require patients to come for refills every month have better adherence than 
patients at facilities with longer refill intervals? 
number of patients enrolled in the art 
programme
Is the size of antiretroviral therapy programmes associated with patients’ adherence?
providers' knowledge of art and 
adherence 
How well do different types of providers understand antiretroviral therapy management and the 
importance of adherence?
Patients’ Health
Concurrent therapies How do patients integrate antiretroviral therapy with other treatment modalities, including traditional and 
"neo-traditional" remedies, and how does this influence adherence? 
depression How do depression, anxiety and hopelessness influence adherence? 
alcohol and drug use Do patients who abuse alcohol or drugs have worse adherence than those who do not? How does 
substitution treatment influence adherence to ART? 
Other Patient-related Factors
economic activity How do patients’ income-generating activities and food security influence their adherence, and how does 
this change over time? 
perceptions and knowledge about art How do patients understand antiretroviral therapy and how does this influence adherence? 
perceptions of adherence What meaning and importance do patients attribute to adherence, and how does this change over the 
course of their treatment? 
perceptions of own health status Do the perceptions that patients have of their own health status influence adherence? 
Social Interactions
Quality of interactions with patients What counselling skills do providers use when interacting with patients (e.g. listening, respect, time for 
questions, confidentiality, non-judgemental interaction, etc.)? 
attitudes towards providing adherence 
support
What are providers’ attitudes when providing adherence support to patients (disciplinary vs. patient-
centred, and value vs. resent time spent on adherence counselling), and how does this influence 
adherence?
stigma What role does stigma or discrimination play in adherence? 
perception of relationships with health 
workers 
How do patients perceive their relationships with health care providers, particularly with regard to trust 
and honesty, and how does this influence their adherence?
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4. METHODS
4.1 Study populations and study design
The primary study population for operational research on 
adherence is that of patients taking antiretroviral therapy, 
because their perspectives and experiences are essential to 
inform interventions and service delivery to improve adherence 
practices. Some additional information may be elicited from key 
informants, health care providers, representatives of AIDS care 
organizations and family and friends (including peer supporters 
or accompagnateurs) of patients taking antiretroviral therapy. 
Patients can be recruited in the clinic setting, using all patients 
on antiretroviral therapy as a sampling frame. Patients should 
be sampled to include variability on key variables, such as 
sex, time on antiretroviral therapy, etc. If possible, data should 
be collected at several points in time, since adherence may 
change over time. But cross-sectional data at a single point in 
time can also be useful, as they can give a snapshot of patients’ 
experience. When designing a sampling plan, researchers should 
consider the possibility that a certain proportion of patients will 
abandon treatment or modify their regimens after treatment has 
begun. Gathering data among this group may provide another 
important perspective on the factors that influence adherence to 
antiretroviral therapy.
Ideally, research methods should integrate both qualitative and 
quantitative data collection from multiple sources, creating 
a comprehensive picture of the multi-faceted influences on 
adherence. Qualitative methods are valuable because they can 
elicit salient issues for a particular group and can shed light on 
the social context of adherence. They can be used to explore and 
explain the findings of a quantative survey, or as part of formative 
research to understand adherence, to elicit the topics and to 
inform the measurements to be used for a quantitative study. 
Qualitative data can be collected through individual interviews, 
focus group discussions and observations. They are generally 
analysed through a process of coding and content analysis for 
themes and patterns (Ulin et al. 2005).
In addition to the topics and open-ended questions that are 
suggested in the Adherence Module of the Client Instrument, 
qualitative data collection on adherence may include narrative 
techniques of asking people about their lives, events that have 
occurred since being diagnosed with HIV, their daily routines and 
how taking antiretroviral therapy fits into those routines. Narrative 
accounts give respondents a chance to identify what factors or 
circumstances they consider most relevant to their situation and 
to describe social interactions that influence adherence.
4.2 Methods and measures: an overview of the literature
Adherence is frequently assessed based on some form of 
observation or patient self-report. Observational methods include 
medication event monitoring systems (MEMS — an electronic 
pill cap that records when it is opened), pill counts (either 
at pharmacy refills or unannounced visits), pharmacy refill 
records and directly observed therapy. Self-reported methods use 
questionnaires that are either self-administered or administered 
by an interviewer. Most self-report measures ask patients to recall 
the proportion of times that they correctly took their medications 
over a defined time period. 
Variability in the observed levels of adherence to antiretroviral 
therapy may depend on the way adherence is measured (e.g. pill 
counts, MEMS, self-reports, etc.) and — in the case of face-to-face 
interviews — who collects the information (e.g. a physician, social 
worker or peer). It is, therefore, important to define standardized 
measures, to clarify appropriate study designs and methods, and 
to foster comparability across studies.
All measures of adherence have limitations, including those 
that are based on “objective” measures rather than self-reports. 
For example, there are errors and biases in measures such as 
electronic drug monitoring and pill counts (Berg and Arnsten 
2006). Even laboratory measurements can be misleading: while 
drug plasma concentration levels may offer a direct measure 
of recent drug consumption in the preceding 24 hours, they 
may also be biased by the possibility that patients who are not 
usually adherent may take their medications appropriately the 
day prior to the medical examination and hence be classified as 
adherent. Thus, the decision of which method to use will depend 
on the trade-offs the investigator is ready to make (see Table on 
next page).
Despite their potential disadvantages, self-report measures 
of adherence are highly correlated with clinical measures of 
viral load (Nieuwkerk and Oort 2005) and other measures 
of adherence, such as pill counts and MEMS (Arnsten et al. 
2001; Liu et al. 2001; Wagner 2002; Oyugi et al. 2004). In 
addition, self-report measures are often chosen because they 
are easier, less costly and more feasible to administer than other 
measures of adherence. Appropriate selection of questions, a 
non-judgemental approach that includes normalizing language 
and good interviewer training can greatly improve the validity and 
reliability of self-reports. 
Self-report measures of adherence take many forms, and 
standardization is necessary to enable comparisons across 
studies. Some self-report measures involve asking patients to 
recall the proportion of pills or the proportion of times that they 
correctly took their medications over the previous three days, four 
days, one week or one month. In shorter periods (three or four 
days) patients are asked to recall which doses they took or did 
not take, each day. There has not been any evidence to suggest 
a difference between the validity of a 3- or 4-day measure, 
suggesting that a 3-day measure may be chosen for its easier 
administration (Simoni et al. 2006a). Instead of using a 1-week 
measure that also includes the weekend, a question about 
adherence during the weekend can be added in those settings 
where weekday and weekend routines are expected to differ. A 
1-month measure seeks to elicit an estimate by respondents of 
their overall adherence. It may be measured using quantitative 
or qualitative categories or using a visual analogue scale (VAS) 
that asks respondents to indicate how high their adherence was 
over the previous month. The VAS provides an ordinal measure 
of adherence and allows respondents to express suboptimal 
HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH
36
ADHERENCE TO ANTIRETROVIRAL THERAPY
37
THE TRADE-OFFS OF DIFFERENT METHODS TO MEASURE ADHERENCE
METHOD ADvANTAgES DISADvANTAgES
MEMS (electronic pill cap) n Sensitive in detecting nonadherence
n Useful for pharmacokinetic studies
n Costly 
n Relies on the assumption that pills are taken when, 
and only when, the pill cap is removed
n Feasible only in specific contexts
Unannounced Pill count n Relatively easy
n Sensitive in detecting nonadherence
n Requires accurate knowledge of the number of pills 
that a patient should have at a given period 
n Feasible only in specific contexts
n Assumes that patients keep their pills in one location
n May violate patients’ privacy and result in involuntary 
disclosure if conducted outside the clinic
Pill count at pharmacy refills n Relatively easy n Requires accurate knowledge of the number of pills 
that a patient should have at a given period
n Assumes that the patient presents all remaining pills
n Not adaptable to all settings
n May overestimate adherence
Pharmacy refill records 
(monitoring on-time pick-up) 
n Relatively easy n Relies on accurate record-keeping
n May overestimate adherence
Directly observed therapy n Useful when feasible
n Sensitive in detecting nonadherence 
(missed visit=missed daily dose)
n Costly and time-consuming
n Time burden on patient
n May violate patients’ privacy and result in involuntary 
disclosure
Self-report (self-administered 
questionnaires or face-to-face 
interview)
n Easy
n Sensitivity depends on instrument, 
interviewer and general approach, but 
can be quite high
n Relies on patients both to recall the pills they have 
taken and to report this truthfully 
n May overestimate adherence if respondent gives the 
desirable response
n The choice of questions, way of questioning and terms 
chosen are crucial
adherence without having to admit to missing specific doses and 
may be desirable in some settings. In other settings, carefully 
worded questions about different levels of adherence may 
facilitate accurate responses.
Given the potential of self-report measures to overestimate 
adherence as a result of desirability bias (whereby respondents 
tend to give ideal rather than accurate answers), some studies 
combine multiple questions into a composite measure. Scores 
based on self-reports have been shown to correlate with virological 
and immunological response (Carrieri et al. 2003) and with 
clinical progression and mortality (Bouhnik et al. 2005), and this 
approach is increasingly used to differentiate between more and 
less adherent respondents (Kleeberger et al. 2001).
Since there is no gold standard to measure adherence, it is not 
possible to recommend a single tool, and it is preferable to include 
more than one measure of adherence (Berg and Arnsten 2006). In 
addition, optimal measures in research settings are not necessarily 
the same as those in clinical settings (Chesney 2006), and some 
“tailoring” is necessary for the specific objectives of the project. A 
single instrument may include multiple self-report measures, as 
well as additional questions about missing pills over the weekend 
or during periods of illness, and about treatment interruptions and 
discontinuations. Questions on self-reported adherence should 
always be preceded by language that normalizes suboptimal 
adherence and gives respondents permission to provide an honest 
response, even if it is incongruent with what they perceive as the 
ideal behaviour (Simoni et al. 2006a).
4.3 recommended methods and measures 
For the purpose of the instruments in this volume, we 
propose multiple measures that can be combined to provide a 
comprehensive view of adherence. These measures are based 
on the literature. The selection of measures and methods reflects 
our efforts to take account of the situation in resource-limited 
countries, where laboratory facilities to measure viral loads are 
lacking and where patient outcomes are largely based on clinical 
assessments. Specifically, we recommend the following:
4	Monitor adherence at several points in time. We recommend 
monitoring adherence at several points in time, both because 
adherence varies over the duration of treatment and because 
longitudinal measures make it possible to predict the risk of 
virological failure. 
4	Use self-reported methods when resources are limited. Self-
reports of adherence are likely to be the best option to measure 
adherence in resource-limited settings, because they are 
inexpensive and relatively easy to collect. 
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4	Ask about adherence in multiple ways. In order to reduce the 
desirability bias, we recommend asking about adherence in 
several different ways. A composite measure can be created 
in order to differentiate between adherent and nonadherent 
respondents.
4	Use a minimum set of core questions to assess adherence and 
add more detailed questions if needed. In this chapter, we 
propose a core set of questions that appear in the Adherence 
Module of the Client Instrument. This chapter also suggests 
some additional questions for researchers who need more 
detailed information on adherence, for example, during in the 
initial phase of treatment when adherence is crucial for the 
durability of treatment response.
5. vAriAbLES AND SUrvEy QUESTiONS 
The Adherence Modules of the Client and Provider Instruments 
in this volume are designed to gather data on the levels and 
patterns of adherence to antiretroviral therapy and on factors that 
may influence adherence. The rest of this section summarizes 
those variables and provides recommendations for constructing 
questionnaires.
5.1 variables and survey questions about adherence in 
the Adherence Module of the Client instrument
The Adherence Module of the Client Instrument contains 
questions that gather data on the following types of variables:
a. Length of time on antiretroviral therapy
Knowing how long the respondent has been taking antiretroviral 
therapy helps differentiate between the induction phase (the first 
4–6 months) and the maintenance phase of treatment.
How long ago did you first start taking antiretroviral therapy 
to manage your Hiv?
Number of months ago:               
Number of years ago:               
b. Antiretroviral therapy regimen (prescribed doses)
In order to determine patients’ adherence to their prescribed 
antiretroviral therapy, it is important to establish the prescribed 
regimen, including the names of the medications and the number 
of pills to be taken at different times of day. Unless the interviewers 
have access to patients’ medical records, interviewers will need 
to ask respondents to identify their prescribed medication. If the 
clinic only prescribes a small number of regimens, it may be 
possible to obtain the information from a key informant prior to 
the interview. 
The following table should be completed according to the 
prescribed antiretroviral therapy dosing, not the 
respondents’ actual behaviour. This information may be 
obtained from the patient, the provider or the health care 
facility. Cross out all non-applicable boxes.
c. Three-day recall of adherence
A detailed 3-day recall will elicit specific information on which pills 
were not taken, as well as whether respondents ever took pills 
later than the prescribed time. This exercise requires thorough 
training of interviewers. To complete this set of questions, the 
interviewers should reference the table that was completed 
for the prescribed antiretroviral therapy regimen in order to 
complete the names of all medications. They should then walk 
the respondents through each of the last three days. To facilitate 
recall, interviewers should use memory prompts. For example, 
they may first ask respondents to think about yesterday and what 
they were doing and if there was anything unique about the day, 
before asking whether they took their antiretroviral therapy. 
This set of questions should be prefaced by normalizing language 
in order to reduce social desirability bias (Vinten 1998). The 
normalizing language suggested here has been adapted from 
language used in other studies (Simoni et al. 2006a), but should 
be piloted and adapted to the study setting. When fixed dose 
regimens are used, the table can be simplified by deleting the 
first column and including only a single row.
Many patients find it difficult to take all their medications as 
prescribed. We would not be surprised if you have missed 
taking some of your medications over the last few days. We 
are trying to find out how difficult it is for patients to take 
their medications, and what things make it difficult. Please 













Source of information above (patient, clinic, medical record, etc.):
vARIAbLES IN THE ADHERENCE MODULE 
OF THE CLIENT INSTRUMENT
a. Length of time on antiretroviral therapy
b. Antiretroviral therapy regimen (prescribed doses)
c. Three day recall of adherence
d. Circumstances of/reasons for nonadherence in the past 3 
days
e. Adherence on weekends
f. One-month estimate of adherence
g. Circumstances of/reasons for nonadherence in the past 
month
h. Modifying time that medications are taken
i. Treatment interruption
j. Changes in adherence over time
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The following table should be completed according to the 
antiretroviral medications that were actually taken over the 
last three days. Use memory prompts to facilitate accurate 
recall. (“What did you do yesterday morning? Did you take 
any Hiv medications that morning?” If yes: “Which pills? 
How many of each?”) If the respondent reports missing a 
pill/dose, circle the cell and assign it a number.
d. Circumstances of/reasons for nonadherence in the past 3 days 
The reasons for missed doses can be investigated by using open-
ended questions that ask respondents about the circumstances 
of and reasons for not taking their medications as prescribed. 
Asking about circumstances may elicit better information about 
poor adherence than simply asking for the reason(s). As noted 
earlier, each time a respondent reports having taken fewer pills 
than prescribed, the box should be circled and numbered (e.g. 
missed dose #1, missed dose #2). For each circled box, the 
interviewer should ask the following questions:
What circumstances led you to miss taking your medication 
as recommended on (name the day and the medication 
missed as identified in the previous question)? Probe for 
what happened and why.
Missed Dose #1                                                          
Missed Dose #2                                                          
Missed Dose #3                                                           (etc.)
e. Challenges adhering on weekends
Information on adherence on weekends can help differentiate 
between adherent and nonadherent patients, since changes in 
routine make it more difficult to keep to the prescribed regimen. 
Again, the question is prefaced with normalizing language 
in order to facilitate disclosure of poor adherence. Additional 
information can be elicited using an open-ended question about 
what happened.
Some people find it difficult to take their antiretroviral 
therapy medications on the weekends. Thinking about the 
past month, how many times did you miss taking a dose of 




q	three or more times
f. One-month estimate of adherence
In order to get a 1-month estimate of adherence, we propose 
three options, namely: a single question about how often patients 
followed their prescribed antiretroviral therapy regimen over 
the previous month, a linear visual analogue scale (VAS) and a 
modified VAS. The first option — the single question — may be 
preferable for ease of administration, but the VAS may be chosen 
because it elicits information on a continuous scale and offers 
visual, rather than verbal, response choices. In some contexts, the 
linear VAS has been found to be highly correlated with viral load 
(Oyugi et al. 2004). The third option, a modified VAS, uses a bead 
count that was developed for use in low-resource countries, but 
its association with virological outcomes has not been established. 
Researchers may want to choose which measure to use for a 
1-month estimate based on the results of piloting the instrument 
in the particular setting.
In the linear VAS, interviewers show respondents a line with two 
endpoints, where the left end represents “no pills taken” and the 
right end represents “all pills taken”. They then ask respondents 
to indicate where on the line their own performance fell regarding 
pill-taking in the previous one month. The coders will later 
measure the marked point in order to estimate the one-month 
self-report of adherence. In the modified VAS (Hardon et al. 2006), 
interviewers show respondents a jar of beads with the number of 
pills they should have taken the previous month. For example, 
if a respondent should have taken one pill twice a day, the jar 
will include 60 beads. The respondents are asked to transfer 
the beads to another jar to indicate the number of pills they 
actually did take in the previous month. The proportion of beads 
transferred from one jar to the other represents the estimated 
1-month self-report of adherence. Visual analogue scales are 
useful for obtaining an overall measure of adherence. 
NAME OF MEDICATION




YESTERDAY 3 DAYS AGO
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g. Circumstances and reasons for nonadherence in the past 
month
The Adherence Module of the Client Instrument asks respondents 
about the circumstances that led to missed and mistimed doses 
of their antiretroviral therapy. In addition, it contains the following 
three open-ended questions to gather qualitative information 
on barriers to adherence and the factors that make it easier for 
patients to achieve adherence:
h. Modifying the time that antiretroviral therapy medications are 
taken 
The Adherence Module also contains detailed questions about 
whether respondents have ever taken multiple doses of their 
medication at one intake, for example:
During the past month, how often did you take a double dose 





Researchers may also want to ask respondents whether they 
have medications that are supposed to be taken more than once 
a day. If they say yes, then the interviewer can ask: “At any point 
during the past month, did you ever take all your daily doses of 
this (these) medication(s) in one intake?” The survey instrument 
can then ask about how often this occurred. 
i. Treatment interruption
The Adherence Module in the Client Instrument measures 
treatment interruption by asking whether a respondent ever 
interrupted treatment during the previous six months, and if so, 
for how long. As noted earlier, evidence suggests that interrupting 
treatment for at least 48 consecutive hours increases the risk of 
resistance to nevirapine and probably to other NNRTIs (Oyugi 
et al. 2007). These questions are followed by an open-ended 
question about the circumstance that led to the respondent 
interrupting treatment.
During the past six months, did you ever stop taking your 
antiretroviral therapy for 48 hours or longer?
If yes: How long did you stop taking your antiretroviral 
therapy?
q	for more than 48 hours and less than a week
q	from one to two weeks
q	for more than two weeks and less than one month
q	for more than one month
j. Changes in adherence over time
Survey items can also be used to gauge changes in adherence 
over time. For example, the linear VAS can be used to ask 
respondents who have been on treatment for at least 2 months to 
recall the first month when they started treatment and to estimate 
their adherence level as follows:
three ways to ask about 1-month estimates of adherenCe 
Question about 1-month adherenCe
we know that it is difficult to take all your antiretroviral therapy just as 
the doctor prescribed. would you say that in the past month you:
q totally followed prescriptions
q generally followed prescriptions but with some deviations
q often modified timing and quantities
q almost never followed prescriptions
q interrupted treatment
linear visual analogue sCale
now i would like to ask you to estimate how much of your prescribed 
art you took in the previous month. it is not likely that most people 
would take all of their doses. a mark at the left end where there is a 
number zero means you have taken no art medications. a mark in the 
middle means you have taken about half of your art medications. a 
mark on the right end where you can see the number ten means you 
have taken every single dose of your art medications. please put a 
mark on this line somewhere between zero and ten to describe your 
best guess about how much of your prescribed art you took in the 
previous month.
    0       10
modified visual analogue sCale using beads
this jar of beads represents the number of pills you were supposed to 
take last month. i want you to move the beads to this jar to represent 
the number of pills you swallowed last month. in other words, if you 
swallowed only half your pills you would move half the beads into this 
jar. or, if you swallowed all the pills you would move all the beads into 
this jar. we would not be surprised if you missed some of your pills in 
the previous month.
open-ended Questions about CirCumstanCes that
influenCe adherenCe
n in general, what helps you take your medications on time?
n in the past month, what circumstances led you to miss taking your 
pills on time?
n what other things make it difficult to take all your medications on 
time?
thinking of the first month when you started 
antiretroviral therapy, please put a mark on this line to 
describe your best guess about how much you followed 
prescriptions. 
    0       10
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examples of survey Questions on soCial support
n does your partner/spouse know that you are taking antiretroviral 
therapy?
n is there any other adult in your household who does not know you 
are taking antiretroviral therapy?
n is it ever difficult for you to take your medications when someone 
from your family can see you?
n is it ever difficult for you to take your medications when someone 
from your community or your workplace can see you? 
n is there anyone who regularly reminds you to take your 
antiretroviral therapy? 
n during the past month, have you ever not taken your antiretroviral 
therapy because you did not want someone to find out? 
5.2 variables and survey questions about factors that 
influence adherence
To identify the factors that influence adherence, we suggest the 
following variables to be considered in operational research. 
The variables that researchers choose in a particular setting 
will depend on the type of epidemic and common modes of 
transmission in the study sites. For example, researchers may 
want to include a module on drug use where appropriate (see the 
Prevention chapter for more information). In addition, formative 
research, anecdotal evidence and programme experiences 
may suggest other variables for inclusion. Unless indicated, 
the questions below are intended to be answered by patients 
currently taking antiretroviral therapy.
a. Demographic variables
Demographic variables, such as the respondent’s sex, age, 
education level and marital status, are clearly important for 
understanding the broader context that may influence adherence, 
as are variables such as socioeconomic status, income-generating 
activities and food security. Questions for gathering information on 
these types of variables can be found in the Sociodemographic 
Module of the Client Instrument.
b. Social support 
The following questions on social support appear in the Adherence 
Module of the Client Instrument. Many of these close-ended 
questions are followed by the question: “Please tell me about 
this”. These questions are closely related to disclosure, which 
is discussed at more length in the previous chapter on HIV 
Stigma. 
Researchers with a particular interest in social support may wish 
to add another question about social support that is not included 
in the Client Instrument: “If you were sick in bed, is there anyone 
who would bring you food?” If the answer is yes, then the interview 
can ask: “Please tell me about this person”.
c. Access to the clinic
The Adherence Module of the Client Instrument contains two 
core questions on access to the clinic, including a question about 
whether respondents have ever been unable to get to the clinic 
and a question about whether cost has ever been a barrier to 
adherence. Researchers who have a particular interest in access 
to care may want to gather more detailed information about how 
often respondents are supposed to go to the clinic, what form of 
transportation they use, how long it takes to reach the clinic and 
how much it costs to get there. It may also be possible to find 
out some of this information from a key informant, such as how 
often most patients are supposed to come to the health facility. 
Examples of more detailed questions about access that are not 
included in the Adherence Module but may be useful include 
the following:
vARIAbLES RELATED TO FACTORS THAT MAy 
INFLUENCE ADHERENCE IN THE CLIENT INSTRUMENT
a. Demographic variables [in the Sociodemographic Module]
b. Social support




g. Perceived changes to the body
h. Additional variables, such as depression and drug use 
(optional)
examples of survey Questions about aCCess
survey Questions on aCCess in the Client instrument
n in the past year, have you ever had problems getting your 
antiretroviral therapy on time because you were not able to reach 
the clinic? If yes: please tell me about this.
n during the past year, has the cost of medications or the cost 
of clinic care ever interfered with your ability to get your 
antiretroviral therapy or take your medications on time? If yes: 
please tell me about this.
examples of other possible survey Questions on aCCess
n how often do you need to get to the clinic to obtain your 
medications or meet with a health care worker regarding your 
treatment?
n what form of transportation do you use to get from your home to 
the place where you get your antiretroviral therapy? (response 
options should be adapted for the setting)
n how long does it normally take you to get from your residence to 
the place where you get your antiretroviral therapy? 
n how much does it cost you to get from your residence to the place 
where you get your antiretroviral therapy? 
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d. Food security
The Adherence Module of the Client Instrument contains one 
closed-ended and one open-ended question about food security, 
as follows: “During the past month, have you missed a dose of 
your antiretroviral therapy because you did not have enough 
food?” If the respondent says yes, then the interviewer can 
ask: “Please tell me about this”. Researchers who want more 
information about the relationship between food security and 
adherence my may use the questions about food security from 
the Sociodemographic Module of the Client Instrument (noted 
below) or add additional items on this topic.
During the past month, how often have you had problems 





If yes: Please tell me about this.
e. Health status
Questions about how respondent rate their health before and after 
they began antiretroviral therapy make it possible to measure 
the effect of antiretroviral therapy on patients’ lives. The two 
questions below appear in the Adherence Module. They are 
designed to to obtain this information efficiently. More developed 
scales are available, however, for researchers who want more 
detailed information on this topic, including, for example, the 
SF-12v2(TM) Health Survey (Ware et al. 2002). 







And now that you are on antiretroviral therapy, how would 






f. Perceived side-effects 
To understand adherence, it is important to ask about both 
patients’ experienced side-effects and the influence that side-
effects have had on patients’ daily lives, as illustrated by the 
questions in the next box. The Adherence Module contains a list 
of symptoms to be read to respondents. This list was adapted 
from the AIDS Clinical Trials Group (ACTG) baseline questionnaire 
(Chesney et al. 2000), from the Justice checklist (Justice et al. 
2001) and from other sources of information about side-effects 
related to antiretroviral therapy such as lipodystrophies (Duran et 
al. 2001). Researchers may want to modify this list of side-effects 
based on the results of formative research. 
g. Perceived changes to the body
In addition to the side effects, it is also important to ask 
respondents about changes in the appearance of the body. The 
Adherence Module contains questions about body changes that 
have a similar structure to the questions about side-effects. The 
instrument provides a list of commonly reported body changes. 
Researchers may want to modify that list based on the results of 
formative research. 
h. Additional variables 
Researchers may consider investigating other variables in addition 
to those that are included in the Adherence Module, depending 
on their particular interest and the context where their studies 
are being carried out. Possible variables of interest may include 
the following: 
4	Depression. Depressive symptoms can be assessed by self-
report measurement tools such as the CES-D scale (Radloff 
1977).
survey Questions about perCeived Changes to the body
n since you started taking art, have you experienced a change in 
the way your body looks? If yes: Can you tell me what changes you 
have experienced?
n in the past month, have you experienced any of the following.
       Read list.
n For each change that the respondent reports: has it been very 
bothersome, somewhat bothersome or not at all bothersome?
n of all the body changes that we have just discussed, please tell me 
more about the changes that are the most bothersome for you? 
Probe for the top 2 or 3. 
survey Questions about side-effeCts
n some people experience side-effects when they take antiretroviral 
therapy. this varies a great deal – some people have a few, while 
others have more. have you experienced any side-effects since 
you started taking art? 
n If yes, which side-effects have been the most bothersome?
n Can you please tell me more about these side-effects?
  
n i’m going to read you a list of side-effects. please tell me whether 
you have experienced any of these side-effects in the past month. 
Read list.
n For each side-effect that the respondent reports: has this side-
effect been very bothersome, somewhat bothersome or not at all 
bothersome?
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4	Drug use. In settings where drug use represents an important 
route of HIV transmission, modules can be added to measure 
the extent to which respondents are injecting drugs or involved 
in related types of high-risk behaviours. More information on 
asking about drug use can be found in the Prevention chapter 
in this volume and in the Alcohol and Drug Module of the 
Client Instrument.
5.3 variables and survey questions for key informants 
working in the health facility
Researchers may want to gather information on possible factors 
that influence adherence by reviewing records or interviewing 
key informants in health care facilities that provide HIV treatment 
and related care. 
a. reliability of antiretroviral therapy supply
To investigate the reliability of antiretroviral therapy supply, 
researchers can ask clinic administrators or pharmacists whether 
the first-line or second-line antiretroviral therapy regimens 
prescribed in the clinic have ever been out of stock or unavailable 
for any reasons when patients needed them during the past year. 
If respondents say yes, then researchers can follow up with a 
question such as: “Please tell me about this”.
b. Cost of treatment
To investigate the cost of treatment, researchers may ask clinic 
administrators, providers or other key informants in the facility: 
“What is the typical cost of antiretroviral therapy per month at this 
clinic?” In addition, researchers may want to ask about additional 
costs that antiretroviral therapy patients must incur in order to 
receive treatment at the facility.
c. Frequency that patients need to come to the clinic
When antiretroviral therapy regimens are fairly standard, it may 
be possible to ask a key informant in the health care facility how 
frequently patients needs to come in to receive their medications. 
This variable may add to an understanding of barriers to access 
as a factor that may influence adherence.
5.4 variables and survey questions for providers
In addition to key informant interviews, researchers may want 
to interview health workers who provide services to patients 
taking antiretroviral therapy. The Provider Instrument in this 
volume contains an Adherence Module for that purpose. The 
key variables addressed by this module are presented in the 
box below:
The Adherence Module of the Provider Instrument contains 
some detailed questions about provider practices, including 
whether the provider is involved in adherence counselling, the 
type of information they give to patients and the frequency and 
methods used to assess adherence. The module also contains 
questions about how many of their patients report problems with 
adherence (of different types), and what the providers perceive 
to be the underlying reasons why their patients sometimes have 
problems adhering to treatment.
ADDITIONAL vARIAbLES RELATED TO ADHERENCE TO 
bE gATHERED FROM kEy INFORMANTS OR CLINICAL OR 
PHARMACy RECORDS
a. Reliability of the antiretroviral therapy supply
b. Cost of treatment
c. Frequency that patients need to come to the clinic for 
medication and other care
kEy vARIAbLES IN THE ADHERENCE MODULE OF THE 
PROvIDER INSTRUMENT
a. Type of interaction with ART patients
b. Perceived effectiveness of adherence counselling
c. Provider practices related to ART service delivery
d. Perceptions about how well ART patients manage to take 
their medication
e. Perceptions of difficulties experienced by patients in 
taking pills on time
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CHAPTER 4
HIV PREVENTION IN THE CONTEXT OF 
SCALED-UP ACCESS TO HIV TREATMENT 
1. bACKGrOUND
1.1 rationale: why research is needed on Hiv prevention 
among those receiving ArT
As HIV treatment programmes scale up across countries, more 
attention is being directed to the implications of greater access 
to antiretroviral therapy for HIV prevention, and it is important to 
assess the potential for both positive and negative consequences. 
New antiretroviral therapy regimens improve longevity and the 
quality of life of individuals with HIV, and they have the potential 
to reduce HIV transmission by suppressing viral loads among 
people living with HIV (Granich et al. 2008). Greater access to 
treatment can also lower stigma and raise awareness of HIV, 
thereby encouraging people to seek testing and adopt preventive 
behaviours. But greater access to treatment may also increase 
the number of sexually active individuals infected with HIV, as 
antiretroviral therapy restores health and extends lifespans, leading 
to a growing pool of individuals who could potentially transmit 
HIV. In addition, some evidence suggests that the availability of 
effective treatment in some settings has reduced concerns about 
HIV transmission and contributed to an increase in high-risk sexual 
practices, such as unprotected sex or multiple partners (Cohen 
2005; Cassell et al. 2006). Documenting and studying the complex 
links between treatment and prevention has, therefore, become a 
priority issue for antiretroviral therapy programmes.
Research on HIV prevention typically relies on behavioural 
surveillance surveys, Reproductive Health Surveys and 
Demographic and Health Surveys that focus on the general 
population or key populations at higher risk of HIV, such as 
men who have sex with men. A small but growing number 
of population-based surveys have gathered data to analyse 
behaviours in relation to respondents’ serostatus, such as the 
2004–2005 Uganda HIV/AIDS Sero-Behavioral Survey (Bunnell et 
al. 2008). Such research designs are key to monitoring trends at 
the population level. By contrast, this chapter focuses on groups 
whose behaviours may be influenced by the scaling up of HIV 
treatment. These groups include: patients receiving antiretroviral 
therapy and HIV-positive individuals who are not receiving 
treatment (e.g. those who are ineligible to initiate treatment or who 
are on waiting lists). Other populations of interest to operational 
research projects may include partners of individuals receiving 
treatment or users of testing and counselling services who test 
negative.
The primary objective of research proposed in this chapter is to 
document sexual risk behaviours among HIV-positive individuals 
receiving health services in order to: a) learn from comparisons 
across programmes, countries, regions or time periods about 
the factors that influence high- or low-risk behaviours; b) 
gather information to inform behaviour change communication 
strategies; and c) identify gaps in service delivery. Researchers 
who want to track changes in sexual behaviours among individuals 
receiving treatment or to evaluate the effectiveness of prevention 
interventions may be able to use the tools in this volume for that 
purpose with some adaptation.
2. FACTOrS AND PrOGrAMME STrATEGiES
2.1 Factors that influence Hiv prevention in the context of 
scaling up treatment
The implications of treatment for HIV prevention is a complex 
issue that involves biomedical, demographic and behavioural 
factors, some of which are summarized below.
biomedical factors that influence prevention
Antiretroviral therapy may influence sexual transmission of HIV in 
a number of ways. First, treatment that suppresses viral loads to 
undetectable levels may reduce but not necessarily eliminate the 
risk of sexual transmission of HIV infection (Quinn et al. 2000). 
Shedding of HIV continues in some patients, possibly related to 
a separate reservoir of infection (Kovacs et al. 2001; Barroso et 
al. 2003; Fiore et al. 2003; Zuckerman et al. 2004) or to the type 
of antiretroviral therapy regimen (Neely et al. 2007), and the risk 
of HIV transmission or re-infection remains. 
Moreover, as discussed in the Adherence chapter, inappropriate 
treatment or poor adherence may result in incomplete viral 
suppression and the development and transmission of drug 
resistant viral strains (Paterson et al. 2000; Bangsberg and Deeks 
2002). In fact, several studies suggest a relationship between 
poor adherence and higher risk sexual behaviours (Wilson et al. 
2002; Flaks et al. 2003; Kozal et al. 2004), which underscores 
the need to document sexual risk behaviour among HIV-positive 
individuals receiving treatment.
Another biomedical factor that may influence HIV transmission is 
the eligibility criteria used to determine who receives antiretroviral 
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therapy. In general, while HIV infectivity in a community may 
decline as antiretroviral therapy programmes scale up (Fang et al. 
2004; Porco et al. 2004), some researchers argue that increased 
access to treatment is unlikely to reduce HIV incidence if eligibility 
criteria substantially limit the proportion of HIV-positive individuals 
who can initiate treatment (Auvert et al. 2004; McClelland et al. 
2006). Mathematical models suggest that universal testing could 
drastically cut HIV incidence, but only if treatment were given 
to all who test positive, not just those who meet strict clinical 
or immunological eligibility requirements (Granich et al. 2008). 
These analyses underscore the need to strengthen behaviour 
change prevention efforts among individuals who are HIV-positive 
but not receiving antiretroviral therapy.
Sexual risk behaviour among those receiving antiretroviral 
therapy
Individuals receiving treatment may resume sexual activity as they 
recover their health and normal functioning. Some researchers 
and policy makers have raised concerns that wider access to 
antiretroviral therapy might lead to increased high-risk sexual 
behaviour — a phenomenon sometimes called “behavioural 
disinhibition” or “risk compensation” (Cohen 2005; Cassell et 
al. 2006). Many studies from Europe and the United States have 
examined whether HIV treatment leads to increased sexual risk 
behaviours among individuals receiving antiretroviral therapy. A 
few studies have reported an association between immunological 
or virological improvements and sexual risk behaviours (or proxy 
measures such as STI rates) among men who have sex with 
men and injecting drug users (Martin et al. 2001; Scheer et al. 
2001; Tun et al. 2004). However, most research has not found 
a consistent or significant association with risk behaviour, even 
when patients achieve an undetectable viral load (Dukers et al. 
2001; Bouhnik et al. 2002; Vanable et al. 2003; Wolf et al. 2003; 
Crepaz et al. 2004; Diamond et al. 2005).
Nevertheless, studies suggest that a substantial minority of 
patients receiving treatment are sexually active, and some engage 
in unprotected sex. Even if receiving treatment does not increase 
levels of unprotected sex, antiretroviral therapy may still increase 
the risk that those patients who do engage in unprotected sex 
will transmit a drug resistant strain of the virus. Surveillance data 
from the United Kingdom suggest that the proportion of new 
HIV infections that involve a drug resistant strain has increased 
between 1994 and 2000, accounting for an estimated 27% of 
new infections in 2000 (Fidler et al. 2001; Cassell et al. 2006).
 
Only limited evidence is available from low- and middle-income 
countries, but a number of studies from Côte d’Ivoire, Kenya, 
South Africa and Uganda have generally failed to find significant 
increases in high-risk sexual behaviour among individuals 
receiving antiretroviral therapy (Moatti et al. 2003; Bateganya 
et al. 2005; Bunnell et al. 2006a; Kennedy et al. 2007; Eisele et 
al. 2008a; Eisele et al. 2008b; Luchters et al. 2008; Sarna et al. 
2008). Thus, while existing research does not support the notion 
of disinhibition, the limited evidence suggests that measuring 
behaviour change and HIV prevention efforts among those 
receiving treatment remains a high priority.
The influence of treatment availability on risk perceptions and 
sexual behaviour
At the community or population level, there are various hypotheses 
regarding the effects of treatment availability on risk perceptions, 
attitudes and behaviours related to HIV transmission. On the one 
hand, expanding treatment availability may increase knowledge 
and awareness of HIV and give people a greater sense of control 
over their lives, resulting in risk avoidance and reduced HIV 
transmission. On the other hand, increased access to treatment 
may reduce concerns about unprotected sex, if people believe 
that treatment lowers the risk of transmission or the negative 
consequences of HIV infection (Valdiserri 2004).
While research does not support the notion of ‘behavioural 
disinhibition’ among individuals receiving treatment, evidence 
from high-income settings does suggest that expanded access 
to treatment may be associated with increased sexual risk 
taking. For example, studies among men who have sex with 
men in Australia, the Netherlands, the United Kingdom and the 
United States found that unprotected sex increased in those 
populations after antiretroviral therapy became widely available 
(CDC 1999; Dodds et al. 2000; Stolte et al. 2001; Wolitski et 
al. 2001; Chen et al. 2002; Katz et al. 2002; Van de Ven et 
al. 2002). High-risk sex may have increased in those settings 
because treatment availability lowered concerns about the risk of 
HIV transmission and the negative consequences of contracting 
the virus. For example, rates of multiple partners, unprotected 
sex and inconsistent condom use were found to be significantly 
higher among those who believed that antiretroviral therapy 
lowers infectivity (Van de Ven et al. 1999; Herlitz and Steel 2001; 
Suarez et al. 2001; Wilson and Minkoff 2001; Elford et al. 2002; 
Ostrow et al. 2002; Stolte et al. 2004). Similarly, a meta-analysis 
by Crepaz et al. (2004) found that rates of unprotected sex 
were significantly higher among respondents who believed that 
treatment availability had reduced the risk of HIV transmission 
or the seriousness of contracting the virus — regardless of their 
treatment or serostatus. 
Research is currently underway to examine whether treatment 
availability is linked to behavioural disinhibition in low- and 
middle-income countries. Little has been published at the time 
this volume is going to press, but one study suggests that this is 
not the case (Bunnell et al. 2006b). 
Other factors that influence sexual behaviour among those living 
with Hiv 
Based on the vast literature on sexual behaviour and its 
determinants, this section summarizes other key factors that 
should be considered when investigating high-risk sexual 
behaviour in the context of scaling up treatment for HIV. These 
include:
4	Number and type of partners. Some studies suggest that the 
number of partners, the number of recent sexual encounters 
and the types of sexual partners are associated with unprotected 
sex (Wenger et al. 1994; Hays et al. 1997; Grulich et al. 1998; 
Heckman et al. 1998; Wilson et al. 1999; Semple et al. 2000; 
Crepaz and Marks 2002). Many prevention programmes 
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have considered sex worker and casual partnerships to be 
higher risk than regular partnerships. In the context of HIV 
prevention among people living with HIV, however, regular 
partnerships pose a particular risk when the regular partner is 
HIV-negative and when condom use is low. Evidence from sub-
Saharan Africa suggests that many HIV-positive individuals 
are married to or living with HIV-negative partners (Dunkle et 
al. 2008). In addition, unprotected sex is common in regular 
partnerships, even when couples are serodiscordant or the 
partner’s serostatus is unknown (Bunnell et al. 2006a).
4	Concurrent partners. There is evidence that sexual concurrency 
(having more than one sexual relationship at the same time) 
is a more important predictor of STI transmission than the 
number of partners. This has been shown in theoretical sexual 
network models (Watts and May 1992; Kretzschmar 2000) and 
confirmed in epidemiological studies (Morris and Kretzschmar 
1997; Potterat et al. 1999; Rosenberg et al. 1999; Koumans 
et al. 2001).
4	Partner serostatus and viral load. Partner serostatus also 
influences sexual risk behaviour. HIV-positive men and women 
were significantly more likely to engage in unprotected sex with 
seroconcordant partners in studies from both developed and 
developing countries (Crepaz and Marks 2002; Hong et al. 
2006; Kiene et al. 2006; Kiene et al. 2008). Similarly, research 
from the United States found that HIV-negative men who have 
sex with men were more likely to engage in unprotected sex 
with an HIV-positive partner if that partner had an undetectable 
viral load (Guzman et al. 2006). It is noteworthy, however, that 
a number of recent studies from sub-Saharan Africa suggest 
that a substantial proportion of patients receiving treatment 
do not know the serostatus of their partner (Bunnell et al. 
2006a; Simbayi et al. 2007; Luchters et al. 2008; Sarna et al. 
2008).
4	Knowledge and attitudes about Hiv and AiDS. Unprotected 
sex among HIV-positive individuals has been found to be 
associated with less knowledge about HIV and transmission 
(Wenger et al. 1994; Muller et al. 1995; Huszti et al. 1998; 
Derlega et al. 2006), with beliefs that condoms decrease 
sexual pleasure (Kline and VanLandingham 1994; Hays et 
al. 1997), with little commitment to self or others (Godin et 
al. 1996; Kalichman et al. 1997), and with perceived lack 
of control and lower confidence in one’s ability to negotiate 
condom use (Crepaz and Marks 2002). 
4	Disclosure. While Crepaz et al. (2002) did not find an 
association between disclosing HIV status and lower condom 
use, recent studies have found an association between non-
disclosure and rates of multiple partners and unprotected 
sex in some settings (Olley et al. 2004; Carballo-Dieguez et 
al. 2006; Derlega et al. 2006; Kiene et al. 2006; Simbayi et 
al. 2007). More research may be needed to sort out these 
inconsistent findings.
4	Desire for children. Living with a sexual partner and a male 
partner’s desire for children were found to be factors that 
increased the likelihood of unprotected sex among HIV-positive 
women in studies from Brazil (Kerrigan et al. 2006), India 
(Sri Krishnan et al. 2007), Togo (Moore and Oppong 2007), 
Uganda (Nakayiwa et al. 2006) and the United States (Crepaz 
and Marks 2002).
The evidence for some of these associations is somewhat circular, 
in that the outcome variable — high-risk behaviour — is not 
always clearly separate from independent variables, such as 
number of partners or lack of control. Nevertheless, these factors 
need to be taken into account in operational research on the links 
between sexual behaviour and HIV treatment.
2.2 Programme strategies related to Hiv prevention in the 
context of treatment 
While most HIV programmes include some information on 
prevention when counselling clients who are tested for HIV or 
who receive treatment, prevention is not always systematically 
integrated into HIV treatment services. Messages about 
prevention are typically delivered at the initiation of treatment 
and infrequently thereafter; and follow-up visits typically focus on 
adherence and management of side-effects with little emphasis 
on preventing transmission. Some observers have noted that this 
represents a missed opportunity for providers to encourage safer 
behaviours and to empower people living with HIV to persuade 
others to avoid risks.
A number of studies in the United States have found that 
individual or small group counselling was associated with 
reports of reduced unprotected sex among those living with HIV 
(Kalichman et al. 2001; Rotheram-Borus et al. 2001; Patterson 
et al. 2003; Sorensen et al. 2003; Richardson et al. 2004; 
Wingood et al. 2004; Kalichman et al. 2005; Wolitski et al. 2005). 
In most cases, these programmes were designed to provide 
skills, to raise awareness of the risks of HIV transmission and to 
address behavioural issues related to treatment and prevention. 
A meta-analysis of controlled trials in the United States found 
14 interventions that significantly reduced unprotected sex 
(Crepaz et al. 2006). Most were based on behavioural theory 
and addressed a range of issues (coping, adherence, etc.) 
but focused extensively on specific skills and behaviours. In 
addition, most were delivered on a one-to-one basis by health 
care providers or professional counsellors and involved at least 
10 sessions over three months.
A meta-analysis of studies from developing countries between 
1990 and 2005 found evidence that client-initiated testing 
(commonly called VCT) may have a moderate but significant 
positive effect on prevention (Denison et al. 2008). Specifically, 
individuals who had received VCT were significantly less likely 
to engage in unprotected sex after being tested, compared with 
their behaviour before testing and compared with participants 
who had not received client-initiated testing; however, the meta-
analysis found no significant effect on the number of sex partners 
(Denison et al. 2008). This review underscores the potential for 
client-initiated testing as a prevention strategy, but also the need 
for more evidence. For example, as mentioned in the chapter on 
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Testing and Counselling in this volume, recent studies from the 
United States and Zimbabwe (neither of which was included in 
the meta-analysis mentioned above) reported that high-risk sex 
increased following rapid HIV testing among men who tested 
negative (Metcalf et al. 2005; Corbett et al. 2007).
Since 2005, there have been a few additional studies in sub-
Saharan Africa that have examined efforts to integrate HIV 
prevention into services for people living with HIV (Kalichman 
2007). For example, prevention efforts by the TASO programme 
in Uganda significantly reduced levels of unprotected sex among 
those living with HIV (Bunnell et al. 2006a; Were et al. 2006). 
Community health workers developed individualized risk reduction 
plans with goal setting, encouraged and facilitated disclosure and 
partner testing, and in some places provided HIV tests at home 
for family members. (These results are similar to an earlier study 
in Zambia where home-based services, partner HIV testing and 
couple counselling among patients receiving antiretroviral therapy 
were found to reduce high-risk sexual behaviours (Allen et al. 
2003).) A recent study from South Africa reported that a brief 
risk reduction intervention delivered by counsellors during routine 
clinical care visits led to a significant decline in unprotected 
sex among those receiving the service compared with those 
in the control group (Cornman et al. 2008). And, a large HIV 
prevention trial has begun among discordant couples in eastern 
and southern Africa (Lingappa et al. 2008). More research is 
needed to examine the extent to which these prevention services 
can be successfully integrated into treatment services and which 
strategies are most effective in different settings.
3. rESEArCH ObjECTivES AND QUESTiONS
As noted earlier, the objective of the research proposed in this 
chapter is to document sexual risk behaviours among specific HIV-
positive populations, with the goal of identifying gaps in service 
delivery, designing prevention programmes or behaviour change 
communications strategies and/or comparing programmes. 
Possible research questions and hypotheses relevant to sexual 
risk behaviours in the context of scaling up HIV treatment are 
given in the box below.
The first two research questions require comparisons of HIV-
positive individuals who are receiving treatment with those 
who are not, or before-and-after comparisons of the same 
individuals over time. (Note, however, that the former design 
presents a challenge, as researchers must ensure that control 
and study groups are comparable and that they do not compare 
healthy controls with symptomatic study group participants.) The 
third research question applies to a broader study population, 
including individuals who are HIV-positive but are not yet receiving 
treatment. The fourth research question can be investigated by 
asking health workers about their practices and by asking users 
of health services about their experiences. The fifth research 
OPERATIONAL RESEARCH qUESTIONS AbOUT HIv PREvENTION 
IN THE CONTExT OF SCALINg UP TREATMENT
1. to what extent is receiving antiretroviral therapy associated with a change in levels of sexual activity (a resumption, an increase, an 
interruption or a reduction of sexual activity)?
 Hypotheses:
n Sexual activity among HIV-positive individuals increases/decreases/stays the same after initiating antiretroviral therapy. 
n Sexual activity among HIV-positive individuals increases/decreases/stays the same with increased duration of antiretroviral 
therapy.
2. to what extent is receiving antiretroviral therapy associated with high-risk sexual behaviour (such as unprotected sex)? 
 Hypotheses:
n High-risk sexual behaviour increases/decreases/stays the same after initiating antiretroviral therapy.
n High-risk sexual behaviour increases/decreases/stays the same with increased duration of antiretroviral therapy.
3. to what extent are knowledge, perceptions or attitudes about hiv and hiv treatment associated with high-risk sexual behaviours?
 Hypotheses:
n Individuals who have limited knowledge of HIV transmission are more likely to report high-risk sexual behaviours, such as 
unprotected sex.
n Individuals who believe that receiving treatment or achieving undetectable viral loads reduces or eliminates the risk of HIV 
transmission are more likely to report high-risk sexual behaviours.
n Individuals who are excessively optimistic about antiretroviral therapy or who express lower concern about HIV in light of 
treatment availability are more likely to report high-risk sexual behaviours.
4. to what extent are prevention services integrated into hiv treatment services? 
5. to what extent do prevention services (delivered in the context of treatment) reduce high-risk sexual behaviours among hiv-positive 
clients?  
 Hypotheses:
n Patients receiving prevention services in the context of HIV treatment will report fewer high-risk sexual behaviours than those who 
do not receive these services.
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wIDELy USED vARIAbLES FOR MEASURINg SExUAL RISk bEHAvIOUR
n multiple partners. Multiple partners can be measured by asking about the number of sexual partners during a defined reference period. 
n Concurrent partners. Concurrent partners are overlapping sexual partners. Concurrency can be measured by asking for the dates that 
partnerships began and ended or, less specifically, by asking about multiple partnerships over a short but defined reference period. 
n type of sexual partners. Partners may be categorized in different ways, such as regular, non-regular (casual) and sex workers. Categories 
of male and female partners can be explored separately or together, depending on the study objectives and the extent to which men have 
sex with men in the community being studied.
n Condom use. Condom use is the key variable when studying sexual risk behaviour. Information on condom use is most often elicited with 
regard to condom use during the last sexual act (for which recall is expected to be accurate for a realistic time frame) and consistent 
condom use (use of condoms every time during the reference period). This information can be asked with respect to a particular partner or 
all partners depending on study objectives and design.
n proportion of unprotected sexual acts. The proportion of penetrative sexual acts (anal and vaginal) in which neither partner used a 
condom can be sought for different sexual partners and various sexual acts.
question would be relevant when seeking to evaluate the effects of 
prevention strategies integrated into treatment services; however, 
investigating this question may require more complex study 
designs than those proposed in this volume.
4. METHODS
4.1 Study populations and study design
The primary population groups to be studied for prevention 
studies in the context of scaling up HIV treatment may include:
4	patients with a diagnosis of HIV who are receiving antiretroviral 
therapy;
4	people living with HIV who are not on treatment but are 
accessing services or are on waiting lists;
4	individuals who have used HIV testing and counselling services 
may be used as a comparison group, depending on the design 
of the study; and
4	health care providers and administrators working in HIV 
testing, counselling and treatment programmes.
Ideally, prevention research should integrate both quantitative and 
qualitative data collection methods in order to monitor changes 
in behaviour as well as to gather an in-depth understanding 
of the context in which these behaviours take place. Possible 
study designs may include repeated cross-sectional surveys 
among different study populations at different points in time. 
For example, researchers may conduct cross-sectional surveys 
among HIV-positive individuals before and after initiating 
treatment and at different points in time thereafter. They may also 
compare treated versus untreated HIV-positive individuals. With 
some adaptation of the instrument, researchers could compare 
individuals who have been tested with those who have not, or with 
general population groups according to treatment availability and 
coverage in different settings.
4.2 Measuring sexual risk behaviour
Sexual risk behaviour has been documented through many 
behavioural surveys conducted among general populations, 
as well key populations at higher risk. Reviews of validity and 
reliability of such research have found that sexual behaviour 
data are fairly consistent (Aral and Peterman 1996; Crosby 1998; 
Fenton et al. 2001; Wellings and Cleland 2001), and that self-
reported data from partners about sexual acts and condom use 
are reasonably congruent, especially for infrequent acts and short 
recall periods (Ellish et al. 1996; Shew et al. 1997; Stone et al. 
1999; Weir et al. 1999; Obermeyer 2005). Quantitative indicators 
of risk behaviours may indicate the magnitude or direction of 
changes over time, but they provide limited information on the 
context of or reasons for high-risk behaviours. Qualitative data 
can improve the quality of self-reports by providing information on 
the context in which sexual risk behaviour takes place (Amon et 
al. 2000). The variables in the box below have been used widely 
to measure sexual risk behaviour in prevention studies because 
they have a direct influence on sexual HIV transmission.
In addition, researchers may need to gather information about 
knowledge of HIV infection and its transmission, attitudes about 
condom use, personal risk perceptions, relationships with 
partners and respondents’ ability to negotiate condom use. 
For such variables, both quantitative and qualitative data are 
recommended.
Operationalizing variables, populations of interest and recall 
periods
Researchers studying HIV prevention in the context of treatment 
may need to consider the following methodological points:
4	Asking respondents to categorize their sexual partners presents 
important methodological challenges. Many studies have used 
categories such as regular, casual and commercial sexual 
partners. Regular partners are often defined as spouses or 
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co-habiting partners, but in some cultural contexts, researchers 
may want to use a broader definition that includes long-term 
partners, even if the couple is not married or cohabiting. Sex 
worker partners are generally defined as sexual partners who 
are paid in exchange for sex, but patterns of exchange of sex 
for money or gifts are complex and the definition is not easy 
to operationalize. Some researchers classify sex workers as 
casual partners for convenience, however, this may lead to a 
loss of information. Non-regular or casual partners are often 
defined as those who are not regular partners and are not sex 
workers. The categories of sexual partnerships commonly used 
by researchers are complex and pose a major measurement 
challenge, since they may not match local understanding and 
may not translate well into different languages (UNAIDS 2007). 
To avoid confusion, researchers may want to explore local 
categories and terms for different types of partnerships before 
finalizing the wording of their questionnaires. They will also 
need to carefully explain these categories to respondents.
4	researchers can gather information on each sexual partner 
individually, or by asking about all partners of a specific type 
during a certain time period. There are two approaches to 
collecting data on sexual partners in prevention studies. One 
approach is to collect information about each individual sexual 
partner in the order that the sexual encounters occurred 
during a specified reference period. Researchers can decide 
how many partners are to be included depending on the study 
objectives. For example, sexual network studies often focus on 
the last three sexual partners (Laumann et al. 2004; Morris et 
al. 2004), while studies examining the risk of HIV transmission 
may focus on all sexual partners during a fixed reference 
period (Bunnell et al. 2006a). The other approach is to collect 
information on each category of sexual partner, for example 
regular partners, casual partners and sex worker partners, in 
a given reference period (Amon et al. 2000; Horizons 2006). 
This method is widely used in behavioural surveillance surveys 
in most countries and can allow comparisons within and 
across countries and geographic regions. It is also the method 
used in the Client Instrument in this volume.
4	recall periods may be 3, 6 or 12 months long. Different recall 
periods have been used to document sexual behaviours. 
Behavioral Surveillance Surveys conducted by Family Health 
International (Amon et al. 2000), National Family Health 
Surveys (IIPS and Macro International 2007) and monitoring 
and evaluation indicators developed by the UNAIDS Monitoring 
and Evaluation Reference Group (MERG) use a 12-month 
reference period, while Centers for Disease Control and 
Prevention studies, such as Reproductive Health Surveys, 
have used a 3-month reference period (Morris et al. 2005; 
Bunnell et al. 2006a). Demographic and Health Surveys 
have used a 6-month reference period (Bateganya et al. 
2005; Sarna et al. 2008). There are advantages and 
disadvantages to each of these recall periods. Shorter recall 
periods provide more reliable responses, but if few respondents 
report sexual activity, researchers may need to lengthen the 
recall period or increase the sample size. In this volume, the 
Prevention Module of the Client Instrument uses a recall period of 
3 months, but researchers can modify this to 6 or 12 months, 
depending on the needs of the particular study.
4	Separate research instruments or questionnaire sections may be 
needed for men and women. It may sometimes be appropriate 
to divide the data collection instrument into different sections 
for men and women respondents to make it easier to seek 
responses related to same sex sexual partners (men who have 
sex with men). If the same instrument is used for both men 
and women, careful skip patterns may be needed.
4	interviewers need special training to gather data on sexual 
behaviour. Training is necessary to ensure that interviewers can 
build rapport with respondents, conduct interviews in a non-
judgemental manner and elicit accurate responses on sensitive 
subjects. Training on other ways to collect sensitive data such 
as ACASI (audio computer-assisted self-interviewing) may also 
be desirable.
4	Studies of sexual behaviour among Hiv-positive respondents 
may need to address slightly different variables than those 
carried out among the general population. Although prevention 
studies among HIV-positive populations may address many of 
the same questions as those among the general population, 
researchers may want to gather more detailed information 
about factors that influence sexual behaviour, depending on 
the scope of the study. In addition, researchers may need to 
add questions pertaining to stigma or disclosure, depending 
on the study population. 
5. vAriAbLES AND SUrvEy QUESTiONS
The following section lists questions that can be used in surveys 
among HIV-positive respondents or health professionals who 
provide HIV-related care. Most but not all these variables are 
included in the Prevention Modules of the Client and Provider 
Instruments in this volume. As noted earlier, the Prevention 
Module uses a reference period of 3 months, but researchers 
can modify this to 6 or 12 months, depending on the study 
design and the preference of the researcher. “Don’t know”, 
“Don’t remember” and “No Response” categories can be added 
as appropriate.
kEy vARIAbLES RELATED TO PREvENTION AMONg 
INDIvIDUALS LIvINg wITH HIv
a. Sociodemographic variables (e.g. educational, 
employment and marital status)
b. Length of time since HIV diagnosis and initiation of 
antiretroviral therapy
c. Sexual activity 
d. Type and number of sexual partners
e. Sexual activity and condom use with regular/casual/sex 
worker partners
f. Knowledge of partner’s HIV status/disclosure of own 
status to partner
g. Sexual activity and condom use among men who have sex 
with men
h. Concurrent sexual partners
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5.1 variables and survey questions related to prevention 
among individuals living with Hiv
a. Sociodemographic variables
Sociodemographic variables should include age, sex, education, 
employment, living conditions and socioeconomic status. Marital 
status is a particularly important sociodemographic variable to 
be included in sexual behaviour studies. In countries where 
polygamy is common, survey instruments should ask married 
individuals about more than one spouse. Researchers may also 
need to disaggregate findings by sex and age in order to identify 
findings that can inform the design of effective programmes for 
women and men, as well as for young people (e.g. aged 15 to 
24 years) versus older adults.
b. Length of time since Hiv diagnosis and initiation of 
antiretroviral therapy
Researchers may want to examine how sexual behaviour changes 
over time among HIV-positive individuals receiving antiretroviral 
therapy. Therefore, asking about the length of time that has 
passed since the respondent received the HIV-positive diagnosis 
or initiated antiretroviral therapy provides important information 
about reference periods. Time on antiretroviral therapy is also a 
key variable for comparing behaviour before and after starting 
treatment and at different points in time over the course of 
treatment, as well as for comparing patient groups.
c. Sexual activity and behaviours 
Asking respondents whether they have had sexual intercourse 
in a recent reference period allows researchers to determine the 
number and proportion of patients on antiretroviral therapy who 
are sexually active. This in turn provides the denominator for the 
proportion of sexually active patients who engage in high-risk 
sexual behaviours.
d. Type (and number of each type) of sexual partners
The Client Instrument includes numerous variables and survey 
questions related to the type and number of sexual partners, 
including the total number of partners and the number of regular 
partners, casual partners, sex worker partners and — for male 
respondents — the number of male partners (whether regular, 
casual or sex workers). Depending on the study objectives, 
researchers might want to include additional questions about 
the lifetime number of sexual partners (which has been found 
to be associated with an increased risk of unprotected sex), the 
age at first sexual intercourse and whether sexual initiation was 
forced or voluntary.
e. Sexual activity and condom use with regular partners/casual 
partners/sex workers
It is expected that the best recall of condom use would be 
for the most recent period, so it is common to enquire about 
condom use at the respondent’s most recent sexual contact. 
But since successful prevention strategies require condoms 
to be used consistently, surveys on prevention should also ask 
about consistent condom use over a specific reference period. 
Consistent condom use is typically assessed on a categorical scale 
for the reference period (e.g. always, almost always, sometimes, 
rarely and never). If researchers need a quantitative measure to 
calculate the proportion of unprotected sexual acts, they may 
want to use a shorter reference period and include more detailed 
questions. Researchers may also want to ask about reasons for 
using or not using condoms.
i. Knowledge and attitudes related to HIV infection and 
treatment 
j. Attitudes and treatment optimism related to antiretroviral 
therapy
k. Fertility desires and family planning methods
variable suggested wording of survey Question
Penetrative sex with 
each type of partner 
(regular, casual, sex 
worker) in the last 3 
months
during the last 3 months, have you had sexual 
intercourse (meaning penetrative vaginal or 
anal sex) with a spouse or a live-in — what we 
call a regular partner?
The same question can be posed for casual 
partners, sex worker partners and male partners 
(for male respondents).
Consistent condom 
use with all partners 
of each type (e.g. 
all regular, casual, 
sexual worker and 
male partners) 
during the last 3 months, when you had sexual 
intercourse with your regular partner(s), 
how often did you and your partner(s) use a 
condom?
The same question can be posed for casual 
partners, sex worker partners and male partners 
(for male respondents).
Consistent condom 
use with all partners
thinking about all the times you had sex with 
any partner during the last 3 months, would 
you say that you and your partner(s) used a 
condom: 





q declined to answer
Condom use at last 
sex with most recent 
partner, by type
the last time that you had sexual intercourse 
with your most recent regular partner, did you 
and your partner use a condom?
The same question can be posed for casual 
partners, sex worker partners and male partners 
(for male respondents).
Reasons for not 
using a condom at 
last sex (optional)
why didn’t you or your partner use a condom 
the last time you had sex with a regular 
partner/non-regular or casual partner/sex 
worker?
variable suggested wording of survey Question
Proportion of 
respondents who are 
sexually active
have you had sexual intercourse (meaning 
penetrative vaginal or anal sex) during the 
last 3 months?
Number of sexual 
partners in last 3 
months
how many different partners have you had 
sexual intercourse with during the last 3 
months?
Reasons for sexual 
inactivity in last 3 
months
If sexually inactive: what are the reasons why 
you have not had sex in the last 3 months?
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f. Knowledge of regular partner’s Hiv status and disclosure of 
own status
Knowledge of regular partner’s HIV status and disclosure of status 
to regular partner are core variables for all prevention studies, 
as they can influence condom use. More details about how to 
collect information on this variable are available in the Testing 
and Counselling chapter. 
g. Sexual activity among men who have sex with men
Depending on the research objectives and the extent of same sex 
behaviour among men who have sex with men in the study sites, 
researchers may want to include a section on this type of sexual 
activity in the questionnaire. For studies exploring whether such 
behaviour exists in the community, this line of enquiry can be 
limited to a few survey questions. For more detailed information, 
researchers can ask survey questions similar to those for other 
types of partners. Variables may include: sexual intercourse 
ever with a male partner (for male respondents), sex with a male 
partner in the last 3 months, number and type of male partners 
in the last 3 months and condom use with male partners in the 
last 3 months.
h. Concurrent sexual partners
Researchers with a special interest in concurrent sexual 
partnerships may want to ask detailed questions about the 
duration of sexual relationships (including start and stop dates) 
with various partners over a fixed time frame. This requires a full 
set of partner related questions, however, which lengthens the 
questionnaire and may not always be feasible. A simpler global 
question is to ask: “During the last 3 months, did you have 
sexual intercourse with any partner during the same period of 
time that you were having an ongoing sexual relationship with 
someone else?”
i. Knowledge and attitudes related to Hiv infection and treatment 
In this volume, survey questions about knowledge and attitudes 
related to HIV and HIV treatment are included in the Testing and 
Counselling Module of the Client Instrument. Therefore, they are 
not repeated in the Prevention Module. Researchers who want 
to gather information on these variables without using the whole 
Client Instrument may want to extract survey questions from the 
Testing and Counselling Module on the following topics:
4	Knowledge of Hiv transmission. What are some ways that 
HIV can be transmitted?
4	Knowledge of ways to reduce the likelihood of sexual Hiv 
transmission. What are some ways that an HIV-positive 
person can reduce the likelihood that he or she might 
transmit the virus to another person through sexual contact? 
4	Knowledge of people infected with Hiv. Does the respondent 
personally know anybody who is infected with HIV or who 
has died of HIV? Or, does the respondent have a close 
relative or close friend who is infected with HIV or who has 
died of HIV? If yes, who was this person in relation to the 
respondent? 
4	Knowledge of Hiv and Hiv treatment. Does the respondent 
believe that antiretroviral therapy can remove the virus from 
the body completely? Can HIV or AIDS be completely cured? 
Does the respondent think that a healthy looking person can 
be infected with HIV?
j. Attitudes and treatment optimism related to antiretroviral 
therapy
The items below have been adapted from questions developed 
and used in studies of treatment optimism (Van de Ven et al. 
1999; Elford et al. 2002; Vanable et al. 2003). These items can 
be analysed individually, or they can be combined to create a 
composite variable for optimism. Ideally they would be used with a 
5-point scale (such as strongly agree, agree, undecided, disagree 
or strongly disagree), but a 3-point scale may be preferable in 
some settings.
Please indicate whether you agree, are undecided or 
disagree with each of the following statements:
4	i would feel safe having intercourse with someone who 
has an undetectable viral load (or who is receiving 
treatment).
4	i am less worried about Hiv infection now than i used 
to be.
4	The new Hiv treatments make me less anxious about 
having unprotected sex.
4	i believe that Hiv treatment makes people with Hiv less 
infectious.
k. Fertility desires and family planning methods 
Given the limited availability of assisted reproduction techniques 
(such as sperm washing or in vitro fertilization) in most developing 
countries, HIV-positive individuals who want children may have 
no other choice but unprotected sex. Research on prevention 
should, therefore, include some survey questions about number 
of living children, desire for more children and use of family 
planning methods, such as:
4	Desire for children. Does the respondent want to have a 
child/another child? If yes, in what timeframe? Does the 
respondent’s spouse or partner want to have a child/another 
child?
4	Current use of family planning. Does the respondent or his/
her partner/spouse use any family planning method? If yes, 
which one?
5.2 Additional variables and questions for research on 
prevention
Depending on feasibility and relevance in particular settings, 
researchers may consider collecting data on the following topics 
in prevention studies.
a. biomedical variables 
If researchers can gather biomedical data, viral load and CD4 
counts are key variables. Viral load may influence the risk of 
transmission and should be obtained where possible. CD4 cell 
HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH
54
HIV PREVENTION IN THE CONTEXT OF SCALED-UP ACCESS TO HIV TREATMENT
55
counts reflect the degree of immune suppression as a result of 
HIV infection. CD4 measures can be used as surrogate markers 
of improved health status, and they are more readily available 
than viral load tests in most resource-limited settings. Variables 
might include:
4	viral load at start of treatment (if available)
4	viral Load – most recent/current 
4	CD4 at start of treatment (if available)
4	CD4 – most recent/current
b. Alcohol and Drug use
Depending upon the context, prevention strategies may need 
to consider addressing alcohol and drug use, either as a mode 
of HIV transmission (in the case of injecting drug users) or as 
a factor that may increase the risk of sexual HIV transmission. 
Alcohol use and drug use questions can be used individually 
or combined to develop index scores. Drug use questions are 
generally structured to ask about ever use, active drug use in 
a certain reference period and high-risk behaviours related to 
injecting drugs that are commonly available in the community. 
The reference period used to define active drug use varies with 
surveys. The widely used Behavioral Surveillance Surveys (Amon 
et al. 2000) use 6 months as the reference period. This volume 
contains an optional module for the purpose of gathering data on 
respondents’ use of alcohol and other types of drugs.
5.3 variables and survey questions related to prevention 
for health care providers
There are a number of variables and survey questions related 
to prevention in the Provider Instrument in this volume. Single 
or composite variables on prevention services can be generated 
from the following types of questions for health care providers:
4	Are clients provided information on risk reduction and 
safer sex at clinics where they receive treatment?
4	Are condoms available at and distributed by the clinic?
4	Do health providers discuss disclosure of Hiv status to 
partners? 
4	Do they recommend partner testing?
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Instructions to interviewers are in italics.
All text that is meant to be read to the respondent is written in bold type.  For example, when multiple choice
options should be read aloud, the options are in bold, like the questions themselves. When options are
intended for the interviewer only, i.e. when they should not be read aloud, they are not in bold type.
If a respondent declines to answer a question that does not have a specific option for this response, please
write “declined to answer” in the margin of the questionnaire. Please do not read the option “declined to
answer” out loud.
Responses to open-ended questions should be recorded as close to verbatim as possible.
2
 
Hello, I am {NAME} working on a research project supported by {NAME OF LOCAL COLLABORATING
INSTITUTION}.  We are conducting a study on HIV testing, treatment and prevention {IF NECESSARY,
ADD DETAILS}. By listening to people who may have had some experience with health services
around HIV, we hope to learn what goes right with the health services, and how to improve them.
You have been selected to represent people in this area [from this clinic] and we would very much like
to hear about your opinions and experiences. Before we get started, I would like to explain to you how
the interview works.
 
Your participation in the interview and in every aspect of the study is completely voluntary.
If some questions are difficult or make you uncomfortable, we can skip them.  You may also ask
me to clarify any questions if you do not understand them. You may also decide to stop the interview
at any time.
All of the information that you provide for the study will be kept completely confidential. We record
your responses, but the questionnaire will not have your name on it, and your responses to our
questions are identified only by a number, never by name.
If you have questions or concerns after we are finished, you may contact {CONTACT PERSON AT
THE COMMUNITY LEVEL}.
Although there are no direct benefits to you from participating in this survey, we hope that the
survey will help to improve health services and support for people living with HIV and AIDS. The
survey will take about {ESTIMATED TIME IN MINUTES} minutes.
Do you have any questions about the survey?  Would you be willing to participate in our study?
3
Depending on local ethical clearance, it may be necessary to fill out a signed consent form. In that case it
would be preferable to design the instrument so as to be able to separate the form from the rest of the
instrument

We have a form that must be read to you before we begin, in order to confirm that we have explained
the study to you and that you have agreed to participate. 
We ask you to sign the form, but we do not keep the form attached to the questionnaire, so your name
will not be linked to the information we write about you, and no one except the people responsible for
the study will have access to this information.  
The form just repeats what I have told you about the study, but I have to read it to you.
I understand that I have been asked by {NAME OF INSTITUTION} to participate in a research project
designed to investigate people's experiences and perspectives regarding HIV testing, counselling and
treatment.
I understand that during this study I will be asked questions about my health and health care, and
that my responses will be recorded in a questionnaire form. But my participation in the study will be
kept confidential, and my identity will be available only to those performing or supervising the
research. I understand that I would never be identified by name in any publications resulting from this
study.
I am aware that there may be some questions asked during the interview which may make me
uncomfortable. I realize that I do not have to answer any question that I do not want to answer. I
understand that I am free to withdraw my consent and to discontinue participation in this research
project at any time, without affecting my future care or treatment.
I realize that I will not benefit directly from this project. However, with my participation, I hope to
help investigators understand how to improve health services.
4

I have read this consent form or have had explained to me to my satisfaction the information relating
to this study. I understand what my participation will involve and agree to take part in this interview
under the terms of this agreement. I have had the opportunity to ask questions about it, and my
questions have been answered to my satisfaction.
I consent voluntarily to participate in this study and I understand that I have the right to withdraw at
any time, without it in any way affecting my future medical care.
Participant                                                                                                                                                                                 
Name __________________________
Date ___________________________











Interviewer can complete this section before the interview starts.
C1.1 Interview ID number in the form of 001, 002, 003...
C1.2 Date of interview DD/MM/YYYY
  _____/_____/______                                                               
C1.3 Interviewer name or code
C1.4 Location of interview
health facility, please specify name and location: _________________________
respondent's home
other, please specify:
C1.5 Time of interview start. Use the 24:00 clock.





C2.1 Sex of the respondent? Do not read this question.
female
male
C2.2 How old are you? In years.
C2.3 What is your {ethnicity/religion/place of residence} {CHOOSE ONE OR SELECT ANOTHER




                .............................................................






post secondary or more
other, please specify:
declined to answer








Now I have some questions about the type of work you do and your access to food.
C2.6 What kind of work do you do? By that I mean, what kind of activities keep you busy during
an average day, whether you earn money from them or not. Record answer as given, and then












none (Probe: No agricultural or housework?)
other, please specify:
declined to answer
                .............................................................
C2.8 During the past month, how often have you had problems getting the food you need?




declined to answer Go to C2.10
C2.9 Please tell me what the problems were.
8
Now I would like to ask you some question about your home and living conditions.
C2.10 Do you live alone?
yes Go to C2.12
no
declined to answer Go to C2.12





                .............................................................
C2.12 Do you [or any member of your household] own any of the following means of
transportation? Adjust wording if respondent lives alone.
vehicle/car




                .............................................................
C2.13 What is the main roofing / flooring / walling material {CHOOSE ONE} of the home you live
in?
{3 COUNTRY-SPECIFIC; BEST TO WORST}
other, please specify:
declined to answer
                .............................................................
9
C2.14 Does your home have any of the following:
1. drinking water from a tap?





6. electric or gas kitchen stove?
7. telephone (not including
mobile)?
C2.15 Do you [or anyone in your household] own any of the following: Adjust wording if respondent
lives alone.
1. land?
yes no declined to answer
2. livestock / animals that are
raised?









Now I would like to ask you some questions about HIV testing and counselling. What we discuss
during the rest of this interview depends on whether or not you have ever been tested for HIV.
C3.1 Have you ever been tested for HIV?
yes
no Go to C3.64 to non-user questions
don't know Go to C3.64 to non-user questions
declined to answer Go to C3.64 to non-user questions
Now I would like to ask you some questions about getting tested for HIV, how you decided to be
tested, what happened and how you felt about it.
C3.2 Would you be willing to discuss these issues with me?
yes
no Go to C3.84
Go to C3.11 if respondent has tested only one time
C3.3 How many times have you been tested for HIV? Emphasize that the questions concern testing
for HIV only, and not other tests such as CD4 counts, etc. If respondent cannot remember the
precise number, a close approximation is sufficient.
number of times tested.........................................
11
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The next few questions are for those who have tested more than once. Please think about when you
had your first HIV test.
C3.4 How long ago did you have your first HIV test? Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.
number of months ago .........................................
number of years ago ............................................





C3.6 Were you tested on your own initiative or because you were offered a test by a health
worker at a facility or at home?
tested on own initiative
offered test by health provider at a health facility
offered test by health worker at home
other, please specify:
                .............................................................
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C3.7 What was the reason for your having a test? Record answer as given, and then choose option/s
below.
C3.8 Mark all that apply. Do not read the options.
respondent wanted to know serostatus
partner--partner's past sexual behaviour
partner--partner told you to get tested
partner--partner ill or died
child--child ill or died
exposure--your own past sexual behaviour
exposure--blood transfusion
exposure--taking care of people with HIV or AIDS
exposure--contaminated instrument
exposure--syringe exchange
symptoms/health--symptoms that made you or a health provider think you might have HIV
symptoms/health--hospitalization for another reason
symptoms/health--giving blood
PMTCT
provider said it was a routine part of care
future plans--marriage
future plans--having children
future plans--planning for future




                .............................................................




don't remember Go to C3.11
declined to answer Go to C3.11
13
C3.10 Why / Why not?
+))-,
Note to interviewer: the following questions are for all those who have had an HIV test, whether just once or
more than once.
For respondents who have had more than one HIV test say: We have been talking about the first time you
were tested for HIV, but now I would like you to think about your most recent HIV test.
C3.11 How long ago did you have your [most recent] HIV test? Choose question wording depending
on whether respondent has had more than one test.  Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.
number of months ago .........................................
number of years ago ............................................
C3.12 Where were you tested?
at a health care or testing facility
at home Go to C3.18
other, please specify: Go to C3.18
.............................................................................
C3.13 What was the name of the health care facility where you had this test?




C3.15 Why did you go to that particular facility?
C3.16 Did anyone accompany you to the facility where you were tested?
yes
no Go to C3.18














C3.19 Were you tested on your own initiative or because you were offered a test by a health
worker at a health facility or at home?
tested on own initiative
offered test by health provider at a health facility
offered test at home
other, please specify:
                .............................................................
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C3.20 What was the reason for your having a test? Record answer as given, and then choose option/s
below.
C3.21 Mark all that apply. Do not read the options.
respondent wanted to know serostatus
partner--partner's past sexual behaviour
partner--partner told you to get tested
partner--partner ill or died
child--child ill or died
exposure--your own past sexual behaviour
exposure--blood transfusion
exposure--taking care of people with HIV or AIDS
exposure--contaminated instrument
exposure--syringe exchange
symptoms/health--symptoms that made you or a health provider think you might have HIV
symptoms/health--hospitalization for another reason
symptoms/health--giving blood
PMTCT
provider said it was a routine part of care
future plans--marriage
future plans--having children
future plans--planning for future
offered test at home
other, please specify:     ........................................................................................
don't know
declined to answer
                .............................................................
C3.22 [When you had your most recent test,] was it hard for you to be tested? Choose question




don't remember Go to C3.24
declined to answer Go to C3.24
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C3.23 Why / why not?
#./&
C3.24 Did you discuss getting tested with anyone before you had your HIV test?
yes
no Go to C3.26
don't remember Go to C3.26
declined to answer Go to C3.26
C3.25 Can you tell me more about this? Probe: for example, who did you talk to and what did you talk
about?
C3.26 Did [someone from the health facility, such as] a health care provider or counsellor meet
with you to discuss the test before you had it? Choose wording depending on whether tested at
home or at a facility.
yes
no Go to C3.29
don't remember Go to C3.28
declined to answer Go to C3.28







C3.28 Before your blood/oral sample was taken for testing, did a health care provider or
counsellor do any of the following:
explain that you had a choice to







tell you that your results would
not be shared with anyone
except for the clinic staff who
care for you?
explain how HIV is transmitted?
x
explain how the test works?
x
explain the meaning of positive
and negative test results?
explain that the test does not
always detect a very recent HIV
infection (this is sometimes
called a window period)?
give you advice on preventing
the spread of HIV?
give you time to ask questions?
x
other, please specify:
                  ...........................................................

Some health workers ask clients whether they agree to the test before they do it, but other health
workers just go ahead with the HIV test without asking first. I would like to ask you about your
experience when you were tested.
C3.29 How important was it for you to be asked if you agreed or refused to be tested for HIV






C3.30 Did a health worker ask you whether you agreed to be tested for HIV before your HIV test
was done?
yes
no Go to C3.32
don't remember Go to C3.32
declined to answer
C3.31 Did you agree to be tested?





C3.32 For those who did not agree or who don't remember whether they agreed: Since you did not
agree [do not remember if you agreed] to be tested, what were the circumstances under
which you were tested?












declined to answer Go to C3.36
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C3.35 Why / why not?
C3.36 Was anyone else involved in getting your agreement to be tested?
yes
no Go to C3.38
don't remember Go to C3.38




Now I would like to ask you about whether you got the results of your most recent HIV test and what
other type of services and care you received at that time. I am not going to ask you to tell me your
results now.
C3.38 Did you receive your results from your most recent HIV test?
yes Go to C3.42
no
declined to answer Go to C3.84
C3.39 Why not?
C3.40 Just to double check, have you ever received results from any previous HIV test?
yes
no Go to C3.84
don't remember Go to C3.84
declined to answer Go to C3.84
C3.41 How long ago did you have that previous test? Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.
number of months ago ... .....................................
number of years ago ............................................
21
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,
C3.42 How long after the test did you receive your results? An approximate guess is fine.
within one hour of the test
same day
1-3 days after the test
4-7 days after the test
more than one week after the test
don't remember
declined to answer
C3.43 Did anyone accompany you to the facility when you received your test results?
yes
no, no one accompanied respondent Go to C3.45
no because received test results at home Go to C3.45









Now I would like to ask you some questions about what information or counselling you received from
the workers who gave you your test results.
C3.45 After giving you your test results, did a health care provider do any of the following:







suggest that you discuss your
status with someone?
suggest that your sexual
partner[s] be tested for HIV?
discuss how to prevent the
transmission of HIV?
22
C3.46 About your meeting with the health care provider after you got your test results:





were you given the opportunity
to ask questions?
on the whole, did you find the
meeting helpful?







Sometimes health workers do everything they can to keep clients’ HIV test results confidential so that
other people do not know about them. Other health workers sometimes say or do things that reveal
clients’ HIV status to other people without their permission. People have different feelings about how
important it is for health workers to keep HIV tests results confidential.
C3.48 How important is it to you that these health workers keep your HIV results confidential and





Now I would like you to think about the health workers who did your HIV test and gave you your
results.
C3.49 Do you think that these health workers have kept your test results confidential?
yes--protected confidentiality






Now, if it is okay with you, the following questions are more personal. I will begin by asking you some
questions about your HIV status and also what happened when you learned your HIV status.
Remember that the survey is confidential, and your name does not appear on the form. As we said at
the beginning of the interview, you are free to decide whether or not you want to answer any question,
and you are free to skip any questions that you would rather not answer.
C3.50 Are you willing to tell me your HIV status?
yes
no Go to C3.84
C3.51 What is your HIV status?








declined to answer Go to C3.54
C3.53 Why / Why not?
Go to C3.84
C3.54 Having given you this result, what did the health worker advise you to do?
24
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,
Now I would like to ask you to think back to the day when you first received the test results that
revealed that you were HIV-positive.




declined to answer Go to C3.57
C3.56 Why / Why not?
)).&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,
The next questions are about what has happened since you received your results.






C3.58 After giving you your test results, did any health care provider do the following:






talk about getting help from a
support group for people living
with HIV or AIDS?
refer you to a support group for
people living with HIV or AIDS?
25
C3.59 After giving you your test results, did any health workers talk to you about how to share





C3.60 Since you received your HIV-positive results, has a health care provider told you that you
needed any sort of care or medication in order to manage your HIV and stay healthy?
yes
no Go to C3.84
don't remember Go to C3.84
declined to answer Go to C3.84




don't know and prescription unavailable
C3.62 Have you been able to obtain the[se] medication[s]?
yes, all Go to C3.84
yes, some of them
no, none of them






C3.64 Have you ever thought about having an HIV test?
yes
no
don't know Go to C3.67
declined to answer Go to C3.67
Go to C3.67 if respondent has not thought about having a test.
C3.65 Why / Why not?
C3.66 Since you have thought about having a test, why have you not had one?
C3.67 Do you know anyone personally who has had an HIV test?
yes
no Go to C3.73
don't know Go to C3.73
declined to answer Go to C3.73
27







                .............................................................
C3.69 Do you think that getting tested was helpful for [any of] them? Phrase questions depending on
response above in C3.68.
yes
no Go to C3.71
don't know Go to C3.71
declined to answer Go to C3.71
C3.70 Who and why?
C3.71 Do you think that getting tested caused any problems for anyone you know?
yes
no Go to C3.73
don't know Go to C3.73
declined to answer Go to C3.73
28
C3.72 Who and why?
C3.73 Do you know any facilities offering HIV testing and counselling to people who live around
here?
yes
no Go to C3.79











don't know Go to C3.77
declined to answer Go to C3.77
29
C3.76 Why?
C3.77 How long would it take you to get to the nearest health facility that offers testing and
counselling from your home? Hours, minutes
hours ....................................................................
minutes ................................................................
C3.78 Do you think that health workers there always keep people's HIV test results confidential





C3.79 If you decided to have an HIV test, how important would it be to you that these health






C3.80 Have you ever had an HIV test offered to you when you were at a health facility or in your
home?
yes
no Go to C3.84
don't remember Go to C3.84
declined to answer Go to C3.84
C3.81 Where was this?
30
C3.82 What were the circumstances?
C3.83 Why did you not accept the offer to have the test?
31
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Now, if you don’t mind, I would like to ask you some general questions about what you think of HIV
testing. These questions will not ask you about your personal experiences.




declined to answer Go to C3.86
C3.85 Why / Why not?
C3.86 What do you think about the practice of offering people HIV testing and counselling at a
health care facility, when they came for something else [For PMTCT: when they came for
ante-natal care?]
32
C3.87 What do you think of the practice of offering people HIV tests in their homes?
C3.88 Do you think that it is okay to require certain people to have an HIV test?
yes
no Go to C3.90
unsure Go to C3.90
C3.89 What types of people do you think should be required to have an HIV test and why?
C3.90 If someone has HIV, do you know of anything that can be done to help them stay healthy
and live longer?
yes
no Go to C3.92
declined to answer Go to C3.92
33
C3.91 What can be done to help them stay healthy and live longer?
C3.92 Do you know anyone personally who is living with HIV or who has died of AIDS? Mark all
that apply.
yes, know someone living with HIV
yes, know someone who has died of AIDS
no, neither
declined to answer
Now I would like to ask you for your ideas about how to improve testing and counselling services in
your community.
C3.93 Do you have any suggestions for how to make it easier for women and men to find out their
HIV status? Record answer as given.
34
C3.94 Do you have any suggestions for how to help people who are HIV-positive get the medical
care they need to stay healthy and live longer? Record answer as given.
%))% ))% 
This concludes this portion of our interview. Thank you very much for your participation.
C3.95 Time of interview or module end. Use the 24:00 clock.







I would like to ask you a few general questions about your opinions regarding who should be tested
and who should know about other people's test results. People have different opinions about this, and
we are interested in your honest feelings.




don't know Go to C4.4
declined to answer Go to C4.4
C4.2 Why / Why not?








               ..............................................................
36
C4.4 Do you think that it is sometimes okay to tell other people that someone else has HIV, even




C4.5 Why or why not?
Go to C4.15 if respondent is HIV-positive
C4.6 In general, how important do you think it is for health workers to keep their clients' HIV
results confidential and not reveal them to anyone else without the client's permission.
37
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The following questions are about fear of AIDS and your feelings towards people living with HIV or
AIDS. We think that different people have different opinions about this, and we are interested in
hearing about your honest feelings and opinions.
C4.7 Please indicate whether you strongly agree, agree, are unsure, disagree or strongly
disagree with each of the following statements:
AIDS is a punishment for bad
behaviour.
strongly






People with AIDS deserve
blame for getting the disease.
Patients with AIDS do not have
the right to the same quality of
medical care as other patients.
Women who are HIV-positive
should be prevented from
having children.
People suspected of having HIV
should be required to be tested.
C4.8 Would you fear getting HIV from any of the following:





sitting next to a person with HIV
or AIDS?
caring for a person with HIV or
AIDS?
This next part is about things that may happen to people when others know they have HIV.
C4.9 Have you heard of people who have been badly treated because they had HIV?
yes
no Go to C4.11
declined to answer Go to C4.11
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C4.10 What happened?
C4.11 Do you personally know anyone who has had any of the following experiences in the past
twelve months because they had HIV or AIDS?
excluded from social events?
yes no declined to answer
abandoned by spouse/partner?
abandoned by other family
members?
verbally abused or ridiculed?
physically assaulted?
fired from work or lost their
job?
expelled from their home?
had property taken away?
denied health services?
C4.12 Do you know of any support groups in this area for people living with HIV or AIDS?
yes
no Go to C4.52
don't know Go to C4.52
declined to answer Go to C4.52
C4.13 What is the group's name?
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C4.14 Please describe the group's activities.
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Now if it is okay with you, I would like to ask you some questions about whether and how you have
shared your HIV status with people around you.





C4.16 Have you shared your HIV test results with anyone outside the health clinic?
yes
no Go to C4.20
declined to answer Go to C4.21










C4.18 After giving you your HIV test results, did any health care provider help you share your
status with people around you?
yes
no Go to C4.21
declined to answer Go to C4.21
Go to C4.21
C4.19 Can you tell me what the health worker did?
C4.20 For respondents who have not disclosed to anyone. Why have you chosen not to share your
HIV status with anyone?
C4.21 Do any other people in your community know that you are HIV-positive even though you
didn't tell them?
yes




C4.22 Who in your community do you think knows that you are HIV-positive even though you
didn't tell them?
health providers
household / family members





Go to C4.37 if no one outside the testing facility knows the respondent's HIV-positive status based on a 'no'
response to both C4.16 and C4.21.






Next, if you don't mind, I would like to ask you a couple questions about how people around you have
reacted when they found out that you have HIV.
C4.24 How did you expect your family or friends would react when they found out you are HIV-
positive?
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Please think of one person whose reaction was the most disappointing to you. Then I will ask you
about the person whose reaction was more supportive or encouraging.
About the person whose reaction was most disappointing:
C4.25 Please tell me about this person. For example, who is this person in relation to you? Probe:
friend, family, etc.
C4.26 How did they know that you are HIV positive?
C4.27 How did this person first react when they found out about your HIV status and how are they
acting now?
About the person whose reaction was most supportive or encouraging:
C4.28 Please tell me about this person. For example, who is this person in relation to you? Probe:
friend, family, etc.
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C4.29 How did they know that you are HIV positive?
C4.30 How did this person first react when they found out about your HIV status and how is this
person acting now?
What about other people who know you are HIV-positive:
C4.31 How did they first react when they learned of your HIV status and how are they acting now?
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Now, if you don't mind, I would like to ask you some other questions about your personal experiences.
C4.32 Have you personally ever been made to feel bad because of things people did or said to you
on account of your HIV status?
yes
no Go to C4.34
declined to answer Go to C4.34
C4.33 Can you tell me what happened?
C4.34 Please indicate whether you agree, are unsure or disagree with the following statements:
Some people avoid touching me





uncomfortable being around me
once they learn I have HIV.
Some people act as though it is
my fault I have HIV, or say I
deserve it for things I have
done.
Now I would like to read you a list of things that have sometimes happened to people living with HIV
because of their HIV status and ask you whether any of these experiences have ever happened to you.
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C4.35 Have you ever experienced any of the following when you thought it was because of your
HIV status? Have you ever been:




abandoned by your spouse or
partner?
abandoned by other family
members?
told that it is your fault you
have HIV?
verbally abused or ridiculed?
physically assaulted by
anyone?
fired from work or lost your
job?
expelled from home?
had property taken away?
 IF ANSWERED NO TO ALL, GO TO C4.37
denied health services?
C4.36 Can you tell me what happened? Record the answer as given.
C4.37 In the past twelve months, have you ever found yourself avoiding or isolating yourself from





C4.38 Now I would like to read two statements. Please tell me whether you agree, are unsure or
disagree with each statement.
I sometimes feel bad about





I sometimes feel guilty because
I have HIV.
Next I would like to ask you some questions about how you are treated when you go to health care
facilities and whether you think you have ever been treated differently than other people because of
your HIV status.
C4.39 When you have used health services in the past year, did any of the following happen to you
when you thought it was because of your HIV status?
staff ignored you or avoided





you were denied care that you
should have received?
you received less care or worse
care than others because of
your HIV status?
the staff seemed uncomfortable
with you because of your HIV
status Probe: for example in the
way they looked at you / talked to
you / handled themselves?
the staff seemed to use more
precautions when treating you
than when treating others
because of your HIV status?
you were treated with
disrespect or abused because
of your HIV status?
I have a few questions about other bad or good things that have happened to you since you found out
your HIV status. Please be as open as you can. We are interested in particular experiences or stories
from your life.
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C4.40 What have been the most difficult things that have happened in your life since you found
out your HIV status?
C4.41 Have there been any good things that have happened in your life as a result of knowing
your HIV status?
yes
no Go to C4.43
don't know Go to C4.43
declined to answer Go to C4.43
C4.42 Please tell me what they were.
&&
C4.43 Since you received your HIV-positive result, have you joined an HIV or AIDS support group?




C4.44 Do you know of any support groups in this area for people living with HIV or AIDS?
yes
no Go to C4.47
declined to answer Go to C4.47
C4.45 What is the group's name?
C4.46 Please describe the group's activities.
C4.47 Since you received your HIV-positive result, have you received any financial assistance,
food assistance, or emotional and social assistance from the government or any HIV or
AIDS support organization?
yes
no Go to C4.49
don't remember Go to C4.49
declined to answer Go to C4.49





                .............................................................




declined to answer Go to C4.51
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C4.50 Why / Why not?
C4.51 Do you have any suggestions for ways that health programs can help improve the lives of
people living with HIV in this community?
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This concludes this portion of our interview. I would like to thank you very much for helping us.  I
appreciate the time that you have taken to answer these questions.  I realize that some of these
questions may have been difficult to answer, but it is only by hearing from women and men about
their firsthand experiences that we can understand how to improve the lives of people who are living
with HIV.
In case you or anyone else you know needs assistance, here is a list of places that provide support
groups, counselling and other services {Phrase according to the services available} for people living with
HIV.
C4.52 Time of interview or module end. Use the 24:00 clock.




In the next section of this interview, I would like to ask you about your experiences with taking ART.
Researchers should choose a term for HIV treatment that is understandable in the local context, whether that
is a complete phrase such as 'antiretroviral therapy', an acronym, such as ART, or another term.
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C5.1 Just to confirm, are you taking ART to manage your HIV? Adjust this question and the next
depending on whether this module is used alone or as part of a larger interview that has already
identified whether or not the respondent is taking ART.
yes
no Go to the end of the Adherence module
C5.2 How long ago did you first start taking antiretroviral therapy to manage your HIV? Record
the number of months and years that have passed. If less than a year has passed, write '0' years;
similarly, if less than a month has passed, write '0' months. Do not leave those spaces blank. Use
probes and memory prompts to help respondent calculate the number of months and years that
have passed.
number of months ago... ......................................
number of years ago ............................................
C5.3 Since learning you are HIV-positive, have you had a blood test to find out your CD4 count?
Use local term if necessary.
yes
no Go to C5.7
don't know Go to C5.7
declined to answer Go to C5.7
C5.4 How long ago did you have your last blood test to find out your CD4 count? Record the
number of months and years that have passed. If less than a year has passed, write '0' years;
similarly, if less than a month has passed, write '0' months. Do not leave those spaces blank. Use
probes and memory prompts to help respondent calculate the number of months and years that
have passed.
number of months ago... ......................................
number of years ago ............................................
C5.5 Do you know your latest CD4 count?
yes
no Go to C5.7
declined to answer Go to C5.7
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C5.6 What was your CD4 count at the last test?
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The next questions are about those people around you who do or do not know you are taking ART,
and how these people may make it easier or harder to take your medications






C5.8 If respondent lives with other people: Do all the other adults living in your household know that




no other adults live in the household
declined to answer
C5.9 Is it ever difficult for you to take your ART when someone from your family can see you?
yes
no Go to C5.11
declined to answer Go to C5.11
C5.10 Please tell me about this.
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C5.11 Is it ever difficult for you to take your ART when someone from your community or your
workplace can see you?
yes
no Go to C5.13
declined to answer Go to C5.13
C5.12 Please tell me about this.
C5.13 Is there anyone who regularly reminds you to take your ART?
yes
no Go to C5.15
declined to answer Go to C5.15
C5.14 Please tell me about how this person reminds you.
C5.15 During the past month, have you ever not taken your ART because you did not want
someone to find out?
yes
no Go to C5.17
declined to answer Go to C5.17
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C5.16 Please tell me about this.
C5.17 In general, do you find it easy, not very easy or difficult to take your ART?







The next questions concern any possible problems you may have had getting your ART.
C5.19  In the past year, have you ever had problems getting your ART on time because you were
not able to reach the clinic?
yes
no Go to C5.21
don't remember Go to C5.21
declined to answer Go to C5.21
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C5.20 Please tell me about this.
C5.21 During the past year, has the cost of medication or the cost of clinic care ever interfered
with your ability to get your ART and take your medication on time?
yes
no Go to C5.23
declined to answer Go to C5.23
C5.22 Please tell me about this.

C5.23 During the past one month, have you ever missed a dose of your ART because you did not
have enough food?
yes
no Go to C5.25
declined to answer Go to C5.25
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C5.24 Please tell me about this.
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Now I would like to ask you some questions about your health before and after starting your ART, and
then I will ask about any side-effects or body changes you experienced after starting ART.













Some people experience side-effects when they take ART. This varies a great deal. Some people have
a few, while others have more.
C5.27 Have you experienced any side-effects since you started taking ART?
yes
no Go to C5.30
don't know Go to C5.30
declined to answer Go to C5.30
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C5.28 Which side-effects have been the most bothersome for you?
C5.29 Please tell me more about these side-effects.
Next, I am going to read you a list of side-effects that some people say they feel when they are on
ART. Of course, not everyone feels these side-effects, so please tell me whether you have experienced
any of these side-effects in the past month. If you have experienced the side-effect, then I will ask you
how much it has bothered you.
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C5.30 In the past month, have you experienced any of the following? If yes: Has this side-effect
been very bothersome, somewhat bothersome or not at all bothersome?








3. not at all 
bothersom
e
2. fevers, chills or sweats?
3. feeling dizzy or light-headed?
4. pain, numbness or tingling in




8. diarrhoea or loose bowel
movements?
9. bloating, pain or gas in your
stomach?
10. heartburn?
11. persistent abdominal pain?
12. loss of appetite or a change
in the taste of food?
13. increased appetite?
14. felt sad, down or
depressed?
15. felt nervous or anxious?
16. difficulty falling or staying
asleep?
17. nightmares or vivid dreams?
18. skin problems, such as
rash, dryness or itching?




22. problems with or pain in
bones or joints?
23. problems with sex, such as
loss of interest or no
satisfaction?
24. problems with weight loss
or wasting?
25. tingling around the mouth?
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Some people say they experience changes to their body while they are taking ART. I would like to ask
you some questions about this.
C5.31 Since you started taking ART, have you experienced a change in the way your body looks?
yes
no Go to C5.33
don't know Go to C5.33
C5.32 Can you please tell me what changes you have experienced?
Now I am going to read you a list of changes that some people say have happened to their body while
they are taking ART. Just like side-effects, not everyone experiences the same changes.  Please tell
me whether or not you have experienced any of these changes in the past month, and if you have
experienced the change, then I will ask you how much it has bothered you.
C5.33 In the past month, have you experienced any of the following: If yes: Has this change been
very bothersome, somewhat bothersome or not at all bothersome?
















2. your belly grew?
3. your arms thinned?
4. your buttocks flattened?
5. your legs thinned?
6. the veins in your legs
increased or became more
visible?
7. your breast grew?
8. a hump appeared on the back
of your neck?
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C5.34 Of all the changes that we have just discussed, please tell me more about the changes that
are the most bothersome for you? Probe the top 2 or 3.
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Now I want to go over your ART medications: I will need to ask you about your prescribed doses of all
ART medications, and then I will ask you how many doses of your medication you actually took at
different time periods.
C5.35 The following should be completed according to the prescribed ART dosing, not the respondent’s
actual behaviour. The information may be obtained from the patient, the provider or the health care
facility. Cross out all non-applicable boxes.
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Many patients find it difficult to take all their ART as prescribed. We would not be surprised if you
have missed taking some of your medications over the last few days. We are trying to find out how
difficult it is for patients to take their ART, and what things make it difficult. Please answer these
questions as honestly as you can about your own experiences.
To complete the following table, the interviewer should reference the table that was completed for the
prescribed regimen in order to fill in the name of each ART medication and total daily # pills prescribed.
Interviewers should then walk the respondent through each of the last three days. In order to facilitate recall,
interviewers should use memory prompts by first asking respondents to think about yesterday and what they
were doing, and if there was anything unique about the day, before asking about specific times respondents
took their ART. For example: “What did you do yesterday morning? Did you take any ART medications that
morning?” If yes: “Which pills?  How many of each?” If the respondent missed a pill/dose, circle the cell.
C5.36 Which prescribed ART medications did you take over the last three days?
C5.37 Only ask this question if respondent missed one or more doses over the last three days. What
circumstances led you to miss taking your ART medications as recommended on {name the
day and the medication missed as identified in the previous question}? Probe for what happened
and why.
Missed dose #1... .................................................
Missed dose #2 ....................................................
Missed dose #3 ....................................................
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C5.38 Some people find it difficult to take their ART medications on the weekends. Thinking about
the past month, how many times did you miss taking a dose of your medications on a
weekend:
never Go to C5.40
once
twice
three or more times
declined to answer Go to C5.40
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C5.39 Please tell me what happened.
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C5.40 Now I would like to ask you to estimate how much of your prescribed ART you took in the
past month. It is not likely that most people would take all of their doses. A mark at the left
end where there is a number zero means you have taken no ART medications.  A mark in the
middle means you have taken about half of your ART medications.  A mark on the right end
where you can see the number ten means you have taken every single dose of your ART
medications.  Please put a mark on this line somewhere between zero and ten to describe
your best guess about how much of your prescribed ART you took in the previous month.
.                                                                             
C5.41 In general, what helps you to take your medication on time?
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C5.42 In the past month, what circumstances led you to miss taking your pills on time?
C5.43 What other things make it difficult to take all your ART medications on time?







C5.45 Do you have any ART medications that are supposed to be taken more than once a day?
Probe further if the answer to this question conflicts with the table in C5.35.
yes
no Go to C5.47
don't know Go to C5.47
declined to answer Go to C5.47
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C5.46 At any point during the past month, did you take all your daily doses of this [these]







C5.47 During the past six months, did you ever stop taking your ART for 48 hours or longer?
yes
no Go to C5.50
declined to answer Go to C5.50
C5.48 How long did you stop taking your antiretroviral therapy? Probe for a guess if respondent
does not remember very clearly.
for more than 48 hours and less than a week
from one to two weeks
for more than two weeks and less than one month
for more than one month
declined to answer




C5.50 We have been talking about just this past month. Now, I would like you to think back to the
first month when you started ART, I would like to ask you to estimate how of your
prescribed ART you took during that first month.  Please put a mark on this line to describe
your best guess about how much of your prescribed ART you took during that first month.
.                                                                                                                                            
C5.51 Overall, how do you feel about being on ART?
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This concludes this portion of our interview. Thank you very much for your participation.
C5.52 Time of interview or module end. Use the 24:00 clock.




For HIV-positive respondents, whether or not they are receiving antiretroviral therapy.
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These first three questions can be skipped if this module is used as part of a broader interview that has
already collected this information.
I would like to begin the next section by asking you how long you have known your HIV status and
whether you are receiving ART. Please excuse me if I have asked any of these questions already. I am
supposed to make sure that all the information is here.
C6.1 How long ago did you first learn you were HIV-positive? Record the number of months and
years that have passed. If less than a year has passed, write '0' years; similarly, if less than a
month has passed, write '0' months. Do not leave those spaces blank. Use probes and memory
prompts to help respondent calculate the number of months and years that have passed.
number of months ago... ......................................
number of years ago ............................................
C6.2 Are you taking ART to manage your HIV?
yes
no Go to C6.4
declined to answer Go to C6.4
C6.3 How long ago did you begin taking ART? Record the number of months and years that have
passed. If less than a year has passed, write '0' years; similarly, if less than a month has passed,
write '0' months. Do not leave those spaces blank. Use probes and memory prompts to help
respondent calculate the number of months and years that have passed.
number of months ago... ......................................
number of years ago ............................................
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This next section of the survey deals with personal matters, beginning with your sexual partners and
activities. Answers are confidential and will help us to better understand how to prevent HIV
transmission. We ask everyone the same questions, and only some of them may pertain to you.
C6.4 Have you had sexual intercourse (meaning penetrative vaginal or anal sex) during the last
three months?
yes Go to C6.7
no
declined to answer Go to C6.45
C6.5 Why haven't you had sex during the last three months? Record answers exactly as given by
the respondent.
C6.6 Next, I am going to read a list of reasons why some people do not have sex to see if any of
these reasons were the same as in your case. During the last three months, can you tell me
whether you did not have sex  because of any of the following:
poor health?
yes no declined to answer
because you were afraid of
infecting your partner?
because you were afraid of re-
infecting yourself?
because you had no partner?
because you had no
desire/interest?
because you just decided to
abstain?
Go to C6.45
you don't know or don't have a
reason?
C6.7 How many different partners have you had sexual intercourse with during the last three
months? Record the total number.
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Now I would like to ask you think about every time you had sexual intercourse with any partner during
the past three months.   I would like to ask about how frequently you and your partner[s] used
condoms.
C6.8 Thinking about all the times you had sexual intercourse with any partner during the past







Now I am going to ask you about different types of sexual partners. First I am going to ask you about
your spouse or any sexual partner with whom you live {FOR A BROADER DEFINITION OF REGULAR
PARTNER, INTERVIEWER COULD SAY or have been with for a while}. We call them 'regular partners'.
Then I am going to ask you about sexual partners to whom you are not married and are not living with
{IF BROAD DEFINTION USED THEN ALSO SAY: and have not been with for a while}. We call these 'non
-regular' partners.
For male respondents only: After that I will ask you about sexual partners who are paid by their
customers to have sex with them--we call these partners 'sex workers'.
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I would like to start by asking you about 'regular partners' - meaning your spouse or a live-in sexual
partner.
For male respondents: Here we are talking about female partners only.
C6.9 During the last three months, have you had sexual intercourse (meaning penetrative vaginal
or anal sex) with a spouse or a live-in partner - what  we call a 'regular partner'?
yes
no Go to C6.18
declined to answer Go to C6.18
C6.10 How many 'regular partners' have you had sexual intercourse with during the last three
months? Again by 'regular partner', I mean a spouse or live-in sexual partner? Record the
number.
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C6.11 During the past three months, when you had sexual intercourse with your 'regular







Now I would like to ask you to think about the last time you had sexual intercourse (meaning
penetrative vaginal or anal sex) with your most recent 'regular partner'.
C6.12 The last time that you had sexual intercourse with your most recent regular partner, did you
and your partner use a condom?
yes
no
declined to answer Go to C6.18 (Non-regular partnerships)
Go to C6.15 if respondent did use a condom
C6.13 Why / why not? Record the answer as given.
70
C6.14 Now I would like to read you a list of reasons why some people say they do not always use
condoms. Please tell me if any of these are reasons why you and your regular partner did
not use a condom the last time you had sex. Was it because: Mark all that apply.
your partner is also HIV-
positive?
yes no declined to answer
your partner would become
suspicious of your HIV status if
you asked him/her to use a
condom?
your partner refused?
you don't like using condoms?
your partner doesn't like
condoms?
you or your partner want to
have children?
you did not have condoms?
you don't know where to get
condoms?
you or your partner had
problems with condoms such
as a rash or burning?
Now I would like to ask you a few questions about whether you and your regular partner have
discussed your HIV status. (If this module is part of a larger interview in which similar questions have
already been asked, then say: Please excuse me if I have already asked any of these questions.)
Please think about your most recent regular partner -meaning your spouse or a live-in sexual partner.
C6.15 Do you know your most recent regular partner's HIV status?
yes
no Go to C6.17
declined to answer Go to C6.17










Now I would like to ask you about 'non-regular' sexual partners you may have had during the past
three months. By 'non-regular' sexual partners I mean partners you were not married to or living with
{WHEN A BROADER DEFINTION OF REGULAR IS USED THEN SAY: and have not been with for a
while}.
For male respondents only: When we talk about 'non-regular' partners, please think about female
partners whom you did not pay to have sex.
C6.18 During the past three months, have you had sexual intercourse (meaning penetrative
vaginal or anal sex) with a 'non-regular' partner?
yes
no Go to C6.25 if respondent is male, C6.39 if
respondent is female.
declined to answer Go to C6.25 if respondent is male, C6.39 if
respondent is female.
C6.19 How many different 'non-regular' sexual partners have you had sexual intercourse with
during the past three months? Record the number.
C6.20 During the past three months, when you had sexual intercourse with your 'non-regular'







Now I would like to ask you to think about your most recent 'non-regular' partner. Repeat definition of
'non-regular' (partners you are not married to and have not been living with) if needed.
C6.21 The last time that you had sex (meaning penetrative vaginal or anal sex) with your most
recent non-regular or casual partner was a condom used?
yes
no
declined to answer Go to C6.23
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C6.22 Why / why not?




Go to C6.39 if respondent is female
C6.24 Thinking about all the non-regular partners that you have had during the past three months,
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I would like to ask you some questions about any female sexual partners whom you have paid to have
sex during the past three months. Specifically, I would like you to think about girls or women who
charge customers to have sex. I will call them 'sex worker' partners.
C6.25 Have you paid any female sex worker partners to have sexual intercourse (meaning
penetrative vaginal or anal sex) during the last three months?
yes
no Go to C6.30
declined to answer Go to C6.30
C6.26 How many different female sex worker partners have you paid to have sex during the last
three months? Record number.
C6.27 During the past three months, when you paid a female sex worker partner to have sexual







C6.28 Please think about the last time you had sexual intercourse with a girl or woman you paid to
have sex. The last time that you paid a female partner to have sexual intercourse (meaning
penetrative vaginal or anal sex) did you and your partner use a condom?
yes
no
declined to answer Go to C6.30
C6.29 Why / why not?
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Some men have sex with other men. We ask all men some questions about whether they have had sex
with male partners.
C6.30 Have you ever had sexual intercourse (meaning penetrative anal sex) with a male partner?
yes
no Go to C6.39
declined to answer Go to C6.39
C6.31 Have you had sexual intercourse (penetrative anal sex) with a male partner during the past
three months?
yes
no Go to C6.39
declined to answer Go to C6.39
C6.32 How many male partners have you had sex with during the past three months? Record
number.
C6.33 How many of these male partners were: Record number.
regular partners (meaning someone that you lived with) .............................................................
non-regular partners (meaning someone you didn't live with and didn't pay for sex) ...............
male sex workers (someone you paid to have sex) ......................................................................
declined to answer
C6.34 During the past three months, when you had sex (penetrative anal sex) with any type of








Please think about the last time you had sexual intercourse with a male partner.
C6.35 The last time that you had sex (penetrative anal sex) with a male partner, did you or your




Now I am going to ask you a few questions about whether you and your most recent male partner
have discussed your HIV status.














I am supposed to ask this next question of everyone, about whether you have ever had sexual
intercourse with someone during the same period of time that you were having an ongoing sexual
relationship with another partner.
IF RESPONDENT DOES NOT REPORT A REGULAR PARTNER, GO TO C6.45
C6.39 During the last three months did you have sexual intercourse with any partner during the







Now I would like to ask you about children and your plans to have any [more].
C6.40 How many living children of your own do you have? Record number.
C6.41 Do you plan to have a/another child? Adjust wording depending on whether respondent already
has a child.
yes
no Go to C6.43
unsure Go to C6.43
declined to answer Go to C6.43
C6.42 In what time frame do you plan to have a / another child?
in the next 1 year
in 2-3 years
after more than 3 years
don't know






Now I would like to talk about family planning, meaning methods that someone can use to delay or
avoid a pregnancy. The methods we will discuss may be used by either you or your regular partner.
Please listen to all the choices, even if you do not think you are using any method. At the end of the
list there is a choice for 'no method'.
C6.44 Which method[s] are you or your regular partner currently using? Read out all methods and
description. Mark all that apply.
pill--women can take a pill every
day
yes no don't know
declined to
answer
IUD--women can have a loop or




pregnancy for several months
diaphragm--women can place a
diaphragm inside themselves
before intercourse
foam or jelly--women can place
foam tablets or jelly inside
themselves before intercourse
male condom--men can use a
rubber sheath on their penis
during sexual intercourse
male sterilization--men can
have an operation to avoid
having any more children
female sterilization--women can
have an operation to avoid
having any more children
natural method--every month
women can avoid having
intercourse on the days of the
month she is most likely to get
pregnant
withdrawal--men can be careful
and pull out before the fluids
come out
implants--women can have
several small rods placed in
their upper arm by a doctor or
nurse which can prevent
pregnancy for several years
other, please specify:
no method
                .............................................................
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Now I would like to ask you some questions about HIV transmission and other people you know who
have HIV.
C6.45 What are some of the ways HIV can be transmitted? Record answer as given.
C6.46 What are some ways that an HIV-positive person can reduce the risk of transmitting the
virus to another person through sexual contact? Do not read aloud. Mark all that apply.
use condoms 100% of the time
use condoms more often
reduce the number of times they engage in sex
don't have sex
stay with one partner whose status one is sure of
reduce the number of partners
other, please specify:
                .............................................................

















C6.50 Do you have a family member or close friend who has HIV or has died of AIDS?
yes
no Go to C6.52
don't know Go to C6.52
declined to answer Go to C6.52
C6.51 Who is this person [or are these people] in relation to you? Record answer as given. Code all












Next I will ask you about your opinions on the following statements about HIV and ART. For each
statement, please tell me whether you strongly agree, agree, are unsure, disagree or strongly
disagree. There are no right or wrong answers for this section. Please feel free to give your opinions.
C6.53 For each of the following statements, please indicate whether you strongly agree, agree, are
unsure, disagree or strongly disagree.
I would feel safe having
intercourse with someone who
is HIV-positive as long as they
are receiving HIV treatment.
{FIND LOCALLY APPROPRIATE
ITEM. IN HIGH LITERACY
SETTINGS, COULD ASK ABOUT
UNDETECTABLE VIRAL LOAD}
strongly






I am less worried about HIV
infection than I used to be.
The new HIV treatments make
me less anxious about having
unprotected sex.
I believe that HIV treatment




This concludes this portion of our interview. Thank you very much for your participation.
C6.54 Time of interview end. Use the 24:00 clock.






Now I would like to ask you two questions about drinking alcohol.
C7.1 During the past month, how often have you had a drink containing alcohol?
daily
nearly every day
3 to 4 times a week
once or twice a week
1 to 3 times a month
never Go to C7.3
C7.2 During the past month, on the days that you drank alcohol, how many alcoholic drinks did




6 or more drinks/day
 %
Now I would like to ask you some questions about non-prescribed drugs, which include
pharmaceutical drugs that have not been prescribed for you by a doctor.
C7.3 Have you ever injected any non-prescribed drugs?
yes
no Go to C7.12
declined to answer Go to C7.12
C7.4 What non-prescribed drugs have you injected?
C7.5 Have you injected any non-prescribed drug in the past month?
yes
no Go to C7.9
don't remember Go to C7.9
declined to answer Go to C7.9
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C7.6 What non-prescribed drugs have you injected in the past month?
C7.7 During the past month, how often would you say you have injected non-prescribed drugs?
daily
nearly every day
3 to 4 times a week
once or twice a week
1 to 3 times a month
declined to answer
C7.8 During the past month, have you done any of the following: Mark all that apply.
injected with a needle or
syringe used by someone else?
yes no declined to answer
passed on your used needle or
syringe to someone else?
injected with a brand new,
unused needle or syringe or
one that was exclusively used
by you?
gave, lent, sold or traded other
injecting equipment with
someone else, such as cotton,
dropper, vial or cooker?
drew up a solution from a
common container?
injected from a pre-filled
syringe?
gave, lent, sold or traded a sniff
straw or crack pipe?
C7.9 Are you currently enrolled in a substitution program?
yes
no Go to C7.12
declined to answer Go to C7.12
C7.10 How long ago did you first enrol in this substitution program? Record the number of months
and years that have passed. If less than a year has passed, write '0' years; similarly, if less than a
month has passed, write '0' months. Do not leave those spaces blank. Use probes and memory
prompts to help respondent calculate the number of months and years that have passed.
number of months ago... ......................................
number of years ago ............................................
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                .............................................................
C7.12 During the past three months, have you ever used any of the following drugs? If yes: How
















                .............................................................
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This concludes our interview. Thank you very much for your participation.
C7.13 Time of interview end. Use the 24:00 clock.




Instructions to interviewers are in italics.
All text that is meant to be read to the respondent is written in bold type.  For example, when multiple choice
options should be read aloud, the options are in bold, like the questions themselves. When options are
intended for the interviewer only, i.e. when they should not be read aloud, they are not in bold type.  
If a respondent declines to answer a question that does not have a specific option for this response, please
write “declined to answer” in the margin of the questionnaire. Please do not read the option “declined to
answer” out loud.
Responses to open-ended questions should be recorded as close to verbatim as possible.
2
Information about the study
Hello, I am {NAME} working on a research project supported by {NAME OF LOCAL COLLABORATING
INSTITUTION}.  We are conducting a study on HIV testing, treatment and prevention {IF NECESSARY,
ADD DETAILS}. By listening to people who may have had some experience with health services around
HIV, we hope to learn what goes right with the health services, and how to improve them.
You have been selected to represent people in this area [from this clinic] and we would very much like
to hear about your opinions and experiences. Before we get started, I would like to explain to you how
the interview works.
Informed consent
 Your participation in the interview and in every aspect of the study is completely voluntary.
 If some questions are difficult or make you uncomfortable, we can skip them.  You may also ask me
to clarify any questions if you do not understand them. You may also decide to stop the interview at
any time.
 All of the information that you provide for the study will be kept completely confidential. We record
your responses, but the questionnaire will not have your name on it, and your responses to our
questions are identified only by a number, never by name.
 The study will not be used to evaluate this facility or to report what the providers tell us to those in
the administration.
 If you have questions or concerns after we are finished, you may contact {CONTACT PERSON AT
THE COMMUNITY LEVEL}.
 Although there are no direct benefits to you from participating in this survey, we hope that the
survey will help to improve health services and support for people living with HIV and AIDS. The
Do you have any questions about the survey?  Would you be willing to participate in our study?
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Depending on local ethical clearance, it may be necessary to fill out a signed consent form. In that case it
would be preferable to design the instrument so as to be able to separate the form from the rest of the
instrument
Consent Form
We have a form that must be read to you before we begin, in order to confirm that we have explained
the study to you and that you have agreed to participate. 
We ask you to sign the form, but we do not keep the form attached to the questionnaire, so your name
will not be linked to the information we write about you, and no one except the people responsible for
the study will have access to this information.  
The form just repeats what I have told you about the study, but I have to read it to you.
 I understand that I have been asked by {NAME OF INSTITUTION} to participate in a research project
designed to investigate the experience of people who undergo HIV testing and counselling.
 I understand that during this study I will be asked questions about my health and health care, and
that my responses will be recorded in a questionnaire form. But my participation in the study will be
kept confidential, and my identity will be available only to those performing or supervising the
research. I understand that I would never be identified by name in any publications resulting from this
study.
 I am aware that there may be some questions asked during the interview which may make me
uncomfortable. I realise that I do not have to answer any question that I do not want to answer. I
understand that I am free to withdraw my consent and to discontinue participation in this research
project at any time, without affecting my future care or treatment.
 I realize that I will not benefit directly from this project. However, with my participation, I hope to
help investigators understand how to improve health services.
4
Certificate
I have read this consent form or have had explained to me to my satisfaction the information relating
to this study. I understand what my participation will involve and agree to take part in this interview
under the terms of this agreement. I have had the opportunity to ask questions about it, and my
questions have been answered to my satisfaction. 
I consent voluntarily to participate in this study and I understand that I have the right to withdraw at
any time, without it in any way affecting my future medical care.
Participant                                                                                                                                                                                 
Name __________________________
Date ___________________________











Interviewer can complete this section before the interview starts.
PR1.1 Interview ID number in the form of 001, 002, 003...
PR1.2 Date of interview DD/MM/YYYY
          /          /                                                                         .
PR1.3 Interviewer name or code
PR1.4 Name of testing facility
PR1.5 Time of interview start. Use the 24:00 clock.
PR1.6 Language of interview
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SOCIODEMOGRAPHIC AND WORK MODULE
PR2.1 Sex of the respondent. Do not read this question.
female
male
If you don’t mind, I would like to start by asking you some questions about your age, education, work
background and training. All the information you give me will be kept confidential and will not be
recorded on the same page as your name.
PR2.2 How old are you? In years.











Now I will ask you some questions about your work and training.
For the following question, if the counsellor has had training as a nurse, please mark the box nurse/midwife.


















In the following questions, if the provider has worked in HIV and AIDS care for less than a year then fill in the
number of months, otherwise you do not need to write out the months.
PR2.6 How long have you worked in HIV and AIDS care? In years and months.
years .......................................................................................
months ....................................................................................
PR2.7 How long have you worked in this facility? In years and months.
years .......................................................................................
months ....................................................................................
PR2.8 Have you had training on HIV or AIDS?
yes
no Go to PR2.11
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Next I am going to ask you a few questions about what type of training you have received, for example,
whether this training was formal or ‘on the job’.  By formal training, I mean training that took place as
part of a class or a workshop.  By ‘on-the-job’ training I mean informal learning in the course of your
work, including advice from colleagues, observation or self-study.
PR2.9 Was the training formal or 'on-the-job'?
formal only
on-the-job only Go to PR2.11
both
PR2.10 Thinking about the formal HIV training you received, what topics did that HIV training cover?









prevention of mother-to-child transmission (PMTCT)




PR2.11 How well prepared do you feel to provide the services that you are responsible for as part of




PR2.12 Why or why not?
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Daily work routine
The following three questions are time consuming and are designed to be asked among a subsample of
respondents.
In the next few questions, I would like to ask about the details of your work in your own words.
PR2.13 Please describe your daily routine, on a typical day.
PR2.14 Does your work vary much from one day to the next?
yes
no Go to PR2.16
it depends
PR2.15 In what way?
PR2.16 How many clients/patients do you personally see everyday?
PR2.17 How much time do you generally spend with each client/patient on average, in minutes?
PR2.18 On a typical day, how easy or difficult is it for you to see all of your clients/patients in the







TESTING AND COUNSELLING (T&C) MODULE
For respondents who work in HIV testing and/or counselling
This next part of the interview includes questions about HIV testing and counselling.  By HIV testing, I
mean testing for HIV antibodies by drawing blood or collecting oral fluids.
PR3.1 Do you personally conduct HIV testing or counselling?
yes
no Go to the end of the T&C module at PR3.51
Sometimes clients decide on their own that they want to know their HIV status, and they come to a
health facility specifically to ask for an HIV test. In other cases, health workers are the ones who
suggest that testing is a good idea. They might offer HIV testing to clients who have come for other
kinds of health services, such as prenatal care. Or, sometimes health workers go out into the
community and offer testing in people's homes or workplaces. In the next few questions I would like to
ask about your experience with offering HIV testing, and whether offering a test is part of your job
responsibility.
PR3.2 As part of your work, do you - personally - ever offer HIV counselling and testing to clients
who have not come to the facility specifically for that purpose?
yes
no
IF RESPONDENT DOES NOT EVER INITIATE TESTING (i.e. HAS SAID NO TO PREVIOUS TWO
QUESTIONS), GO TO PR3.6




PR3.4 What is the most frequent or typical way that you offer HIV testing? Probe for typical
circumstances, use of guidelines.
PR3.5 How do clients generally respond to your offer of an HIV test? Probe: do they readily accept?
Do they ever get upset?
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PR3.6 What do you think hinders people in this community from being tested for HIV?
PR3.7 What could be done to improve access to testing for those who want it?
PR3.8 Do some of your clients have repeated HIV tests?
yes
no Go to PR3.10
don't know Go to PR3.10
PR3.9 What do you think are the reasons that some clients have repeated HIV tests?
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The next few questions are about counselling, meaning the discussions that health workers have with
clients about HIV tests and the meaning of test results.
Some testing facilities provide pre-test counselling, while others do not.
PR3.10 What do you think about not having pre-test HIV counselling?
PR3.11 As part of your work do you personally conduct pre-test counselling?
yes
no Go to PR3.13
PR3.12 Do you find that the time that you can give for pre-test counselling is usually too long, about




PR3.13 In general, do you think that the pre-counselling information that is provided at this facility







For the following question, please make certain that the respondent obtains consent him/herself from the
client. If he or she does not obtain consent personally then skip to the next section.
PR3.15 Do you personally obtain consent from clients for HIV testing, or does that responsibility fall
to other staff members?
yes, obtains consent
no, doesn't obtain consent Go to PR3.24
Only for respondents who personally obtain consent
PR3.16 How do you typically obtain a client's consent to have an HIV test?
PR3.17 Is the consent usually obtained...
in writing
verbally




PR3.18 After you offer a test, how much time is the client usually given to think about the test before
deciding whether to consent?
less than 5 minutes
more than 5 minutes, but less than 15 minutes
15-30 minutes
more than 30 minutes, up to an hour
more than an hour, up to 2 hours




PR3.19 Are there guidelines or a protocol that you are supposed to follow when obtaining consent?
yes
no Go to PR3.22
don't know Go to PR3.22








PR3.22 In general, when you ask clients for their consent to have an HIV test, what proportion





PR3.23 In this facility, are clients ever tested without getting their consent first?
yes, often
yes, sometimes
yes, but only occasionally
no, never Go to PR3.25
declined to answer
Testing without consent [all respondents]
PR3.24 Can you describe some instances when clients were tested for HIV even when they did not
want to or were not given a chance to consent?
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The next questions ask for your opinions about who should receive HIV testing. People have different
opinions about this, and we would appreciate hearing about your honest feelings.
PR3.25 Do you think that there are reasons to require somebody to have an HIV test?
yes
no Go to PR3.27
unsure
PR3.26 Who do you think should be required to have an HIV test and why?
Privacy and confidentiality [all respondents]
Now I would like to ask you a few questions regarding how you feel about giving information to other
people about someone else’s HIV status. People have different opinions about this, and we would like
to know your honest feelings.
PR3.27 Do you think that it is sometimes okay to tell other people that someone else has HIV even if




PR3.28 Why or why not?
PR3.29 In your opinion, do you think that it is ever okay for a health worker to tell someone outside
the facility that a client tested positive for HIV, even if that client did not give permission to
tell?
yes
no Go to PR3.31
unsure Go to PR3.31
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PR3.30 Under what circumstances is it okay and why?
PR3.31 What do you do to try to protect confidentiality within your HIV testing and counselling
work?
Many health workers try hard to protect the confidentiality of client information - including HIV test
results and medical histories.  But sometimes, health workers talk about clients’ confidential
information in places where they can be overheard by other clients.  For example, a receptionist may
ask a client to state the reason for the visit in front of other clients.  Or, health workers sometimes
have conversations or collect medical histories in places where they can be overheard, such as
waiting areas.
PR3.32 In your experience, do staff members in this facility ever talk about or ask patients about
confidential client information in places where they can be overheard by other clients?
Probe: this includes asking clients the reason for their visit in front of other clients.
yes
no
PR3.33 Does this facility have guidelines, rules or a protocol for protecting clients’ confidentiality?
yes
no Go to PR3.35
don't know Go to PR3.35
PR3.34 In your experience, how closely do staff members follow these guidelines in practice?
















most of the time
some of the time
PR3.37 What are the main challenges that staff in this facility face in protecting confidentiality?
PR3.38 Can you describe instances at this facility when it was difficult to protect confidentiality?
Results
PR3.39 In your experience, what proportion of clients in this facility receive their test results? Would
you say:





don't know Go to PR3.41
19
PR3.40 Why don't clients always receive their results?
Post-test counselling
Earlier, we talked about pre-test counselling.  Now I would like to ask some questions about post-test
counselling.
PR3.41 As part of your work, do you personally conduct post-test counselling?
yes
no Go to PR3.49
Only for those who conduct post-test counselling
PR3.42 On average, when you conduct post-test counselling with a client, how long (in minutes) do
you typically spend?
PR3.43 Do you find that the duration of post-test counselling that you are able to provide is too




PR3.44 In general, do you think that the post-counselling information that is provided at this facility














neither easy nor difficult
somewhat difficult
very difficult
PR3.48 What would make it easier for you to conduct post-test counselling?
Follow-up care and support after the test [all respondents]
Next, I would like to ask about follow-up care and support for those clients who test positive at this
facility.








PR3.50 Do you have any suggestions for making it easier for HIV-positive clients to get the follow-
up care and support they need? Probe further about both medical care and social support.
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Testing and counselling module closing statement
This concludes this portion of our interview. Thank you very much for your participation.
PR3.51 Time of interview or module end. Use the 24:00 clock.
PR3.52 Additional interviewer notes
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DISCLOSURE, SUPPORT AND STIGMA MODULE
Disclosure
Now I would like to ask you about what happens when your HIV-positive clients disclose their test
results to their family, friends and people in their community.
PR4.1 If a client has HIV, do you think that client should tell anyone else?
yes
no Go to PR4.3
it depends




people they live with
friends
co-workers
it depends on the client
other, please specify:
 ...............................................................................................






PR4.4 What challenges do your clients face in disclosing their status?
23




abandoned by other family
members?
physically assaulted/beaten?
fired from their job?
expelled from their home?





abandoned by other family
members?
physically assaulted or beaten?
fired from their job?
IF RESPONDENT SAID NO TO ALL THE SUB-ITEMS IN THE TWO QUESTIONS ABOVE, THEN GO TO
PR4.8
expelled from their home?
PR4.7 How did you respond when the client told you this? Probe to refer back to any affirmative
answers from the previous two questions.
PR4.8 Do you think enough support is given to clients to help them disclose to other people?
yes Go to PR4.10
no
don't know
PR4.9 How could this be improved?
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Health care discrimination
The following questions are about fear of HIV and your feelings towards people living with HIV and
AIDS. People have very different feelings about this, and we are interested in hearing about your
honest opinions.
PR4.10 Have you ever seen or heard of clients who have been badly treated at this facility because
they had HIV or AIDS?
yes
no Go to PR4.12
declined to answer Go to PR4.12
PR4.11 Can you tell me what happened?
PR4.12 In the past 12 months have you seen the following happen in this health facility because a
client was known to have, or was suspected of having HIV or AIDS?
staff seemed uncomfortable
with a client because of his or
her HIV status?
yes no declined to answer
health worker gossiped about a
client's status?
client was ignored or received
less care than other clients?
client was denied care that he
or she should have received?
staff used excessive
precautions with clients
suspected of having HIV or
AIDS, for example, using latex
gloves for non-invasive
procedures?
client was treated with
disrespect or abused?
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PR4.13 Please indicate whether you agree with, are undecided or disagree with the following
statements:
People with AIDS deserve
blame for getting the disease.
agree disagree undecided
I think patients with AIDS have
the right to the same quality of
care as other patients.
PR4.14 Aside from your pay, do you find that your work presents you with any particular rewards?
Probe: job satisfaction, not financial.
yes
no Go to PR4.16
don't know Go to PR4.16
PR4.15 Can you give some examples?
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FEAR OF INFECTION AND WORK SAFETY MODULE
The following questions are about fear of HIV and the safety of the work environment in your health
facility.
PR4.16 How concerned are you about getting infected with HIV in the course of your  work? Would





not concerned at all Go to PR4.18
PR4.17 What types of situations at work cause you most concern?
PR4.18 How concerned would you feel about getting HIV if you had to do any of the following.
Please indicate if you would be very concerned, somewhat concerned, not sure, not very
concerned or not at all concerned.
take the blood pressure of a









change the bed linens of a
person with HIV or AIDS?
change the clothes of a person
with HIV or AIDS?
give an injection to a person
with HIV or AIDS?
dress the wound of a person
with HIV or AIDS?






PR4.20 Are you concerned about getting other types of infections - besides HIV - from HIV-positive
clients?
yes
no Go to PR4.22




PR4.22 In the past year, have you been accidentally exposed to HIV?
yes
no Go to PR4.24
don't know Go to PR4.24
declined to answer Go to PR4.24
PR4.23 Please tell me what happened, and how you dealt with the situation.
PR4.24 In the past year, do you know of any other staff member in this health facility that has been
accidentally exposed to HIV?
yes
no
Now I would like to ask you some questions about whether this health facility has enough supplies
and protocols in place to protect the health and safety of the people who work here.
PR4.25 Do you or other staff members ever run out of supplies that you need to implement
universal precautions? Probe and give examples, such as latex gloves, if needed.
yes
no Go to PR4.27
don't know Go to PR4.27
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PR4.28 In your experience, would you say that staff in this health facility use universal precautions:
always
almost always
most of the time
some of the time
not much at all
don't know
PR4.29 Do you have any suggestions for improving workplace safety in this health facility?
PR4.30 What are the main challenges that staff at this facility face in providing services related to
HIV and AIDS?
PR4.31 What--if anything--could be done to make your work easier?
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PR4.32 Do you participate in any activities or groups that help you cope with the emotional
demands of your work?
yes
no Go to PR4.34
PR4.33 What type of activities or groups?
Fear of infection and work safety module closing statement
This concludes this portion of our interview. Thank you very much for your participation.
PR4.34 Time of interview end. Use the 24:00 clock.
PR4.35 Additional interviewer notes
30
ADHERENCE MODULE
For health workers who care for patients living with HIV
I would like to begin this portion of the interview by asking you more questions about the type of care
and services you personally provide as part of your work.  In particular, we are interested in whether
and how you help patients who are taking antiretroviral therapy adhere to their treatment regimen.  So
when I ask about adherence during this portion of the interview, I specifically mean adherence to
antiretroviral therapy.
PR5.1 Do you provide care for patients taking antiretroviral therapy on a regular basis as part of
your work?
yes
no Go to PR5.23
PR5.2 Do you personally provide adherence counselling to HIV-positive patients as part of your
work?
yes
no Go to PR5.4




PR5.4 Do you think the adherence counselling provided at this facility is very effective, somewhat





PR5.5 Why or why not?
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PR5.6 When you consult with a patient who is taking antiretroviral therapy, do you assess a





never Go to PR5.9
 ...............................................................................................
PR5.7 On average, when you assess adherence during a patient consultation, how long do you
typically spend? In minutes.
minutes....................................................................................
PR5.8 How do you assess adherence? Record answer as given, then select option below. Do not read






on-time pharmacy pick ups
other, please specify:
 ...............................................................................................
PR5.9 What advice do you give to patients about how to take all their pills and adhere to their
antiretroviral therapy regimen?
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PR5.10 What information do you give patients to explain why all pills have to be taken?
PR5.11 What do you tell patients to do if a dose is missed?
PR5.12 What do you tell patients about side-effects and what they should do when they experience
them?







PR5.14 What are the most common problems your patients face adhering to their antiretroviral
therapy?
PR5.15 How frequently do you have patients who report interrupting their antiretroviral therapy for
more than 48 hours?
very frequently (at least one patient a
week)
somewhat frequently (at least one patient a
month)
not frequently (less than one patient a
month)
never Go to PR5.18
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PR5.16 What reasons do patients give for interrupting their antiretroviral therapy?
PR5.17 How do you deal with that situation?
PR5.18 In the past year, have any of the antiretroviral regimens prescribed in this clinic been out of




PR5.19 Would you say there are certain types of patients who tend to adhere better to antiretroviral
therapy than others?
yes
no Go to PR5.23
don't know Go to PR5.23
PR5.20 What types of patients are better adherers and why?
PR5.21 What types of patients are poor adherers and why?
PR5.22 What do you think could be done to help these patients adhere better?
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Adherence module closing statement
This concludes this portion of our interview. Thank you very much for your participation.
PR5.23 Time of interview end. Use the 24:00 clock.
PR5.24 Additional interviewer notes
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PREVENTION MODULE
The next portion of this interview addresses services to help patients living with HIV prevent the
transmission of HIV.
PR6.1 Do you personally provide HIV prevention information to HIV-positive patients on a regular
basis as a part of your work?
yes
no Go to PR6.8
PR6.2 When you consult with an HIV-positive patient, what is the average amount of time (in
minutes) that you spend talking about HIV prevention with HIV-positive patients?
minutes....................................................................................
PR6.3 What type of prevention information do you discuss with them? Record answer as given, then
mark all the options that apply.  Do not read the options.
PR6.4 Mark all that are mentioned.
information about HIV transmission/prevention
how to protect themselves and their sexual partners
disclosure of HIV status
referral of partners for HIV test
safer sex practices
advice on condom use
provision of information on support groups
referral to support groups
discuss family planning options
discuss options for prevention of mother-to-child HIV transmission
discuss breastfeeding in relation to prevention of mother to child HIV transmission
discuss HIV discordance between couples





PR6.6 In your experience, which groups of patients need special advice for prevention?





PR6.8 Do you think that people in this community think that HIV or AIDS is less dangerous than it
used to be now that antiretroviral therapy is available?
yes
no
don't know Go to PR6.10
PR6.9 Why or why not?









don't know Go to PR6.13
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PR6.12 Why or why not?
PR6.13 What suggestions do you have for improving HIV prevention services for patients receiving
antiretroviral therapy?
Prevention module closing statement
This concludes our interview. Thank you very much for your participation.
PR7.1 Time of interview end. Use the 24:00 clock.
PR7.2 Additional interviewer notes
